cancer incidence report saudi arabia 2006

Cancer Incidence ReportSaudi Arabia

2006

Kingdom of Saudi ArabiaMinistry of Health

Saudi Cancer Registry

SCR2006 Part01.indd 1 09-04-2010 3:27:39 AM

Report prepared by: Haya S. Al-Eid, BDS, DFE, CTRMarielen S. Manalo, Secretary

Reviewed by: Shouki Bazarbashi, MDAli Al-Zahrani, MD, PhD

SCR2006 Part01.indd 2 09-04-2010 3:27:39 AM

3

AcknowledgmentForewordThe Saudi Cancer registry (SCR) established in 1992 conducts nationwide cancer surveillance to guide cancer control programs planning. The registry began collecting information on all reportable cancers diagnosed as of January 01, 1994. The purpose of the SCR is to provide information to design, target, monitor, facilitate, and evaluate efforts; to determine the causes or sources of cancer among the Saudi population; and accordingly to reduce the burden of cancer. Data from SCR provide an overview of all reportable cancers diagnosed in reporting, provide a more complete picture of cancer among Saudis than can be obtained from Hospital based registers. This information is useful for cancer among Saudis than can be obtained Hospital based registers. This information is useful for cancer prevention programs, clinicians, policy makers, and for the public to understand the impact of cancer on the population. By combining information from SCR reports, and other Ministry of Health resources, there is an opportunity to answer a variety of epidemiological questions. This information will help cancer control programs identify at-risk population as well as support epidemiologic studies of risk factors and cancer etiology. Many such questions are covered in this report including the following:

• How many Saudis are diagnosed with cancer each year? • Which cancers are the most common cancers? • What are the trends in cancer incidence? • Which groups of the population are dispropor- tionately affected by cancer? • What geographic areas in the country have higher cancer incidence?

SCR also collects information on stage at the time of diagnosis. This is an important indicator of the effectiveness of screening efforts, as well as a determinant of treatment options and a predictor of survival for many types of cancers.

Shouki Bazarbashi, MDChairman

To be reviewed by Dr. Bazarbashi

The production of this report has been made possible by the active cooperation of staffs from hospitals, clinics, pathology laboratories, and others within the Kingdom of Saudi Arabia. The Registry is indebted to all those who have helped in identifying and collecting cases and whose support has been given over many years.

The statistics in this report have been derived from data collected from all sectors of patient care, both governmental and private. We hope the individuals and institutions will find the report useful.

We would also like to acknowledge the relentless support of his Excellency Dr. Hamad Al Manea, Minister of Health and Dr. Mansour Al Hawasi, Deputy Minister of Health for the ongoing operation of the Saudi Cancer Registry. We are in debt for the support given to us by the King Faisal Specialist Hospital and Research Centre administration represented by Dr. Qassim Al Qasabi, Chief Executive Director and Dr. Adnan Ezzat, Executive Director, Medical and Clinical Operation.

Special thanks to our registry staff who worked hard to make this publication possible, and to all previous staff involved in SCR operation for the report period.

SCR2006 Part01.indd 3 09-04-2010 3:27:39 AM

4

SCR2006 Part01.indd 4 09-04-2010 3:27:39 AM

5

This is the ninth incidence report published by the Saudi Cancer Registry. Previous publications include the 1994 Summary Report, 1994-1996 Incidence Report, 1997-1998 Incidence Report, 1999-2000 Incidence Report, 2001 Incidence Report, 2002, 2003, 2004 and 2005 Incidence Reports.

The structure of this report can be outlined as follows:

Part I Materials and Methods

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II Overview of Cancer Incidence

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2006. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2006 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex, in each of the 13 administrative regions of Saudi Arabia.

Part III Incidence of Selected-Sites

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2006, the ASR for each sex and the specific cancer rank for both sexes is presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries.

IntroductionPart IV Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25-44 age group.

Part V Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2006:

• Distribution of cancer cases among Saudis by age group and sex

• Distribution of cancer cases among Non-Saudis by age group and sex

• Cancer Incidence (per 100,000 population)among Saudis by age group and sex

• Cancer Incidence (per 100,000 population)among Non-Saudis by age group and sex

• Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex and administrative regions

Part VI Appendices

Appendix A: Regional listing of all health care facilities from which cancer cases have been reported. The objective is to receive feedback from facilities that have not been included in order to improve our case-finding and reporting processes.

Appendix B: Names of the members of the Board of Directors.

Appendix C: Copy of the cancer registration abstract form which is completed by cancer registrars for each cancer case

Appendix D: Arabic Summary of Cancer Statistics in Saudi Arabia for the year 2006

SCR2006 Part01.indd 5 09-04-2010 3:27:39 AM

Table of Contents

Foreword ....................................................................................................................................................................... 3Acknowledgement ....................................................................................................................................................... 3Introduction .................................................................................................................................................................. 5

PART I ................................................................................................................................................. 9

Background on Saudi Arabia ................................................................................................................................... 10Saudi Cancer Registry ............................................................................................................................................... 10Definitions of Statistical Terms .............................................................................................................................. 13

PART II ...................................................................................................................15

Cancer in Saudi Arabia 2006 ................................................................................................................................... 16Adult Cancers in Saudi Arabia, 2006 (above 14 years) ..................................................................................... 21Childhood Cancers in Saudi Arabia 2006 (14 years and below) .................................................................... 24Cancer in the 13 Administrative Regions of the Kingdom .............................................................................. 27International Comparison of Age-Standardized Incidence Rates .................................................................. 32

PART III .................................................................................................................33

Cancer Incidence for Most Common Sites, 2006 .............................................................................................. 35Female Breast (C 50) ................................................................................................................................................ 36Colo-rectal (C18-C20) ............................................................................................................................................. 38Non-Hodgkin Lymphoma (C82-C85; C96) ......................................................................................................... 40Thyroid (C73) ............................................................................................................................................................. 42Leukemia (C91-C95)................................................................................................................................................. 44Liver (C22) .................................................................................................................................................................. 46Skin (Non-Melanoma) (C44) ................................................................................................................................... 48Lung (C33-C34) ......................................................................................................................................................... 50Hodgkin Disease (C81) ............................................................................................................................................ 52Stomach (C16) ........................................................................................................................................................... 54Prostate (C61) ............................................................................................................................................................ 56Bladder (C67) ............................................................................................................................................................. 58Corpus Uteri (C55) .................................................................................................................................................. 60Ovarian Cancer (C56) .............................................................................................................................................. 62Sources ......................................................................................................................................................................... 64

PART IV .................................................................................................................65

Cancer Among Non-Saudi Population 2006 ...................................................................................................... 67

SCR2006 Part01.indd 6 09-04-2010 3:27:39 AM

PART V ..................................................................................................................69

Table 5.1.1 Age Distribution of Cancer Cases among Saudi Males, 2006 .................................................... 70Table 5.1.2 Age Distribution of Cancer Cases among Saudi Females, 2006 ............................................... 71Table 5.1.3 Cancer Incidence Cases among Saudi Males by Age Group (per 100,000), 2006 ................ 72Table 5.1.4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2006 ............ 73Table 5.2.1 Number, Relative Frequencies, Age Standardized Rates and Crude Rates

for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region(Asir, Baha, Jazan), 2006 ..................................................................................................................... 74

Table 5.2.2 Number, Relative Frequencies, Age Standardized Rates and Crude Ratesfor all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Madinah, Hail, Qassim), 2006 .......................................................................................................... 75

Table 5.2.3 Number, Relative Frequencies, Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Najran, Jouf, Tabuk, Northern), 2006 ........................................................................................... 76

Table 5.2.4 Number, Relative Frequencies, Age Standardized Rates and Crude Ratesfor all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Riyadh, Makkah, Eastern Province), 2006 ..................................................................................... 77

Table 5.3.1 Number, Relative Frequencies, Age Standardized Rates and Crude Ratesfor all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Asir, Baha, Jazan), 2006 ..................................................................................................................... 78

Table 5.3.2 Number, Relative Frequencies, Age Standardized Rates and Crude Ratesfor all Cancer Cases among Saudi Females by Cancer Site and Administrative Region(Madinah, Hail, Qassim), 2006 .......................................................................................................... 79

Table 5.3.3 Number, Relative Frequencies, Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Najran, Tabuk, Jouf, Northern Region), 2006 ............................................................................. 80

Table 5.3.4 Number, Relative Frequencies, Age Standardized Rates and Crude Ratesfor all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Riyadh, Makkah, Eastern Province), 2006 ..................................................................................... 81

Table 5.4.1 Age Distribution of Cancer among non-Saudi Males, 2006 ....................................................... 82Table 5.4.2 Age Distribution of Cancer among non-Saudi Females, 2006 ................................................... 83Table 5.4.3 Incidence Rates for Cancer Cases among non-Saudi Males

by Age Group (per 100,000), 2006 ................................................................................................. 84Table 5.4.4 Incidence Rates for Cancer Cases among non-Saudi Females

by Age Group (per 100,000), 2006 ................................................................................................. 85Table 5.5.1 Number of Cases by Primary Site and Years among Saudi Males, 1994-2006 ...................... 86Table 5.5.2 Number of Cases by Primary Site and Years among Saudi Females, 1994-2006 .................. 87Table 5.5.3 Age Adjusted Incidence Rate by Primary Site and Years

among Saudi Males, 1994-2006......................................................................................................... 88Table 5.5.4 Age Adjusted Incidence Rate by Primary Site and Years

among Saudi Females, 1994-2006 .................................................................................................... 89

PART VI .................................................................................................................91

APPENDIX A: Reporting Health Care Facilities .................................................................................... 92-95APPENDIX B: Members of SCR Board of Directors ........................................................................... 96-97APPENDIX C: Cancer Registration Abstract Form ..................................................................................... 98APPENDIX D: Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2006 .................100

SCR2006 Part01.indd 7 09-04-2010 3:27:39 AM

8

SCR2006 Part01.indd 8 09-04-2010 3:27:39 AM

9

PART IMATERIALS AND METHODS

SCR2006 Part01.indd 9 09-04-2010 3:27:39 AM

10

The estimated Saudi national population for year 2006 was 17,270,181**. Of these, 8,663,597 were males and 8,606,584 were females. The Non-Saudi population in 2006 was 6,408,668**; of these 4,427,243 were males and 1,981,425 females.

Figures 1-2 and 1-3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.

Figure 1.1 Administrative Regions of Saudi Arabia

Figure 1.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2006

Figure 1.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2006

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1-1).

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999** Source: SCR Estimation based on 2007 demographic survey with a 213% growth rate for Saudis and 2.5% for non-Saudis

The Saudi Cancer Registry (SCR) of Saudi Arabia is a population-based registry established in 1992 under the jurisdiction of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The SCR commenced reporting cancer cases from 01 January 1994.

Objectives:

The primary goal of the SCR is to define the population-based incidence of cancer in Saudi Arabia. Additional objectives include programs for early detection and cancer screening, as well as cancer research projects. Organizational Structure:

A Board of Directors was appointed to include representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, the National Guard, King Saud University, King Faisal University, King Abdul-Aziz University and King Khalid University. The Board is charged with the responsibility of overseeing the SCR’s establishment, defining demographic and cancer-related data to be collected, approving research requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.

Saudi Cancer Registry

02468101214161820 0 2 4 6 8 10 12 14 16 18 20FemaleMale

1,150,8381,053,503992,516947,277921,201790,897641,382538,387441,223357,533265,838180,568140,50375,59682,94883,387

8,663,597 8,606,584

0-4 5-9

10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-7475+1.0 1.0

0.80.91.62.1

2.93.9

5.16.3

7.58.8

10.811.111.712.413.1

1.00.9

1.62.1

3.14.1

5.16.2

7.49.1

10.610.9

11.512.2

13.3

1,128,0271,066,6481,006,745953,607930,729756,035649,555542,498436,455338,937248,587177,132134,96275,47471,90189,293

02468101214161820FemaleMale

0 2 4 6 8 10 12 14 16 18 20

234,249223,553182,903140,083205,614546,379769,978779,905560,063372,550221,924107,27042,33817,30210,71712,415

229,785208,883175,798137,355148,014223,915297,197243,108132,73773,01146,11526,00314,4108,9458,4107,7410-4

5-9 10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-7475+0.3 0.4

0.40.50.71.3

2.33.7

6.712.3

15.011.3

7.56.9

8.910.5

11.6

0.20.4

1.02.4

5.08.4

12.417.617.4

12.34.6

3.24.1

5.05.3

4,427,243 1,981,425

SCR2006 Part01.indd 10 09-04-2010 3:27:43 AM

11

Figure 1.4 Organizational Chart of the Saudi Cancer Registry of Saudi Arabia

Format

The format of the current report is similar to the previous reports.

The SCR Main Office, including administrative and technical staff, is located in the premises of the KFSH&RC in Riyadh. Additionally, five regional branches and four hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

Regional Offices:

1 Central Region: King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.

2 Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.

3 Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.

4 Southern Region: King Khalid University, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.

5 Madinah/Northern Region: King Fahad Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or Oncology Department of the following establishment

1 Ministry of Defense and Aviation, Armed Forces Hospital, Riyadh

2 National Guard, Abdulaziz Medical City, Princess Nourah Oncology Center, Jeddah

3 Ministry of Interior, Security Forces Hospital, Riyadh.

4 King Faisal Specialist Hospital and Research Centre, Riyadh.

5 King Abdul Aziz University Hospital, Jeddah

Each of the SCR offices operates under the supervision of a member of the Board of Directors who is responsible for the daily management of that office. Staffing consists of tumor registrars and secretarial staff.

The SCR Main Office indirectly supervises the regional offices and is responsible for ensuring the accuracy and quality of data collected in all of the regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares periodic reports for dissemination of information to the medical community, government establishments, international organizations and the media.

Ministry of HealthSaudi Arabia

Saudi Cancer RegistryMain Office

Central Region (Riyadh, Qassim & Hail)

King Faisal Specialist Hospital& Research Centre (Riyadh)

National Guard Hospitals

Armed Forces Hospitals

Security Forces Hospital

Madinah Region (Madinah, Tabuk, Jouf & Northern Region)

Southern Region (Asir, Baha, Jazan & Najran)

Western Region (Jeddah, Makkah, Taif & Qunfudah)

Eastern Region (Dammam, Ahsa & Hafr Al Batin)

SCR2006 Part01.indd 11 09-04-2010 3:27:43 AM

12

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients’ medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars.

The data abstract (see appendix D) includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000.

Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, is available on the web at: http:/seer.cancer.gov/tools/ssm/. Cases diagnosed on or after 01 January 2006 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now

The computer software programs used for data entry and incidence tables output are CanReg 4.33, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinicopathological details for the 14 most common cancers among Saudi nationals for the year 2006. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2006, the age-standardized incidence rate (ASR) per 100,000 population for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented.

Useful international statistics for the specified cancer include the ranking of the cancer worldwide. The source for this information is summarized on page 64.

counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However, as with the new staging guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis.

Data management

SCR2006 Part01.indd 12 09-04-2010 3:27:43 AM

13

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable.

2. A table lists the percentages of the most common histology sub-types for each specific cancer.

3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.

4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.

5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

In reviewing the data, its collection and analysis, two qualifying statements can be made:

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several popu lations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Stan dardized Incidence Rate. The rate is expressed per 100,000 populations.

Notification

The data included in this report were abstracted up to June 2006. 2006 incident cases which are identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

The relevant data incorporate details for all patients presented over the year 2006. For each cancer there are five figures:

a. The number of patients presenting with malignant disease from Riyadh region exceeds the anticipated number per population. The reason for this is that Riyadh has many referral centers providing patients from outside the region with cancer-related care. Many of these patients fail to provide their permanent address, but instead, provide a temporary Riyadh address. This situation is partially resolved through tumor and patient linkage of cases from all regions based on identifiers such as national ID.

b. As previously noted, the software used in analyzing this report, CanReg 4.33, does not include in situ cases in the incidence tables. These cases were added to the total cancer cases in the overview.

* Doll R. Payne P. Waterhouse J. Cancer incidence in Five Continents Vol. I. International Union Against Cancer. 1966

Age Class Population

0-4 12,000 5-9 10,000

10-14 9,000 15-19 9,000 20-24 8,000 25-29 8,000 30-34 6,000 35-39 6,000 40-44 6,000 45-49 6,000 50-54 5,000 55-59 4,000 60-64 4,000 65-69 3,000 70-74 2,000 75+ 2,000

Total 100,000

SCR2006 Part01.indd 13 09-04-2010 3:27:43 AM

14

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

Mean

The simple mathematical average of two or more numbers.

Median

The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range

Is the difference between the maximum and minimum values in a set of observations.

Rank

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio

The relation between two quantities. The first quantity as numerator and the second as denominator

Relative Frequency

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

The crude incidence rate for a cancer site is the total number of cases registered as a pro portion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the de mographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to com pare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Cumulative Incidence rate

Cumulative incidence is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups.

ICD-10

The World Health Organization’s International Classification of Diseases, tenth edition.

ICD-O-3

The World Health Organization’s International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Crude Incidence Rate Incidence Rate

SCR2006 Part01.indd 14 09-04-2010 3:27:43 AM

PART IIOVERVIEW OF CANCER INCIDENCE

2006

SCR2006 Part02.indd 15 09-04-2010 3:28:01 AM

16

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex 2006

As shown on table 2.1, 10,378 cases were analyzed, of which 8,054 (77.6%) were Saudis and 2,324 (22.4%) were Non-Saudis. Among the Saudis, 3,898 (48.4%) were male and 4,156 (51.6 %) were female. The male to female ratio was 94:100. The crude incidence rate (CIR) of all cancers among the Saudi population was 44.6/100,000 (45/100,000 among males and 48.3/100,000 among females). The overall age-standardized incidence rate (ASR) for all Saudis with a world standard population reference was 83.2/100,000 (83.6/100,000 in males and 82.7/100,000 in females). For all sites, the age-specific incidence rate (AIR) increased with age for both males and females. After the age of 64 years, the increase was nearly one and one half folds for males compared to females. The median age at diagnosis was 60 years for men and 50 years for women. The five geographic regions with the highest ASR were Riyadh region at 98.1/100,000, Eastern region at 94.0/100,000, Tabuk region at 89.6/100,000, Makkah region at 77.7/100,000, and Madinah region at 77.2/100,000.

Between January 01 and December 31, 2006, the total number of cancer incident cases reported to the SCR was 11,0 0. Overall and for the first time, cancer was slightly more among women than men. Cancers affected 5,476 (49.6%) males and 5,564 (50.4%) females, with a male to female ratio of 98:100. 8,253 cases were reported among Saudis, 2,395 among Non-Saudis. The total number of cases excluded from analysis included 392 cases of unknown nationalities. Other exclusions were 222 in situ cases. The current software program CanReg-4 version 4.33, does not include in situ cases in the statistical analysis. Also, 58 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12). This puts the total number of exclusions from the analysis as 662 cases. Table 2.1 illustrates the distribution of the cases by sex.

Diagnosis of malignancy was confirmed histologically in 86% of the cases, and hematological & cytologically in 6. of cases. Clinically confirmed cases were 0.2 ; radiologically confirmed cases were 2.2 ; cases confirmed by Death Certificate Only were 3.2 and 1. of the cases were confirmed by other methods. The method of diagnosis was unknown for 1.6% of the cases.

Reported Cancer Incidence Cases in Saudi Arabia, 2006

* ICD-10 conversion failure ** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Saudis Non-Saudis Unknown Nationality All

Behavior Male Female Total Male Female Total Male Female Total Total

Total 4003 4250 8253 1276 1119 2395 197 195 392 11040

Invasive 3923 4178 8101 1238 1093 2331 189 193 382 10814

In-Situ 77 72 149 37 26 63 8 2 10 222

ICD 10 * 25 22 47 4 3 7 3 1 4 58

Analyzed ** 3898 4156 8054 1234 1090 2324 186 192 378 10378

SCR2006 Part02.indd 16 09-04-2010 3:28:01 AM

Dr. Suliman Alsagaby

17

Cancer among Saudis 2006

Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2006

As explained earlier the total number of cancer cases analyzed among Saudis during the year 2006 were ,0 . Following are figures presenting the percentage distributions of cancer incidence and most frequent types of cancers among Saudis by sex.

Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex among Saudis, 2006* 4 male cases and 8 female of unknown age are included only in the total as they may not be added to any age group

01020304050Other sites

Female (4156)Male (3898)

Prostate Skin

LungLiverLeukemiaNHLColo-rectal

BladderStomach

Hodgkin Disease

10 20 30 40 50

All Ages

Corpus UteriSkin

OvaryLiver

Hodgkin diseaseOther sites

Leukemia

ThyroidColo-rectal

Breast

NHL

10.6 23.610.2

8.95.65.1

3.43.2

3.23.02.9

30.9

9.07.67.56.05.85.04.44.34.2

35.6

Other Sites


EyeKidney

BoneHodgkin DiseaseNHLBrain, CNS

Connective, Soft TissueNasopharynx

Adrenal Gland

8.31.5

3.43.74.35.5

7.010.1

11.614.1

30.6

01020304050

8.32.93.84.25.05.45.45.8

11.314.6

33.3

10 20 30 40 50

0-14 Years

EyeKidney

Connective, Soft TissueAdrenal Gland

ThyroidOther sites

Bone

Brain, CNSHodgkin Disease

NHL

Leukemia Leukemia

Connective, Soft Tissue


NasopharynxTestis

Brain, CNSThyroidBoneNHLLeukemia

Other sites

OvarySkin

15-29 Years

Brain, CNSBone

Colo-rectalStomach

Other sites

LeukemiaNHL

Hodgkin DiseaseBreast

Colo-rectal Placenta

Hodgkin Disease Thyroid

01020304050 10 20 30 40 50

20.019.4

11.48.3

5.65.64.74.43.13.11.9

12.5

26.514.0

11.58.17.1

4.13.83.83.6

2.02.0

13.5

23.32.62.82.83.34.04.2

5.76.66.6

8.512.7

16.7

01020304050

Testis


Nasopharynx Brain, CNS

LeukemiaThyroidHodgkin DiseaseColo-rectalNHL

StomachKidney

Bladder

16.91.81.81.81.92.02.32.52.5

4.4

17.138.4

6.5

0 10 20 30 40 50

30-44 Years

OvarySkin

Brain, CNSStomach

Corpus Uteri

Other sites

Cervix UteriLeukemia

ThyroidColo-rectal

Breast

Other Sites

Hodgkin Disease

Skin

NHL

Other sites


LungBladder

LiverNHLColo-rectal

ThyroidStomach

Kidney

45-59 Years

Corpus UteriOvary

SkinLeukemia

Liver

Other sites

ThyroidNHL

BreastColo-rectal

SkinProstate Kidney

01020304050

16.4 33.111.5

7.74.84.03.93.12.72.42.3

24.6

8.67.36.9

5.84.54.34.24.03.8

34.3

10 20 30 40 50

01020304050

12.7

10.5

9.58.1

6.05.85.55.4

4.13.3

29.2

15.3

12.3

6.55.95.5

4.94.43.6

3.43.3

35.0Other sites


Skin Stomach

NHLProstateLungLiverColo-rectal

PancreasLeukemia

Bladder

10 20 30 40 50

60-74 Years

ThyroidStomach

OvaryLung

LeukemiaOther sites

Corpus Uteri

Colo-rectalNHL

Breast

Liver

22.92.2

3.64.35.1

6.36.4

7.98.38.6

11.412.9

01020304050

Other sites


LungsStomach

NHLSkinColo-rectalLiverProstate

LeukemiaEsophagus

Bladder

36.23.23.23.53.73.74.2

6.77.0

9.2

9.79.5

10 20 30 40 50

75+ Years

StomachEsophagus

Gallbladder, etc.

Lungs

Other sites

NHLLiver

SkinColo-rectal

Breast

Thyroid

Corpus UteriGallbladder, etc.

0

5

10

15

20

9.5

5.8

9.2 9.510.9

22.820.4

27.025.1

30.5

18.5

9.6

25

30

35

Perc

enta

ge

Age Group0-14 15-29 30-44 45-59 60-74 75+

MaleFemale

SCR2006 Part02.indd 17 09-04-2010 3:28:08 AM

18

Table 2.2 Ten Most Common Cancers among Saudis, 2006 (All Ages)

Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2006

Cancer No. %

Breast 999 12.4

Colo-rectal 784 9.7

NHL 585 7.3

Thyroid 541 6.7

Leukemia 508 6.3

Liver 416 5.2

Skin 327 4.1

Lung 312 3.9

Hodgkin Disease 293 3.6

Stomach 275 3.4

3898 4156Male Female

414Colo-rectal

351NHL

296Leukemia

291Liver

232Lung

228Prostate

193Skin

173Hodgkin Disease

169Bladder

162Stomach

981 23.6%10.6%

9.0%

7.6%

7.5%

6.0%

5.8%

5.0%

4.4%

4.3%

4.2%

10.2%

8.9%

5.6%

5.1%

3.4%

3.2%

3.2%

3.0%

2.9%

Breast

424Thyroid

370Colo-rectal

234NHL

212Leukemia

140Corpus Uteri

134Skin

132Ovary

125Liver

120Hodgkin Disease

SCR2006 Part02.indd 18 09-04-2010 3:28:08 AM



19

Figure 2.5 Age Standardized Rate ( ASR) Regional Distribution (per 100,000) of All Sites of Cancer among Saudis, 2006

ig re Age-Specific Incidence Rates (AIR) for All ancers among Sa dis

101.894.4

92.495.6

83.395.8

76.978.4

81.273.2

62.275.8

66.469.6

55.555.8

59.151.3

38.062.0

45.042.2

36.243.3

30.720.8

0 20 40 60 80 100 120

Jazan

Baha

Hail

Najran

Qassim

Asir

Jouf

Northern

Madinah

Makkah

Tabouk

Eastern

Riyadh

0

100

200

300

400

500

600

700

800

900

1000

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

SCR2006 Part02.indd 19 09-04-2010 3:28:08 AM

20

Table 2.3 Number, Percentage, ASR,CIR, and Cumulative Rates (per 1000) of New Cases by Primary Site and Sex among Saudis, 2006

ICD-10 Site No. % Crude ASR No. % Crude ASRRate World 0-64 0-74 Rate World 0-64 0-74

All All sites Total 3898 100.0% 45.0 83.6 36.6 94.1 4156 100.0% 48.3 82.7 50.6 93.9Not C 44 All sites but C 44 3705 95.0% 42.8 79.0 35.0 89.4 4022 96.8% 46.8 79.8 49.5 91.0C00 Lip 6 0.2% 0.1 0.1 0.0 0.1 4 0.1% 0 0.1 0.0 0.1C01-C02 Tongue 37 0.9% 0.4 0.8 0.4 0.8 26 0.6% 0.3 0.6 0.4 0.8C03-C06 Mouth 30 0.8% 0.3 0.8 0.2 0.9 34 0.8% 0.4 0.8 0.5 0.9C07-C08 Salivary glands 14 0.4% 0.2 0.2 0.1 0.3 12 0.3% 0.1 0.2 0.1 0.2C09 Tonsil 0 0.0% 0 0 0.0 0.0 2 0.0% 0 0 0.0 0.0C10 Other Oropharynx 0 0.0% 0 0 0.0 0.0 0 0.0% 0 0 0.0 0.0C11 Nasopharynx 95 2.4% 1.1 1.7 1.0 1.8 43 1.0% 0.5 0.8 0.6 0.8C12-C13 Hypopharynx 9 0.2% 0.1 0.2 0.1 0.2 11 0.3% 0.1 0.2 0.2 0.2C14 Pharynx unspecified 3 0.1% 0 0.1 0.0 0.0 1 0.0% 0 0 0.0 0.1C15 Oesophagus 55 1.4% 0.6 1.4 0.5 1.2 64 1.5% 0.7 1.6 0.6 2.1C16 Stomach 162 4.2% 1.9 3.9 1.3 4.7 113 2.7% 1.3 2.7 1.1 3.5C17 Small intestine 18 0.5% 0.2 0.4 0.2 0.5 14 0.3% 0.2 0.3 0.3 0.4C18 Colon 232 6.0% 2.7 5.3 3.0 6.7 227 5.5% 2.6 5.3 3.4 6.7C19-C20 Rectum 182 4.7% 2.1 4.4 2.3 5.2 143 3.4% 1.7 3.3 2.1 3.7C21 Anus 8 0.2% 0.1 0.2 0.1 0.3 9 0.2% 0.1 0.2 0.2 0.3C22 Liver 291 7.5% 3.4 7.5 2.6 8.9 125 3.0% 1.5 3.1 1.7 3.8C23-C24 Gallbladder etc. 46 1.2% 0.5 1.2 0.4 1.4 70 1.7% 0.8 1.7 0.9 2.0C25 Pancreas 93 2.4% 1.1 2.4 1.0 3.5 73 1.8% 0.8 1.8 0.8 2.5C30-C31 Nose, sinuses etc. 10 0.3% 0.1 0.2 0.0 0.0 10 0.2% 0.1 0.2 0.0 0.2C32 Larynx 62 1.6% 0.7 1.6 0.8 1.9 9 0.2% 0.1 0.2 0.1 0.2C33-C34 Trachea, Bronchus, Lung 232 6.0% 2.7 6.1 2.3 8.1 80 1.9% 0.9 2 1.0 2.5C37-C38 Other Thoracic organs 14 0.4% 0.2 0.2 0.1 0.2 10 0.2% 0.1 0.2 0.1 0.2C40-C41 Bone 64 1.6% 0.7 0.7 0.4 0.6 36 0.9% 0.4 0.4 0.2 0.3C43 Melanoma of Skin 11 0.3% 0.1 0.2 0.1 0.3 12 0.3% 0.1 0.3 0.2 0.3C44 Other Skin 193 5.0% 2.2 4.6 1.7 4.8 134 3.2% 1.6 3 1.2 3.0C45 Mesothelioma 8 0.2% 0.1 0.2 0.0 0.3 5 0.1% 0.1 0.1 0.0 0.3C46 Kaposi sarcoma 22 0.6% 0.3 0.5 0.3 0.6 14 0.3% 0.2 0.3 0.3 0.4C47;C49 Connective, Soft tissue 57 1.5% 0.7 0.9 0.5 0.9 37 0.9% 0.4 0.5 0.3 0.5C50 Breast 18 0.5% 0.2 0.4 0.3 0.3 981 23.6% 11.4 18 14.0 19.5C51 Vulva − − − − − − 4 0.1% 0 0.1 0.1 0.1C52 Vagina − − − − − − 1 0.0% 0 0 0.0 0.0C53 Cervix Uteri − − − − − − 74 1.8% 0.9 1.5 0.9 1.7C54 Corpus Uteri − − − − − − 140 3.4% 1.6 3.6 2.2 4.5C55 Uterus unspecified − − − − − − 22 0.5% 0.3 0.5 0.3 0.7C56 Ovary − − − − − − 132 3.2% 1.5 2.8 1.8 3.3C57 Other Female Genital − − − − − − 9 0.2% 0.1 0.2 0.1 0.3C58 Placenta − − − − − − 19 0.5% 0.2 0.2 0.2 0.2C60 Penis 1 0.0% 0 0 0.0 0.1 − − − − − −C61 Prostate 228 5.8% 2.6 6.1 1.5 6.6 − − − − − −C62 Testis 38 1.0% 0.4 0.5 0.3 0.4 − − − − − −C63 Other male genital 3 0.1% 0 0.1 0.0 0.2 − − − − − −C64 Kidney 111 2.8% 1.3 2.4 1.3 2.9 78 1.9% 0.9 1.5 0.9 1.7C65 Renal Pelvis 5 0.1% 0.1 0.1 0.1 0.2 4 0.1% 0 0.1 0.1 0.1C66 Ureter 1 0.0% 0 0 0.0 0.1 2 0.0% 0 0 0.0 0.0C67 Bladder 169 4.3% 2 4.1 1.8 4.8 42 1.0% 0.5 1 0.4 1.2C68 Other Urinary organs 0 0.0% 0 0 0.0 0.0 0 0.0% 0 0 0.0 0.0C69 Eye 26 0.7% 0.3 0.3 0.2 0.3 19 0.5% 0.2 0.3 0.2 0.2C70-C72 Brain, Nervous system 149 3.8% 1.7 2.5 1.4 2.7 103 2.5% 1.2 1.6 1.1 1.7C73 Thyroid 117 3.0% 1.4 2.1 1.2 2.5 424 10.2% 4.9 6.5 4.7 6.5C74 Adrenal gland 19 0.5% 0.2 0.2 0.1 0.2 10 0.2% 0.1 0.1 0.1 0.1C75 Other Endocrine 5 0.1% 0.1 0.1 0.0 0.0 5 0.1% 0.1 0.1 0.0 0.2C81 Hodgkin disease 173 4.4% 2 2.1 1.4 1.5 120 2.9% 1.4 1.6 0.8 1.6C82-C85;C96 Non-Hodgkin lymphoma 351 9.0% 4.1 6.6 3.3 6.7 234 5.6% 2.7 4.8 2.8 5.6C88 Immunoproliferative dis. 0 0.0% 0 0 0.0 0.0 0 0.0% 0 0 0.0 0.0C90 Multiple Myeloma 48 1.2% 0.6 1.2 0.5 1.6 26 0.6% 0.3 0.6 0.3 0.8C91 Lymphoid Leukemia 155 4.0% 1.8 2.3 1.0 2.0 90 2.2% 1 1.2 0.5 0.9C92-C94 Myeloid Leukemia 115 3.0% 1.3 1.8 0.8 1.6 113 2.7% 1.3 2 1.2 2.2C95 Leukemia unspecified 26 0.7% 0.3 0.4 0.1 0.4 9 0.2% 0.1 0.2 0.1 0.3Other Other & unspecified 186 4.8% 2.1 4.3 1.9 5.1 177 4.3% 2.1 4.1 1.9 4.9

Cumulative Rate Cumulative RateFemaleMale

SCR2006 Part02.indd 20 09-04-2010 3:28:09 AM

21

Between January and December 2006, the total number of adult cancer incidence cases reported was 10,218. Overall cancer was slightly more in females than in males. Cancer affected 5,014 (49.1.%) males and 5,204 (50.9%) females, with a

Table 2.4 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex 2006

Figure 2.6 Ten Most Common Cancers among Saudi Adults, 2006

ratio of 96:100. Of all cases, there were 7,666 Saudis, 2,287 of Non-Saudis and 265 of unknown nationalities. As shown on table 2.4, the total number of analyzed cases were 9691.

Adult Cancers in Saudi Arabia, 2006 (>14 years)




Total 3669 3997 7666 1216 1071 2287 129 136 265 10218

Invasive 3591 3926 7517 1178 1045 2223 123 136 259 9999

In-Situ 76 71 147 37 26 63 6 0 6 216

ICD 10 * 24 18 42 4 3 7 3 1 4 53

Analyzed ** 3567 3908 7475 1175 1042 2216 120 135 255 9691


414Colo-rectal

313NHL

251Liver

232Leukemia

227Lung

195Prostate

190Stomach

169Bladder

162Skin

139Hodgkin Disease

979 25.0%11.6%

8.7%

7.0%

6.5%

6.3%

5.4%

5.3%

4.7%

4.5%

3.9%

10.6%

9.4%

5.6%

3.5%

3.3%

3.3%

3.3%

3.1%

2.8%

Breast

417Thyroid

370Colo-rectal

220NHL

139Corpus Uteri

132Leukemia

131Skin

130Ovary

122Liver

112Stomach

SCR2006 Part02.indd 21 09-04-2010 3:28:09 AM

22

Primary Site Code Morphology Male % Female %

Breast 85003 Infiltrating duct carcinoma, NOS 14 82.4 739 75.585203 Lobular carcinoma, NOS 0 0.0 62 6.380103 Carcinoma, NOS 2 11.8 40 4.180003 Neoplasm, malignant 0 0.0 22 2.285223 Infiltrating duct and lobular carcinoma 0 0.0 15 1.585103 Medullary carcinoma, NOS 0 0.0 13 1.381403 Adenocarcinoma, NOS 1 5.9 11 1.185233 Infiltrating duct mixed with other types of carcinoma 0 0.0 12 1.285413 Paget disease and infiltrating duct carcinoma of breast 0 0.0 12 1.290203 Phyllodes tumor, malignant 0 0.0 10 1.0

All Others 0 0.0 43 4.4

Colo-rectal 81403 Adenocarcinoma, NOS 313 75.6 277 74.984803 Mucinous adenocarcinoma 34 8.2 27 7.380003 Neoplasm, malignant 11 2.7 22 5.982613 Adenocarcinoma in villous adenoma 11 2.7 8 2.281443 Adenocarcinoma, intestinal type 9 2.2 6 1.684813 Mucin-producing adenocarcinoma 9 2.2 6 1.682633 Adenocarcinoma in tubulovillous adenoma 6 1.4 7 1.980103 Carcinoma, NOS 6 1.4 5 1.484903 Signet ring cell carcinoma 1 0.2 7 1.9

All Others 14 3.4 5 1.4

NHL 96803 Malignant lymphoma, large B-cell, diffuse, NOS 140 44.7 108 49.195903 Malignant lymphoma, NOS 28 8.9 18 8.295913 Malignant lymphoma, non-Hodgkin, NOS 19 6.1 16 7.396993 Marginal zone B-cell lymphoma, NOS 22 7.0 12 5.597023 Mature T-cell lymphoma, NOS 15 4.8 6 2.796703 Malignant lymphoma, small B lymphocytic, NOS 10 3.2 10 4.597003 Mycosis fungoides 6 1.9 11 5.096873 Burkitt lymphoma, NOS 8 2.6 6 2.797143 Anaplastic large cell lymphoma, T cell and Null cell type 10 3.2 4 1.896903 Follicular lymphoma, NOS 11 3.5 2 0.996983 Follicular lymphoma, grade 3 6 1.9 6 2.796753 Malignant lymphoma, mixed small and large cell, diffuse 7 2.2 2 0.996913 Follicular lymphoma, grade 2 6 1.9 3 1.496953 Follicular lymphoma, grade 1 3 1.0 5 2.3

All Others 22 7.0 11 5.0

Thyroid 82603 Papillary adenocarcinoma, NOS 70 60.9 228 54.783403 Papillary carcinoma, follicular variant 12 10.4 67 16.183413 Papillary microcarcinoma 6 5.2 34 8.283433 Papillary carcinoma, encapsulated 2 1.7 14 3.483353 Follicular carcinoma, minimally invasive 3 2.6 12 2.983303 Follicular adenocarcinoma, NOS 5 4.3 9 2.280003 Neoplasm, malignant 3 2.6 8 1.985103 Medullary carcinoma, NOS 2 1.7 8 1.980213 Carcinoma, anaplastic, NOS 3 2.6 6 1.482903 Oxyphilic adenocarcinoma 3 2.6 6 1.483443 Papillary carcinoma, columnar cell 1 0.9 7 1.7

All Others 5 4.3 18 4.3

Liver 81703 Hepatocellular carcinoma, NOS 218 76.0 78 63.980003 Neoplasm, malignant 35 12.2 17 13.981603 Cholangiocarcinoma 13 4.5 9 7.480103 Carcinoma, NOS 5 1.7 5 4.181403 Adenocarcinoma, NOS 4 1.4 4 3.3

All Others 12 4.2 7.4

Leukemia 98633 Chronic myeloid leukemia, NOS 29 14.9 29 22.098613 Acute myeloid leukemia, NOS 29 14.9 26 19.798233 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 31 15.9 11 8.398353 Precursor cell lymphoblastic leukemia, NOS 21 10.8 7 5.398363 Precursor B-cell lymphoblastic leukemia 14 7.2 3 2.398913 Acute monocytic leukemia 11 5.6 6 4.598663 Acute promyelocytic leukemia, t(15;17) (q22;q11-12) 10 5.1 6 4.598003 Leukemia, NOS 9 4.6 4 3.098673 Acute myelomonocytic leukemia 3 1.5 8 6.198743 Acute myeloid leukemia with maturation 6 3.1 4 3.098013 Acute leukemia, NOS 7 3.6 2 1.598373 Precursor T-cell lymphoblastic leukemia 7 3.6 1 0.899403 Hairy cell leukemia 4 2.1 2 1.599453 Chronic myelomonocytic leukemia, NOS 1 0.5 5 3.898723 Acute myeloid leukemia, minimal differentiation 2 1.0 3 2.398203 Lymphoid leukemia, NOS 4 2.1 0 0.098733 Acute myeloid leukemia without maturation 0 0.0 4 3.0

All Others 7 3.6 11 8.3

Skin 80903 Basal cell carcinoma, NOS 90 47.4 53 40.580703 Squamous cell carcinoma, NOS 42 22.1 33 25.280713 Squamous cell carcinoma, keratinizing, NOS 17 8.9 8 6.188323 Dermatofibrosarcoma, NOS 10 5.3 9 6.980973 Basal cell carcinoma, nodular 5 2.6 7 5.380943 Basosquamous carcinoma 6 3.2 5 3.884103 Sebaceous adenocarcinoma 3 1.6 4 3.180983 Adenoid basal carcinoma 3 1.6 3 2.380913 Multifocal superficial basal cell carcinoma 1 0.5 3 2.380923 Infiltrating basal cell carcinoma, NOS 4 2.1 0 0.0

All Others 9 4.7 6 4.6

Table 2.5 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Adults, 2006

SCR2006 Part02.indd 22 09-04-2010 3:28:10 AM

23

Table 2.5 continued .....


Lung 81403 Adenocarcinoma, NOS 51 0 32 40.080703 Squamous cell carcinoma, NOS 46 0 5 6.380003 Neoplasm, malignant 23 0 11 13.880413 Small cell carcinoma, NOS 29 0 5 6.380463 Non-small cell carcinoma 27 0 6 7.580103 Carcinoma, NOS 10 0 4 5.080123 Large cell carcinoma, NOS 8 0 3 3.882503 Bronchiolo-alveolar adenocarcinoma, NOS 9 0 2 2.580713 Squamous cell carcinoma, keratinizing, NOS 9 0 0 0.082603 Papillary adenocarcinoma, NOS 1 0 3 3.880133 Large cell neuroendocrine carcinoma 3 0 0 0.080203 Carcinoma, undifferentiated, NOS 2 0 1 1.3

Others 14 0 8 10.0

Stomach 81403 Adenocarcinoma, NOS 74 45.7 45 40.284903 Signet ring cell carcinoma 37 22.8 34 30.481443 Adenocarcinoma, intestinal type 18 11.1 6 5.480103 Carcinoma, NOS 5 3.1 5 4.580003 Neoplasm, malignant 3 1.9 6 5.484803 Mucinous adenocarcinoma 4 2.5 3 2.780703 Squamous cell carcinoma, NOS 1 0.6 3 2.781453 Carcinoma, diffuse type 3 1.9 1 0.982603 Papillary adenocarcinoma, NOS 4 2.5 0 0.0

All Others 13 8.0 9 8.0

Hodgkin Disease 96633 Hodgkin lymphoma, nodular sclerosis, NOS 51 36.7 39 41.996523 Hodgkin lymphoma, mixed cellularity, NOS 27 19.4 18 19.496503 Hodgkin lymphoma, NOS 22 15.8 14 15.196513 Hodgkin lymphoma, lymphocyte-rich 9 6.5 5 5.496593 Hodgkin lymphoma, nodular lymphocyte predominance 10 7.2 4 4.396653 Hodgkin lymphoma, nodular sclerosis, grade 1 6 4.3 4 4.396673 Hodgkin lymphoma, nodular sclerosis, grade 2 6 4.3 4 4.396533 Hodgkin lymphoma, lymphocyte depletion, NOS 6 4.3 2 2.296643 Hodgkin lymphoma, nodular sclerosis, cellular phase 2 1.4 3 3.2

Prostate 81403 Adenocarcinoma, NOS 199 87.7 - -80003 Neoplasm, malignant 12 5.3 - -80103 Carcinoma, NOS 7 3.1 - -85503 Acinar cell carcinoma 3 1.3 - -

All Others 6 2.6 - -

Bladder 81203 Transitional cell carcinoma, NOS 81 47.9 17 41.581303 Papillary transitional cell carcinoma 64 37.9 11 26.880703 Squamous cell carcinoma, NOS 5 3.0 7 17.180713 Squamous cell carcinoma, keratinizing, NOS 5 3.0 1 2.480003 Neoplasm, malignant 5 3.0 0 0.081403 Adenocarcinoma, NOS 4 2.4 1 2.480103 Carcinoma, NOS 1 0.6 1 2.4


Corpus Uteri 83803 Endometrioid adenocarcinoma, NOS - - 70 50.481403 Adenocarcinoma, NOS - - 25 18.089503 Mullerian mixed tumor - - 8 5.889303 Endometrial stromal sarcoma, NOS - - 5 3.684603 Papillary serous cystadenocarcinoma - - 4 2.985603 Adenosquamous carcinoma - - 4 2.988903 Leiomyosarcoma, NOS - - 4 2.989313 Endometrial stromal sarcoma, low grade - - 4 2.9

All Others - - 15 10.8

Ovary 81403 Adenocarcinoma, NOS - - 25 19.284603 Papillary serous cystadenocarcinoma - - 24 18.584413 Serous cystadenocarcinoma, NOS - - 13 10.080003 Neoplasm, malignant - - 11 8.584703 Mucinous cystadenocarcinoma, NOS - - 10 7.784613 Serous surface papillary carcinoma - - 9 6.983803 Endometrioid adenocarcinoma, NOS - - 8 6.280103 Carcinoma, NOS - - 4 3.184803 Mucinous adenocarcinoma - - 4 3.190603 Dysgerminoma - - 4 3.189803 Carcinosarcoma, NOS - - 2 1.590643 Germinoma - - 2 1.590803 Teratoma, malignant, NOS - - 2 1.5

All Others - - 12 9.2

SCR2006 Part02.indd 23 09-04-2010 3:28:10 AM

24

The total incident cases reported among children (0-14 years) between January and December 2006 were 706. This represents 6.6 % of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls. 403 (57.1%) cases were reported among boys and 303 (42.9%) among girls, with a male to female ratio of 133:100. Of all the cases reported

there were 573 Saudis, 106 non-Saudis and 27 of “unknown nationality”. Based on table 2-6, the total number of cases analyzed was 673 including 567 (82.2%) Saudis and 106 (16.6%) non-Saudis. Among Saudis, 327(57.8%) were male and 240 (42.3%) were female. The male to female ratio among Saudis was 137:100.

Figure 2.7 Ten Most Common Cancers among Saudi Children by Sex, 2006

Childhood cancer is very important, not only because of the age of occurrence, but also because 41.7% of the Saudi population is under 15 years of age. In addition to this, recent years have shown a breakthrough for the cure of many childhood cancers. Childhood cancers accounted for 6.9% of all cancer among Saudis. The leading cancer

among Saudi children was leukemia, which accounted for 31.7 %, followed by Brain (CNS) 14.3 % then Hodgkin’s disease 12.9 % and NHL 8.1 %. Figure 2-7 shows the top ten sites by sex and frequency, and table 2-7 shows the number and proportion of the morphological types for the most common types of cancer.



Total 330 243 573 58 48 106 15 12 27 706

Invasive 328 243 571 58 48 106 15 12 27 704

In-situ 1 0 1 0 0 0 0 0 0 1

ICD 10 * 1 3 4 0 0 0 0 0 0 4

Analyzed ** 327 240 567 58 48 106 15 12 2 673


327 240Male Female

100Leukemia

46Brain

38NHL

33Hodgkin Disease

23Bone

18Eye

14Kidney

12Adrenal Gland

11Connective, Soft Tissue

5Nasopharynx

80 33.3%30.6%

14.1%

11.6%

10.1%

7.0%

5.5%

4.3%

3.7%

3.4%

1.5%

14.6%

11.3%

5.8%

5.4%

5.4%

5.0%

4.2%

3.8%

2.9%

Leukemia

35Brain

27Hodgkin Disease

14NHL

13Bone

13Eye

12Kidney

10Connective, Soft Tissue

9Adrenal Gland

7Thyroid

Table 2.6 Distribution of Reported Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 2006

ild ood ancers in Sa di Ara ia ( 14 years)

SCR2006 Part02.indd 24 09-04-2010 3:28:10 AM

25

Table 2.7 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Children, 2006


Leukemia 98363 Precursor B-cell lymphoblastic leukemia 39 39.0 33 41.398353 Precursor cell lymphoblastic leukemia, NOS 33 33.0 27 33.898613 Acute myeloid leukemia, NOS 6 6.0 4 5.098633 Chronic myeloid leukemia, NOS 2 2.0 4 5.098013 Acute leukemia, NOS 3 3.0 2 2.598743 Acute myeloid leukemia with maturation 2 2.0 3 3.898913 Acute monocytic leukemia 3 3.0 1 1.398263 Burkitt cell leukemia 1 1.0 2 2.599103 Acute megakaryoblastic leukemia 2 2.0 1 1.3


Brain, CNS 94703 Medulloblastoma, NOS 12 26.1 12 34.393803 Glioma, malignant 7 15.2 2 5.793913 Ependymoma, NOS 7 15.2 1 2.995083 Atypical teratoid/rhabdoid tumor 3 6.5 2 5.794003 Astrocytoma, NOS 0 0.0 4 11.494403 Glioblastoma, NOS 2 4.3 2 5.794713 Desmoplastic nodular medulloblastoma 1 2.2 2 5.794733 Primitive neuroectodermal tumor, NOS 3 6.5 0 0.080003 Neoplasm, malignant 2 4.3 0 0.093903 Choroid plexus carcinoma 1 2.2 1 2.995053 Ganglioglioma, anaplastic 1 2.2 1 2.9

All Others 7 15.2 8 22.9

Hodgkin Disease 96633 Hodgkin lymphoma, nodular sclerosis, NOS 13 39.4 14 51.996523 Hodgkin lymphoma, mixed cellularity, NOS 7 21.2 5 18.596593 Hodgkin lymphoma, nodular lymphocyte predominance 5 15.2 2 7.496503 Hodgkin lymphoma, NOS 0 0.0 4 14.896513 Hodgkin lymphoma, lymphocyte-rich 3 9.1 1 3.796533 Hodgkin lymphoma, lymphocyte depletion, NOS 3 9.1 0 0.096653 Hodgkin lymphoma, nodular sclerosis, grade 1 1 3.0 1 3.796673 Hodgkin lymphoma, nodular sclerosis, grade 2 1 3.0 0 0.0

NHL 96873 Burkitt lymphoma, NOS 20 52.6 6 42.997293 Precursor T-cell lymphoblastic lymphoma 4 10.5 2 14.395903 Malignant lymphoma, NOS 3 7.9 2 14.397273 Precursor cell lymphoblastic lymphoma, NOS 2 5.3 2 14.395913 Malignant lymphoma, non-Hodgkin, NOS 2 5.3 1 7.196803 Malignant lymphoma, large B-cell, diffuse, NOS 3 7.9 0 0.096703 Malignant lymphoma, small B lymphocytic, NOS 1 2.6 0 0.096733 Mantle cell lymphoma 0 0.0 1 7.196983 Follicular lymphoma, grade 3 1 2.6 0 0.096993 Marginal zone B-cell lymphoma, NOS 1 2.6 0 0.097003 Mycosis fungoides 1 2.6 0 0.0

Bone 91803 Osteosarcoma, NOS 10 43.5 5 38.592603 Ewing sarcoma 7 30.4 5 38.591813 Chondroblastic osteosarcoma 3 13.0 1 7.788063 Desmoplastic small round cell tumor 0 0.0 1 7.791823 Fibroblastic osteosarcoma 1 4.3 0 0.091833 Telangiectatic osteosarcoma 0 0.0 1 7.793703 Chordoma, NOS 1 4.3 0 0.094733 Primitive neuroectodermal tumor, NOS 1 4.3 0 0.0

SCR2006 Part02.indd 25 09-04-2010 3:28:11 AM

26

Table 2.7 continued .....


Eye 95103 Retinoblastoma, NOS 6 33.3 6 46.295113 Retinoblastoma, differentiated 6 33.3 4 30.895123 Retinoblastoma, undifferentiated 2 11.1 3 23.189103 Embryonal rhabdomyosarcoma, NOS 2 11.1 0 0.089003 Rhabdomyosarcoma, NOS 1 5.6 0 0.095133 Retinoblastoma, diffuse 1 5.6 0 0.0

Kidney 89603 Nephroblastoma, NOS 10 71.4 10 83.380003 Neoplasm, malignant 0 0.0 1 8.383123 Renal cell carcinoma, NOS 1 7.1 0 0.089633 Malignant rhabdoid tumor 1 7.1 0 0.089643 Clear cell sarcoma of kidney 0 0.0 1 8.390643 Germinoma 1 7.1 0 0.095003 Neuroblastoma, NOS 1 7.1 0 0.0

Connective Tissue 88003 Sarcoma, NOS 2 18.2 1 10.089103 Embryonal rhabdomyosarcoma, NOS 3 27.3 0 0.093643 Peripheral neuroectodermal tumor 2 18.2 1 10.089203 Alveolar rhabdomyosarcoma 1 9.1 1 10.094733 Primitive neuroectodermal tumor, NOS 0 0.0 2 20.088063 Desmoplastic small round cell tumor 0 0.0 1 10.088523 Myxoid liposarcoma 0 0.0 1 10.088913 Epithelioid leiomyosarcoma 0 0.0 1 10.089633 Malignant rhabdoid tumor 1 9.1 0 0.091503 Hemangiopericytoma, malignant 1 9.1 0 0.093703 Chordoma, NOS 0 0.0 1 10.094903 Ganglioneuroblastoma 1 9.1 0 0.095003 Neuroblastoma, NOS 0 0.0 1 10.0

Adrenal Gland 95003 Neuroblastoma, NOS 9 75.0 7 77.883703 Adrenal cortical carcinoma 1 8.3 1 11.194903 Ganglioneuroblastoma 2 16.7 0 0.088063 Desmoplastic small round cell tumor 0 0.0 1 11.1

Thyroid 82603 Papillary adenocarcinoma, NOS 1 50.0 4 57.183403 Papillary carcinoma, follicular variant 0 0.0 2 28.683503 Nonencapsulated sclerosing carcinoma 0 0.0 1 14.385103 Medullary carcinoma, NOS 1 50.0 0 0.0

Nasopharynx 80203 Carcinoma, undifferentiated, NOS 3 60.0 0 0.080103 Carcinoma, NOS 1 20.0 0 0.080723 Squamous cell carcinoma, large cell, nonkeratinizing, NOS 0 0.0 1 100.089003 Rhabdomyosarcoma, NOS 1 20.0 0 0.0

SCR2006 Part02.indd 26 09-04-2010 3:28:11 AM

27

Cancer in the 13 Administrative Regions of the Kingdom, 2006

Figure 2.8.2 Makkah Region, 2006 (Percentage Distribution)

Figure 2.8.1 Riyadh Region, 2006 (Percentage Distribution)

The following bar charts list the most common cancer sites in the 13 administrative regions of Saudi Arabia by sex. These sites are listed on the basis of the total number of cases for each site reported by permanent address (region) of the patient at the time of diagnosis. In most regions breast cancer was the leading cancer among women, while among men Colo-rectal, NHL, liver and

Leukemia interchange. It is worth noting that the major regions such as Riyadh, Makkah and Eastern Province represent the majority of cases. This can be attributed to the increasing number of people seeking medical attention in these urbanized cities with modern hospital facilities where permanent addresses may not be documented in source records.

0 10 20 30 40

Other sitesHodgkin Disease

ThyroidBrain, CNS

SkinBladder

LungProstate

LeukemiaNHLLiver

Colo-rectal

Males (1022)

0 10 20 30 40 0 10 20 30 40

Females (1170) All (2192)

Other Sites

Skin

Hodgkin Disease

Corpus Uteri

Ovary

Liver

Leukemia

NHL

Colo-rectal

Thyroid

Breast

Other Sites

Prostate

Skin

Hodgkin Disease

Lung

Liver

Leukemia

NHL

Thyroid

Colo-rectal

Breast12.3 23.5 12.9

11.0

8.1

7.6

6.6

6.3

3.6

3.2

3.2

3.1

34.3

12.1

9.9

6.4

5.5

3.7

3.2

3.1

2.9

2.6

27.3

9.48.9

7.96.8

5.44.13.93.93.63.6

30.1

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

Hodgkin Disease

Other Sites

Skin

Leukemia

Bladder

Stomach

Liver

Lung

Prostate

NHL

Colo-rectal

Other Sites

Skin

Cervix Uteri

Ovary

Stomach

Leukemia

Corpus Uteri

NHL

Thyroid

Colo-rectal

Breast

Other Sites

Skin

Prostate

Liver

Stomach

Leukemia

Lung

Thyroid

NHL

Colo-rectal

Breast

Males (929) Females (958) All (1887)

11.2 25.1

9.2

8.7

5.3

4.7

4.2

2.9

2.9

2.8

2.4

31.8

13.0

10.2

6.9

5.3

4.8

4.6

4.3

4.0

3.7

3.4

39.7

8.6

7.5

7.4

6.1

5.7

5.2

5.14.4

4.2

34.6

SCR2006 Part02.indd 27 09-04-2010 3:28:11 AM

28

Figure 2.8.5 Northern Region, 2006 (Percentage Distribution)

Figure 2.8.4 Madinah Region, 2006 (Percentage Distribution)

Cancer in the 13 Administrative Regions of the Kingdom

Figure 2.8.3 Eastern Region, 2006 (Percentage Distribution)

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

Other Sites

Brain, CNS

Bladder

Hodgkin Disease

Prostate

Liver

Lung

Leukemia

NHL

Colo-rectal

Other Sites

Cervix Uteri

Liver

Ovary

Hodgkin Disease

Leukemia

NHL

Colo-rectal

Thyroid

Breast

Other Sites

Brain, CNS

Hodgkin Disease

Liver

Lung

Leukemia

Thyroid

NHL

Colo-rectal

Breast10.3

9.8

8.7

8.2

6.0

5.6

4.7

3.9

3.9

39.0

28.5 15.5

10.2

8.7

5.4

5.2

4.1

3.8

3.5

3.4

9.4

7.5

6.9

6.8

4.9

4.6

4.3

2.8

27.4 37.2


0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

ThyroidBrain, CNS

KidneyBladder

Other SitesHodgkin Disease

LungSkin

LeukemiaNHL

Colo-rectalLiver

LungStomach

Liver

Other SitesLeukemia

Ovary

EsophagusSkin

Brain, CNSThyroid

NHLColo-rectal

Breast

Lung

Brain, CNS


Leukemia

Thyroid

Skin

Liver

NHL

Colo-rectal

Breast


11.59.79.0

8.26.8

5.74.73.93.93.9

3.928.7 25.5

2.52.52.53.23.54.14.5

5.46.77.6

10.811.1

10.3

8.3

7.3

5.6

5.4

5.2

4.7

4.0

3.035.1

21.0

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

KidneyLung

PancreasStomach

Other SitesThyroid

NHLBrain, CNS

Hodgkin DiseaseColo-rectal

BladderLeukenia

Thyroid

Kidney

Other Sites

Corpus Uteri

Skin

Lung

Gall bladder, etc.

Colo-rectal

Leukemia

Breast

ThyroidBrain, CNS

Other Sites

PancreasSkinNHL

KidneyLung

Hodgkin DiseaseBladder

Colo-rectalBreast

Leukemia


20.89.4

7.5

7.55.75.7

3.83.8

3.83.83.8

24.5 29.7

5.4

5.4

5.4

5.4

5.4

5.4

5.4

13.5

18.9 17.87.8

6.75.65.6

4.44.44.44.43.33.33.3

28.9

SCR2006 Part02.indd 28 09-04-2010 3:28:12 AM

29

Figure 2.8.7 Jazan Region, 2006 (Percentage Distribution)

Figure 2.8.8 Hail Region, 2006 (Percentage Distribution)


Figure 2.8.6 Qassim Region, 2006 (Percentage Distribution)

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40


Brain, CNS

Prostate

Skin

Nasopharynx

Other Sites

Thyroid

Liver

Leukemia

NHL

Hodgkin Disease

Colo-rectal

EsophagusOvary

Lung

LeukemiaStomach

Other SitesMultiple Myeloma

NHLCorpus Uteri

SkinHodgkin Disease

Colo-rectalThyroidBreast

Liver

Other Sites

Nasopharynx

Brain, CNS

Skin

NHL

Leukemia

Hodgkin Disease

Colo-rectal

Thyroid

Breast10.7 27.2 14.2

10.5

9.0

7.5

6.05.4

4.84.2

3.03.0

32.2

15.07.5

6.44.6

3.53.52.92.32.32.32.32.3

17.9

8.8

8.8

8.8

6.9

5.7

5.0

5.0

4.4

4.4

31.4

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

NasopharynxMouth

Hodgkin DiseaseLung

LiverOther Sites

StomachTongue

Brain, CNSColo-rectal

SkinNHL

Colo-rectalGall bladder, etc.

Liver

EsophagusThyroid


Pancreas

NHLLeukemia

BreastTongue

Mouth

Brain, CNS

Other Sites

Hodgkin Disease

Stomach

Leukemia

Skin

Colo-rectal

Breast

Tongue

NHL

Mouth


11.5 14.19.19.1

5.14.04.0

3.03.03.03.0

29.3

10.2

8.5

7.9

5.6

5.1

5.1

5.1

4.5

4.5

4.0

39.5

7.16.1

9.07.77.7

6.46.46.46.4

5.13.8

3.825.6

0 10 20 30 40 0 10 20 30 40


19.010.1

8.97.67.6

6.33.83.8

3.83.83.8

21.5

31.310.8

7.2

6.06.0

4.84.8

3.63.6

2.42.4

16.9

16.0

12.3

9.37.4

6.2

5.6

5.6

4.3

3.1

3.1

27.2

0 10 20 30 40

Gall bladder, etc.Stomach

Corpus Uteri

Hodgkin DiseaseSkin

Other SitesKidney

Colo-rectalNasopharynx

Brain, CNSThyroidBreast

Nasopharynx

Leukemia

Kidney

Hodgkin Disease

Brain, CNS

Other Sites

Stomach

Skin

Thyroid

Colo-rectal

Breast

KidneyConnective, Soft Tissue

Brain, CNS

LarynxHodgkin Disease

Other SitesNHL

LeukemiaThyroid

StomachSkin

Colo-rectal

SCR2006 Part02.indd 29 09-04-2010 3:28:12 AM

30

Figure 2.8.11 Asir Region, 2006 (Percentage Distribution)

Figure 2.8.10 Baha Region, 2006 (Percentage Distribution)


Figure 2.8.9 Najran Region, 2006 (Percentage Distribution)

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

ProstateLung

StomachNasopharynx

KidneyBladder

EyeOther Sites

LeukemiaHodgkin Disease

Colo-rectalSkinNHLLiver

KidneyPancreasStomach

Leukemia

ThyroidNHL

Other Sites

Brain, CNSOvaryLiver

Colo-rectalCervix Uteri

Breast

Stomach

Brain, CNSOther Sites

Cervix UteriKidney

Hodgkin DiseaseBreast

SkinLeukemia

Colo-rectalNHLLiver


23.8 13.3 16.7

9.36.56.5

5.65.6

4.6

3.73.73.73.7

30.6

8.96.76.76.76.76.7

22.2

4.44.44.44.44.4

12.79.5

6.36.36.3

3.23.23.23.23.23.23.2

12.7

0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

BoneLiver

StomachLung

Melanoma of SkinBladder

Other Sites

EsophagusHodgkin Disease

SkinLeukemia

NHLColo-rectal

Placenta

Ovary

Gall bladder, etc.

NHL

Other Sites

Corpus Uteri

Skin

Leukemia

Colo-rectal

Thyroid

Breast

Esophagus

LungOther Sites

StomachLiver

Hodgkin DiseaseThyroidBreast

SkinNHL

LeukemiaColo-rectal


11.5 14.0 9.99.9

9.07.2

6.35.45.4

3.63.63.6

3.632.4

12.08.0

8.0

6.0

6.0

6.04.04.0

4.028.0

11.511.5

8.28.2

6.66.6

4.94.9

3.33.33.3

16.4

0 10 20 30 40 0 10 20 30 400 10 20 30 40

Brain, CNS

Lung

Bladder

Prostate

Other Sites

Stomach

Liver

NHL

Colo-rectal

Leukemia

Skin

Hodgkin Disease

Liver

Ovary

Stomach

Other Sites

NHL

Skin

Leukemia

Colo-rectal

Thyroid

Breast

Liver

Other Sites

Bladder

Prostate

Stomach

ThyroidNHL

BreastSkin

Leukemia

Colo-rectal


9.2 16.4 9.0

8.58.2

8.2

6.56.4

5.75.5

3.7

3.534.7

11.6

9.67.9

7.2

5.1

4.13.8

3.4

3.4

27.4

9.2

8.5

7.9

7.5

7.2

6.9

5.6

3.0

3.0

32.1

SCR2006 Part02.indd 30 09-04-2010 3:28:13 AM

31

Figure 2.8.12 Tabuk Region, 2006 (Percentage Distribution)

Figure 2.8.13 Jouf Region, 2006 (Percentage Distribution)


0 10 20 30 40 0 10 20 30 40 0 10 20 30 40

Hodgkin Disease

Bone

Ovary

Skin

Other Sites

Pancreas

NHL

Colo-rectal

Leukemia

Thyroid

Breast

Liver

Thyroid

Bladder

Skin

Other Sites

Colo-rectal

Lung

Leukemia

Hodgkin Disease

Brain, CNS

NHL

Hodgkin Disease

Other Sites

Lung

Bladder

Brain, CNS

Skin

Colo-rectal

NHL

Leukemia

Thyroid

Breast8.7 22.1 10.9

8.4

7.7

7.3

5.85.1

5.1

5.1

3.6

3.637.2

12.5

8.1

5.9

5.9

4.4

4.43.7

2.9

2.9

27.2

8.0

7.2

7.26.5

5.8

5.8

5.8

4.3

3.637.0


0 10 20 30 40 0 10 20 30 40 0 10 20 30 40 50

Corpus UteriLung

Colo-rectalStomach

ThyroidHodgkin Disease

Other Sites

MouthOvary

SkinPancreas

NHLBreast

Connective, Soft TissueBoneLiver

Colo-rectal

Prostate

LeukemiaHodgkin Disease

Brain, CNSKidney

Other Sites

StomachThyroid

LungSkinNHL

Pancreas

LeukemiaOther Sites

Hodgkin DiseaseBrain, CNS

Colo-rectalStomach

ThyroidLungSkin

BreastNHL12.9 18.5 11.3

8.17.3

4.84.8

4.04.04.0

4.03.23.2

41.1

9.37.47.4

5.63.73.73.73.73.73.73.7

25.9

7.15.75.7

4.34.34.34.34.34.34.34.34.34.3

25.7


SCR2006 Part02.indd 31 09-04-2010 3:28:13 AM

32

Worldwide, it is estimated that 10,862,496 people developed cancer in 2002. Of these, 53.7% were in developing countries and 46.5% were in developed countries. According to 2002 estimates, the most common cancer site worldwide among men was lung cancer, followed by prostate then stomach then colo-rectal. However; in developed countries prostate was the leading cancer followed by lung, colo-rectal, and stomach, while in developing countries, lung cancer

Figure 2.9.A Comparison of ASR* for Saudi Males with Selected Countries**

Figure 2.9.B Comparison of ASR* for Saudi Females with Selected Countries**

was first followed by stomach, liver, esophagus and colo-rectal cancers. In women, the most common cancer site was breast followed by cervix uteri then colo-rectal then lung cancers. Among women, breast cancer was the most common followed by colo-rectal, lung and corpus uteri cancers in developed countries. While in the developing countries breast cancer was the leading cancer followed by cancers of the cervix, stomach and lung.

International Comparison of Age-Standardized Incidence Rates

* ASR Per 100,000 ** Source for this information is summarized on page 64

0 50 100 150 200 250 300 350 400 450

401.6

356.7

301.9

293.3

282.8

269.6

189.5

179.6

156.7

137.2

116.0

101.1

87.8

82.7

79.3

United Arab Emirates

Saudi Arabia

Jordan

Oman

Thailand, Bangkok

Kuwait

Bahrain

Qatar

Poland

Wales

United States (All Races)

Norway

Australia

Canada

Croatia

70.9

459.6

451.9

421.8

354.8

348.0

320.0

249.8

168.6

157.6

125.8

117.4

97.6

83.6

74.8

0 50 100 150 200 250 300 350 400 450 500

Saudi Arabia

United Arab EmiratesJordan

OmanThailand, Bangkok

Kuwait

Bahrain

Qatar

Poland

Wales

Norway


Australia

Croatia

Canada

SCR2006 Part02.indd 32 09-04-2010 3:28:14 AM

PART IIICANCER INCIDENCE FOR MOST COMMON SITES

2006

SCR2006 Part03.indd 33 09-04-2010 3:28:38 AM

34

SCR2006 Part03.indd 34 09-04-2010 3:28:38 AM

35

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative

Table 3.1 Most Common Cancers among Saudis, 2006

frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2006.

Cancer Incidence for Most Common Sites, 2006

Cancer Male Female All %

Breast 18 981 999 12.4Colo-rectal 414 370 784 9.7NHL 351 234 585 7.3Thyroid 117 424 541 6.7Leukemia 296 212 508 6.3Liver 291 125 416 5.2Skin 193 134 327 4.1Lung 232 80 312 3.9Hodgkin Disease 173 120 293 3.6Stomach 162 113 275 3.4Prostate 228 - 228 2.8Bladder 169 42 211 2.6Corpus Uteri - 140 140 1.7Ovary - 132 132 1.6Others 1254 1049 2303 28.6

Total 3898 4156 8054 100.0

SCR2006 Part03.indd 35 09-04-2010 3:28:38 AM

36

Figure 3.1.2 Stage Distribution of Female Breast Cancer, 2006

ig re Age-Specific Incidence Rate (AIR) for emale reast ancer in Sa di Ara ia

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2006

There were 981 female breast cancer cases for year 2006. Breast cancer ranked first among females accounting for 23.6% of all newly diagnosed female cancers (4,156) in year 2006. The ASR was 18.4/100,000 for female population. The five regions with the highest

ASR were Eastern region at 25.0/100,000, Riyadh region at 22.6 /100,000, Makkah region at 18.0/100,000, Madinah region at 17/100,000 and Tabuk region at 17/100,000. The median age at diagnosis was 47 years (Range 91-107 years).

emale reast ( )

0

10

20

30

40

50

60

70

female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Total %

8500 Infiltrating duct carcinoma, NOS 741 75.58520 Lobular carcinoma, NOS 62 6.38010 Carcinoma, NOS 40 4.18000 Neoplasm, malignant 22 2.28522 Infiltrating duct and lobular carcinoma 15 1.58510 Medullary carcinoma, NOS 13 1.38523 Infiltrating duct mixed with other types of carcinoma 12 1.28541 Paget disease and infiltrating duct carcinoma of breast 12 1.28140 Adenocarcinoma, NOS 11 1.19020 Phyllodes tumor, malignant 10 1.0

Others 43 4.4

13.0%

26.6%45.5%

14.9%

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 36 09-04-2010 3:28:38 AM

37

Figure 3.1.4 Comparison of ASR for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.1.3 ASR* Regional Distribution of Female Breast Cancer in Saudi Arabia, 2006


0 5 10 15 20 25 30

Jazan

Najran

Baha

Asir

Jouf

Northern

Qassim

Hail

Tabuk

Madinah

Makkah

Riyadh

Eastern 25.0

22.6

18.0

17.0

17.0

15.4

15.0

13.0

9.8

9.4

5.2

4.5

2.6

0 20 40 60 80 100 120

Oman

Saudi Arabia


Thailand, Bangkok

Jordan

Poland

Kuwait

Qatar

Bahrain

Norway

Wales


Canada

Australia 117.3

97.3

89.5

89.0

73.7

53.4

48.2

46.6

44.2

27.6

24.3

22.8

21.9

18.0

SCR2006 Part03.indd 37 09-04-2010 3:28:39 AM

38

ig re Age-Specific Incidence Rate (AIR) for olo-rectal ancer in Sa di Ara ia

Table 3.2.1 Morphological Distribution of Colo-rectal Cancer in Saudi Arabia, 2006

Figure 3.2.2 Stage Distribution of Colo-rectal Cancer, 2006

There were 784 cases of colo-rectal cancer accounting for 9.7% of all newly diagnosed cases in year 2006. This cancer ranked first among male population and third among female population. It affected 414 (52.8%) males and 370 (47.2%) females with a male to female ratio of 112:100. The overall ASR was 8.6 /100,000. ASR for males was 9.7/100,000 and for females 8.6/100,000.

The five regions with the highest ASR were Riyadh region at 12.4/100,000, Eastern region at 10.0/100,000, Madinah region at 8.7/100,000, Makkah region at 8.6 /100,000 and Tabuk region at 6.4/100,000. The median age at diagnosis was 61 years among males (range 17-110 years) and 57 years among females (range 20-109 years).

olo-rectal ( - )

0

10

20

30

40

50

60

70

80

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male % Female %

8140 Adenocarcinoma, NOS 313 75.6 277 74.98480 Mucinous adenocarcinoma 34 8.2 27 7.38000 Neoplasm, malignant 11 2.7 22 5.98261 Adenocarcinoma in villous adenoma 11 2.7 8 2.28144 Adenocarcinoma, intestinal type 9 2.2 6 1.68481 Mucin-producing adenocarcinoma 9 2.2 6 1.68263 Adenocarcinoma in tubulovillous adenoma 6 1.4 7 1.98010 Carcinoma, NOS 6 1.4 5 1.48490 Signet ring cell carcinoma 1 0.2 7 1.9

Others 14 3.4 5 1.4

12.1%

39.1% 26.8% 38.6%

15.1%24.9%

21.4% 38.9%

13.5%23.3%

24.2%

22.0%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 38 09-04-2010 3:28:39 AM

39

Figure 3.2.4 Comparison of ASR for Colo-rectal Cancer among Saudis with ASR in Selected Countries**

Figure 3.2.3 ASR* Regional Distribution of Colo-rectal Cancer in Saudi Arabia, 2006


12.312.4

9.011.0

9.57.9

7.69.5

6.16.7

5.26.6

3.08.8

6.2

6.33.0

4.92.6

5.33.4

3.00.7

1.9

5.43.0

0 2 4 6 8 10 12 14

Jazan

Jouf

Najran

Northern

Baha

Asir

Hail

Qassim

Tabuk

Makkah

Madinah

Eastern

Riyadh

40.059.9

36.752.0

26.341.0

26.035.3

16.228.8

14.116.1

12.615.2

8.714.3

8.69.7

7.18.6

5.78.6

6.57.1

0 10 20 30 40 50 60 70


Oman

Jordan

Saudi Arabia

Bahrain

Kuwait

Qatar

Poland


Wales

Australia

Canada

SCR2006 Part03.indd 39 09-04-2010 3:28:39 AM

40

ig re Age-Specific Incidence Rate (AIR) for N in Sa di Ara ia

Ta le orp ological Distri tion of N in Sa di Ara ia

There were 585 cases of Non-Hodgkin Lymphoma accounting for 7.3 % of all newly diagnosed cancers in year 2006. This cancer ranked second among male population and fourth among female population. It affected 351(60%) males and 234 (40%) females with a male to female ratio of 150:100. The overall ASR was 5.7/100,000. ASR for males was 6.6/100,000 and

. 100,000 for females. The five regions with the highest ASR were Riyadh region at 7.3/100,000, Tabuk region at 6.6/100,000,Eastern region at 6.5/100,000, Madinah region at 6.2/100,000 and Makkah regions at 5/100,000. The median age at diagnosis was 50 years among males (range 2-102 years) and 54 years among females (range 2-96 years).

ig re Stage Distri tion of N ancer

Non- odg in mp oma ( - )

0

10

20

30

40

50

60

70

80

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


9680 Malignant lymphoma, large B-cell, diffuse, NOS 143 40.7 108 46.29590 Malignant lymphoma, NOS 31 8.8 20 8.59687 Burkitt lymphoma, NOS 28 8.0 12 5.19591 Malignant lymphoma, non-Hodgkin, NOS 21 6.0 17 7.39699 Marginal zone B-cell lymphoma, NOS 23 6.6 12 5.19670 Malignant lymphoma, small B lymphocytic, NOS 11 3.1 10 4.39702 Mature T-cell lymphoma, NOS 15 4.3 6 2.69700 Mycosis fungoides 7 2.0 11 4.79714 Anaplastic large cell lymphoma, T cell and Null cell type 10 2.8 4 1.79690 Follicular lymphoma, NOS 11 3.1 2 0.99698 Follicular lymphoma, grade 3 7 2.0 6 2.69675 Malignant lymphoma, mixed small and large cell, diffuse 7 2.0 2 0.99691 Follicular lymphoma, grade 2 6 1.7 3 1.39729 Precursor T-cell lymphoblastic lymphoma 7 2.0 2 0.99695 Follicular lymphoma, grade 1 3 0.9 5 2.1

Others 21 6.0 14 6.0

31.9% 35.0%

16.5%16.5%

32.1%

17.5% 15.8%

34.6% 32.0%

16.9% 16.2%

34.9%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 40 09-04-2010 3:28:40 AM

41

ig re ASR Regional Distri tion of N ancer in Sa di Ara ia

ig re omparison of ASR for N ancer among Sa dis it ASR in Selected o ntries


6.97.6

5.87.4

7.85.1

6.95.5

3.86.2

5.24.8

1.96.0

3.24.3

1.84.8

2.04.1

2.12.5

0.02.8

0.41.8

0 1 2 3 4 5 6 7 8 9

Hail

Northern

Jazan

Qassim

Najran

Asir

Baha

Jouf

Makkah

Madinah

Eastern

Tabuk

Riyadh

14.419.3

11.216.6

10.915.5

9.212.9

9.112.7

8.411.2

7.010.8

6.27.9

4.57.7

4.86.6

4.45.7

3.65.2

3.04.6

3.13.8

0 2 4 6 8 10 12 14 16 18 20

Thailand, Bangkok

Jordan

Poland


Saudi Arabia

Oman

Bahrain

Kuwait

Qatar

Norway

Wales


Australia

Canada

SCR2006 Part03.indd 41 09-04-2010 3:28:40 AM

42

There were 541 cases of thyroid cancer for year 2006. This cancer ranked second among female population and twelfth among male population. It affected 117(21.6%) males and 424 (78.4%) females with a male to female ratio of 28:100. The overall ASR was 4.3/100,000. ASR was 2.1/100,000 for males and 6.5/100,000 for females.

ig re Stage Distri tion of T roid ancer

The five regions with the highest ASR were Riyadh region at 6/100,000, Tabuk region at 5.7/100,000, Eastern region at 5.1/100,000, Qassim region at 5 /100,000 and Hail region at 4/100,000. The median age at diagnosis was 47 years among males (range 12-84 years) and 39 years among females (range 9-109 years).

Ta le orp ological Distri tion of T roid ancer in Sa di Ara ia

ig re Age-Specific Incidence Rate (AIR) for T roid ancer in Sa di Ara ia

T roid ( )

02468

1012141618202224

femalemale

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

AIR

(per

100

,000

)


8260 Papillary adenocarcinoma, NOS 71 60.7 232 54.78340 Papillary carcinoma, follicular variant 12 10.3 69 16.38341 Papillary microcarcinoma 6 5.1 34 8.08343 Papillary carcinoma, encapsulated 2 1.7 14 3.38335 Follicular carcinoma, minimally invasive 3 2.6 12 2.88330 Follicular adenocarcinoma, NOS 5 4.3 9 2.18000 Neoplasm, malignant 3 2.6 8 1.98510 Medullary carcinoma, NOS 3 2.6 8 1.98021 Carcinoma, anaplastic, NOS 3 2.6 6 1.48290 Oxyphilic adenocarcinoma 3 2.6 6 1.48344 Papillary carcinoma, columnar cell 1 0.9 7 1.7

Others 5 4.3 19 4.5

18.8%12.0%

33.3%

35.9%

23.1%6.8%

41.0%

29.0%

22.2%7.9%

39.4%

30.5%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 42 09-04-2010 3:28:41 AM

43

ig re ASR Regional Distri tion of T roid ancer in Sa di Ara ia

ig re omparison of ASR for T roid ancer among Sa dis it ASR in Selected o ntries


0 1 2 3 4 5 6 7 8 9 10

9.52.5

8.52.8

7.13.1

7.22.8

4.43.6

5.61.3

4.22.5

5.70.8

3.03.3

1.83.5

4.20.0

1.10.0

0.80.0Najran

Jazan

Baha

Jouf

Northern

Asir

Madinah

Makkah

Hail

Qassim

Eastern

Tabuk

Riyadh

0 2 4 6 8 10 12 14 16 18 20

16.75.0

14.24.0

11.83.8

10.43.1

8.33.3

8.22.1

6.52.1

6.91.7

4.92.4

5.71.4

6.30.2

4.61.1

3.91.2

Jordan

Thailand, Bangkok

Oman

Poland

Norway


Saudi Arabia

Bahrain

Kuwait

Australia


Qatar

Canada

SCR2006 Part03.indd 43 09-04-2010 3:28:41 AM

44

ig re Age-Specific Incidence Rate (AIR) for e emia in Sa di Ara ia

Ta le orp ological Distri tion of e emia in Sa di Ara ia

There were 508 cases of leukemia accounting for 6.3 % of all newly diagnosed cancers in year 2006. This cancer ranked third for males and fifth for females and affected 296(58.3%) males and 212 (41.7%) females with a male to female ratio of 140:100. The overall ASR was 4/100,000. ASR for males was 4.5/100,000 and

3. 1000,000 for females. The five regions with the highest ASR were Northern region at 9.8/100,000, Riyadh region at 5/100,000, Eastern region at 4.8/100,000, Tabuk region at 4.7/100,000 and Asir region at 3.6/100,000. The median age at diagnosis is 25 years among males (range 0-99 years) and 28 years among females (range 1-88 years).

e emia ( - )

male female

0

5

10

15

20

25

30

35

40

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


9836 Precursor B-cell lymphoblastic leukemia 53 17.9 36 17.09835 Precursor cell lymphoblastic leukemia, NOS 54 18.2 34 16.09861 Acute myeloid leukemia, NOS 35 11.8 30 14.29863 Chronic myeloid leukemia, NOS 31 10.5 33 15.69823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 31 10.5 11 5.29891 Acute monocytic leukemia 14 4.7 7 3.39866 Acute promyelocytic leukemia, t(15;17) (q22; q11-12) 11 3.7 7 3.39800 Leukemia, NOS 12 4.1 4 1.99874 Acute myeloid leukemia with maturation 8 2.7 7 3.39801 Acute leukemia, NOS 10 3.4 4 1.99867 Acute myelomonocytic leukemia 4 1.4 8 3.89837 Precursor T-cell lymphoblastic leukemia 7 2.4 3 1.49873 Acute myeloid leukemia without maturation 2 0.7 4 1.99940 Hairy cell leukemia 4 1.4 2 0.99945 Chronic myelomonocytic leukemia, NOS 1 0.3 5 2.49805 Acute biphenotypic leukemia 4 1.4 1 0.59826 Burkitt cell leukemia 2 0.7 3 1.49872 Acute myeloid leukemia, minimal differentiation 2 0.7 3 1.49910 Acute megakaryoblastic leukemia 3 1.0 2 0.9

Others 8 2.7 8 3.8

SCR2006 Part03.indd 44 09-04-2010 3:28:41 AM

45

ig re omparison of ASR for e emia among Sa dis it ASR in Selected o ntries

ig re ASR Regional Distri tion of e emia in Sa di Ara ia


10.09.5

4.85.2

3.46.1

5.14.2

3.43.8

2.93.2

2.14.0

1.44.6

1.73.8

2.42.8

2.32.1

0.42.5

1.50.3

0 1 2 3 4 5 6 7 8 9 10 11 12

Jazan

Hail

Jouf

Najran

Qassim

Madinah

Baha

Makkah

Asir

Tabuk

Eastern

Riyadh

Northern

9.314.5

9.712.6

7.711.4

7.011.0

6.510.7

4.68.1

4.77.6

4.66.3

6.44.4

4.25.5

2.75.9

3.44.5

4.02.9

2.32.6

0 2 4 6 8 10 12 14 16

Saudi Arabia


Thailand, Bangkok

Oman

Jordan

Poland

Kuwait

Qatar

Bahrain

Wales


Australia

Norway

Canada

SCR2006 Part03.indd 45 09-04-2010 3:28:42 AM

46

ig re Age-Specific Incidence Rate (AIR) for i er ancer in Sa di Ara ia

ig re Stage Distri tion of i er ancer

Ta le orp ological Distri tion of i er ancer in Sa di Ara ia

There were 416 cases of liver cancer accounting for 5.2% of all newly diagnosed cases in year 2006. This cancer ranked fourth in males, and ninth in females and affected 291 (70%) males and 125 (30%) females with a male to female ratio of 233:100. The over all ASR was 5.3/100,000. ASR was 7.5/100,000 for males and 3.1/100,000 for

females. The five regions with the highest ASR were Najran region at 10/100,000, Riyadh region at 8/100,000, Madinah region at 6.6/100,000, Eastern region at 5/100,000 and Makkah region at 3.5/100,000. The median age at diagnosis was 67 years in males (range 0-105 years) and 64 years in female (range 0- 93 years).

i er ( )

0

20

40

60

80

100

120

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


8170 Hepatocellular carcinoma, NOS 219 75.3 79 63.28000 Neoplasm, malignant 35 12.0 17 13.68160 Cholangiocarcinoma 13 4.5 9 7.28010 Carcinoma, NOS 5 1.7 5 4.08140 Adenocarcinoma, NOS 4 1.4 4 3.28970 Hepatoblastoma 2 0.7 2 1.6

Others 13 4.5 9 7.2

63.2% 6.9%

16.2%

13.7%

60.8% 7.2%

20.0%

12.0%

62.5% 7.0%

17.3%

13.2%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 46 09-04-2010 3:28:42 AM

47

ig re omparison of ASR for i er ancer among Sa dis it ASR in Selected o ntries

ig re ASR Regional Distri tion of i er ancer in Sa di Ara ia


2.517.4

4.711.2

3.39.9

4.25.8

1.85.2

2.14.4

4.61.6

1.54.3

0.04.6

0.42.2

1.10.6

1.30.0

0.70.0

0 2 4 6 8 10 12 14 16 18 20

Hail

Northern

Jazan

Baha

Jouf

Qassim

Tabuk

Asir

Makkah

Eastern

Madinah

Riyadh

Najran

7.615.1

4.313.4

3.17.5

3.27.2

2.47.1

3.15.2

2.06.0

1.75.6

1.74.4

1.73.1

1.22.6

0.82.3

0 2 4 6 8 10 12 14 16

Norway


Poland

Oman

Canada

Australia

Bahrain


Kuwait

Saudi Arabia

Thailand, Bangkok

Qatar

SCR2006 Part03.indd 47 09-04-2010 3:28:43 AM

48

S in (Non- elanoma) ( )

There were 327 cases of skin cancer accounting for 4.1% of all newly diagnosed cases in year 2006. This cancer ranked seventh for males and females. It affected 193(59%) males and 134(41%) females with a male to female ratio of 144:100. The overall ASR was 3.8/100,000. ASR was 4.6/100,000 for males and 3/100,000

ig re Stage Distri tion of S in ancer in Sa di Ara ia

for females. The five regions with the highest ASR were Jouf region at 5.7/100,000, Tabuk region at 5.6/100,000, Asir region at 4.8/100,000, Madinah region at 4.7/100,000 and Riyadh region at 3.4/100,000. The median age at diagnosis was 68 years among males (range 12-101 years) and 62 years among female (range 14-109 years).

ig re Age-Specific Incidence Rate (AIR) for S in ancer in Sa di Ara ia

Ta le orp ological Distri tion of S in ancer in Sa di Ara ia

0

10

20

30

40

50

60

70

80

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


8090 Basal cell carcinoma, NOS 91 47.2 55 41.08070 Squamous cell carcinoma, NOS 43 22.3 33 24.68071 Squamous cell carcinoma, keratinizing, NOS 18 9.3 8 6.08832 Dermatofibrosarcoma, NOS 10 5.2 10 7.58097 Basal cell carcinoma, nodular 5 2.6 7 5.28094 Basosquamous carcinoma 6 3.1 5 3.78410 Sebaceous adenocarcinoma 3 1.6 4 3.08098 Adenoid basal carcinoma 3 1.6 3 2.28091 Multifocal superficial basal cell carcinoma 1 0.5 3 2.28092 Infiltrating basal cell carcinoma, NOS 4 2.1 0 0.0

Others 9 4.7 6 4.5

37.3%

7.8%52.3%

2.6%35.8%

1.5%

56.7%6.0% 7.0%

36.7%2.1%

54.1%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 48 09-04-2010 3:28:43 AM

49

ig re omparison of ASR for S in ancer among Sa dis it ASR in Selected o ntries

ig re ASR Regional Distri tion of S in ancer in Sa di Ara ia


4.76.6

4.07.2

4.15.5

3.95.4

2.64.2

6.41.7

0.0

4.42.2

3.93.0

2.82.1

3.42.6

2.83.0

1.10.9

2.0

0 1 2 3 4 5 6 7 8

Jazan

Northern

Eastern

Makkah

Qassim

Hail

Baha

Najran

Riyadh

Madinah

Asir

Tabuk

Jouf

0 2 4 6 8 10 12 14 16

10.315.3

10.914.6

5.36.6

4.15.1

3.04.6

3.63.4

2.53.7

1.93.9

1.51.5

0.81.0

Canada

Kuwait

Bahrain


Thailand, Bangkok

Saudi Arabia

Oman

Qatar

Poland

Norway

SCR2006 Part03.indd 49 09-04-2010 3:28:43 AM

50

ig re Age-Specific Incidence Rate (AIR) for ng ancer in Sa di Ara ia

Ta le orp ological Distri tion of ng ancer in Sa di Ara ia

There were 312 cases of lung cancer accounting for 3.9% of all diagnosed cases in year 2006. Lung cancer ranked fifth among male population and thirteenth among female population. It affected 232 (74.4 %) males and 80 (25.6%) females with a male to female ratio of 290:100. The overall ASR was 4.1/100,000. ASR was 6.1/100,000 for males and 2/100,000 for females.

The five regions with the highest ASR were Eastern region at 6.2/100,000, Northern region at 5.0/100,000, Tabuk region at 4.5/100,000, Riyadh region at 4.4/100,000 and, Makkah and Jouf region at 4.3 /100,000. The median age at diagnosis was 67 years among males (range 23-100 years) and 62 years among females (range 17-91 years).

ig re Stage Distri tion of ng ancer

ng ( - )

0

10

20

30

40

50

60

70

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

10.3%

13.8%

24.6%

51.3%

40.0%

13.8% 10.0%

36.3%

28.5%

13.8%10.3%

47.4%

Male AllFemale

Distant Localised

RegionalUnknown


8140 Adenocarcinoma, NOS 51 22.0 32 40.08070 Squamous cell carcinoma, NOS 46 19.8 5 6.38000 Neoplasm, malignant 23 9.9 11 13.88041 Small cell carcinoma, NOS 29 12.5 5 6.38046 Non-small cell carcinoma 27 11.6 6 7.58010 Carcinoma, NOS 10 4.3 4 5.08012 Large cell carcinoma, NOS 8 3.4 3 3.88250 Bronchiolo-alveolar adenocarcinoma, NOS 9 3.9 2 2.58071 Squamouscell carcinoma, keratinizing, NOS 9 3.9 0 0.08260 Papillary adenocarcinoma, NOS 1 0.4 3 3.88013 Large cell neuroendocrine carcinoma 3 1.3 0 0.08020 Carcinoma, undifferentiated, NOS 2 0.9 1 1.3

Others 14 6.0 8 10.0

SCR2006 Part03.indd 50 09-04-2010 3:28:44 AM

51

ig re omparison of ASR for ng ancer among Sa dis it ASR in Selected o ntries

ig re ASR Regional Distri tion of ng ancer in Sa di Ara ia


2.410.0

4.45.5

1.17.9

2.56.3

2.06.6

3.55.1

2.44.9

1.32.0

0.02.9

0.71.8

0.02.2

0.01.4

0.00.0

0 1 2 3 4 5 6 7 8 9 10 11

Hail

Jazan

Najran

Asir

Baha

Qassim

Madinah

Jouf

Makkah

Riyadh

Tabuk

Northern

Eastern

58.7

47.167.7

33.647.7

15.1

27.843.9

21.741.2

23.936.7

12.231.4

5.520.9

6.518.4

5.415.7

3.67.6

2.08.9

2.88.1

2.06.1

0 10 20 30 40 50 60 70


Jordan

Oman

Saudi Arabia

Kuwait

Thailand, Bangkok

Qatar

Bahrain

Norway

Australia

Wales

Poland


Canada

SCR2006 Part03.indd 51 09-04-2010 3:28:44 AM

52

There were 293 cases of hodgkin disease cancer accounting for 3.6% of all newly diagnosed cases in year 2006. This cancer ranked eighteenth among male and tenth in female population. It affected 173 (59%) males and 120 (41%) females with a male to female ratio of 144:100. The overall ASR was 1.9/100,000. ASR was 2.1/100,000 for males

and 1.6 100,000 for females. The five regions with highest ASR were Qassim region at 3.3/100,000, Tabuk region at 2.4/100,000, Eastern region at 2.1/100,000, Baha and Riyadh and Northern regions at 1.9/100,000 for each. The median age at diagnosis was 24 years (range 3-85 years) in males and 22 year in females (range 4-80).

Ta le orp ological Distri tion of odg ins disease in Sa di Ara ia

ig re Stage Distri tion of odg ins disease

ig re Age-Specific Incidence Rate (AIR) for odg ins disease in Sa di Ara ia

odg in Disease ( )

0

2

4

6

8

10

12

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


9663 Hodgkin lymphoma, nodular sclerosis, NOS 65 37.6 53 44.29652 Hodgkin lymphoma, mixed cellularity, NOS 34 19.7 23 19.29650 Hodgkin lymphoma, NOS 22 12.7 18 15.09659 Hodgkin lymphoma, nodular lymphocyte predominance 15 8.7 6 5.09651 Hodgkin lymphoma, lymphocyte-rich 12 6.9 6 5.09665 Hodgkin lymphoma, nodular sclerosis, grade 1 7 4.0 5 4.29653 Hodgkin lymphoma, lymphocyte depletion, NOS 9 5.2 2 1.79667 Hodgkin lymphoma, nodular sclerosis, grade 2 7 4.0 4 3.39664 Hodgkin lymphoma, nodular sclerosis, cellular phase 2 1.2 3 2.5

31.2%

24.9% 12.7%

31.2%34.2%

24.2% 12.5%

29.2%32.4%

24.6% 12.6%

30.4%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 52 09-04-2010 3:28:45 AM

53

ig re ASR Regional Distri tion of odg ins disease in Sa di Ara ia

ig re omparison of ASR for odg ins disease among Sa dis it ASR in Selected o ntries


2.73.8

1.0

2.23.8

2.00.6

3.21.9

1.81.2

2.51.3

2.21.1

2.10.4

2.60.8

2.10.8

2.01.8

0.80.6

1.0

0 1 2 3 4

Jazan

Asir

Jouf

Makkah

Najran

Madinah

Hail

Northern

Riyadh

Baha

Eastern

Tabuk

Qassim

2.64.5

2.43.0

1.83.3

1.63.4

2.32.7

2.22.5

2.22.5

2.12.5

1.82.2

1.62.1

1.71.8

0.72.1

1.31.5

0.20.4

0 1 2 3 4 5


Oman

Poland

Thailand, Bangkok

Saudi Arabia

Bahrain

Norway

Australia

Jordan


Wales

Kuwait

Canada

Qatar

SCR2006 Part03.indd 53 09-04-2010 3:28:45 AM

54

Stomac ( )

Table 3.10.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2006

Figure 3.10.2 Stage Distribution of Stomach Cancer, 2006

There were 275 cases of stomach cancer accounting for 3.4% of all newly diagnosed cases in year 2006. This cancer ranked tenth among male population and eleventh among female population. It affected 162(58.9%) males and 113 (41.1%) females with a male to female ratio of 143:100. The over all ASR was 3.3/100,000. ASR was 3.9/100,000 for male

and 2. 100,000 for females. The five regions with the highest ASR were Makkah region at 3.6/100,000, Asir and Jouf regions at 3.4/100,000 for each, Riyadh region at 3.2/100,000, and,Hail and Eastern regions at 2./100,000 for each. The median age at diagnosis was 69 years among males (range 20-112 years) and 61 years among female (range 19-89 years).

ig re Age-Specific Incidence Rate (AIR) for Stomac ancer in Sa di Ara ia

0

10

20

30

40

50

60

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


8140 Adenocarcinoma, NOS 74 45.7 46 40.78490 Signet ring cell carcinoma 37 22.8 34 30.18144 Adenocarcinoma, intestinal type 18 11.1 6 5.38010 Carcinoma, NOS 5 3.1 5 4.48000 Neoplasm, malignant 3 1.9 6 5.38480 Mucinous adenocarcinoma 4 2.5 3 2.78070 Squamous cell carcinoma, NOS 1 0.6 3 2.78145 Carcinoma, diffuse type 3 1.9 1 0.98260 Papillary adenocarcinoma, NOS 4 2.5 0 0.0

Others 13 8.0 9 8.0

30.2%

21.6% 27.8%

20.4%

31.9%

21.2% 16.8%

30.1% 25.8%

26.5% 18.9%

28.7%

Male AllFemale

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 54 09-04-2010 3:28:46 AM

55

Figure 3.10.4 Comparison of ASR for Stomach Cancer among Saudis with ASR in Selected Countries**

Figure 3.10.3 ASR* Regional Distribution of Stomach Cancer in Saudi Arabia, 2006


0 1 2 3 4 5

2.54.7

2.64.2

2.74.0

2.83.5

1.93.9

1.93.8

3.21.7

1.52.6

0.03.6

2.60.6

1.41.6

0.91.5

0.61.4Jazan

Baha

Tabuk

Qassim

Northern

Najran

Madinah

Eastern

Hail

Riyadh

Jouf

Asir

Makkah

0 2 4 6 8 10 12 14

6.512.0

13.14.8

4.8

4.210.6

9.45.6

7.63.4

8.94.2

7.24.0

7.03.4

6.73.6

6.52.7

3.92.5

3.62.2

3.92.4

2.7

Kuwait

Thailand, Bangkok

Saudi Arabia

Jordan



Norway

Qatar

Australia

Bahrain

Wales

Canada

Poland

Oman

SCR2006 Part03.indd 55 09-04-2010 3:28:46 AM

56

ig re Age-Specific Incidence Rate (AIR) for rostate ancer in Sa di Ara ia

Figure 3.11.2 Stage Distribution of Prostate Cancer, 2006

Table 3.11.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2006

There were 228 cases of prostate cancer accounting for 5.8% of all newly diagnosed cases among males in year 2006. The ASR was 6.1/100,000 among male population. This cancer ranked sixth among males. The five regions with

the highest ASR were Riyadh region at 7.8/100,000, Eastern region at 7.7/100,000, Makkah region at 6.6/100,000, Tabuk region at 4.2/100,000 and Asir region at 3.8/100,000. The median age at diagnosis was 71 years (range 1-101 years).

rostate ( )

0

20

40

60

80

100

120

male

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male %

8140 Adenocarcinoma, NOS 199 87.38000 Neoplasm, malignant 12 5.38010 Carcinoma, NOS 7 3.18550 Acinar cell carcinoma 3 1.38021 Carcinoma, anaplastic, NOS 1 0.48130 Papillary transitional cell carcinoma 1 0.48246 Neuroendocrine carcinoma, NOS 1 0.48320 Granular cell carcinoma 1 0.48480 Mucinous adenocarcinoma 1 0.48490 Signet ring cell carcinoma 1 0.48910 Embryonal rhabdomyosarcoma, NOS 1 0.4

21.5%

10.1%

43.0%

25.4%

Male

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 56 09-04-2010 3:28:47 AM

57

Figure 3.11.4 Comparison of ASR for Prostate Cancer among Saudi Males with ASR in Selected Countries**

Figure 3.11.3 ASR* Regional Distribution of Prostate Cancer in Saudi Arabia, 2006


0 1 2 3 4 5 6 7 8

7.8

7.7

6.6

4.2

3.8

3.6

2.8

2.4

2.2

1.4

1.3

0.7

0.5Baha

Jazan

Hail

Northern

Najran

Qassim

Madinah

Jouf

Asir

Tabuk

Makkah

Eastern

Riyadh

125.4

122.5

107.0

96.2

69.8

27.2

13.3

12.6

10.3

8.2

6.8

6.7

6.1

4.6

0 20 40 60 80 100 120 140

Saudi Arabia

Thailand, Bangkok


Jordan

Oman

Qatar

Kuwait

Bahrain

Poland

Wales

Norway


Australia

Canada

SCR2006 Part03.indd 57 09-04-2010 3:28:47 AM

58

ig re Age-Specific Incidence Rate (AIR) for ladder ancer in Sa di Ara ia

Table 3.12.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2006

Figure 3.13.2 Stage Distribution of Bladder Cancer, 2006

There were 211 cases of bladder cancer accounting for 2.6% of all newly diagnosed cases in year 2006. This cancer ranked ninth among male population and twentieth among female population. It affected 169 (80.1%) males and 42 (19.9%) females with a male to female ratio of 403:100. The overall ASR was 2.6/100,000. ASR was 4.1/100,000 for males

and 1 100,000 for females. The five regions with the highest ASR were Tabuk region at 4.6/100,000, Northern region at 4/100,000, Riyadh region at 2.9/100,000, Makkah region at 2.7 /100,000 and Eastern region at 2.6 /100,000. The median age at diagnosis was 64 among males (range 24-110 years) and 69 among females (range 30-100 years).

ladder ( )

05

10

1520

2530

35

404550

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)


8120 Transitional cell carcinoma, NOS 81 47.9 17 40.58130 Papillary transitional cell carcinoma 64 37.9 11 26.28070 Squamous cell carcinoma, NOS 5 3.0 7 16.78000 Neoplasm, malignant 5 3.0 1 2.48071 Squamous cell carcinoma, keratinizing, NOS 5 3.0 1 2.48140 Adenocarcinoma, NOS 4 2.4 1 2.4

Others 5 3.0 4 9.5

Distant Localised

RegionalUnknown

17.8%

21.3%9.5%

51.5%14.3%

21.4%9.5%

54.8%17.1%

21.3%9.5%

52.1%

Male AllFemale

SCR2006 Part03.indd 58 09-04-2010 3:28:47 AM

59

Figure 3.12.4 Comparison of ASR for Bladder Cancer among Saudis with ASR in Selected Countries**

Figure 3.12.3 ASR* Regional Distribution of Bladder Cancer in Saudi Arabia, 2006


0 1 2 3 4 5 6

2.36.8

0.0

1.47.9

0.84.4

4.6

4.1

3.6

1.1

0.6

0.83.2

1.12.4

0.91.3

0.01.9

0.01.2

0.90.3

0.00.4

7 8 9

Hail

Jazan

Qassim

Najran

Baha

Jouf

Asir

Madinah

Eastern

Makkah

Riyadh

Northern

Tabuk

7.527.4

5.5

3.0

5.7

3.0

1.9

3.1

4.9

2.7

1.8

1.9

0.7

1.04.1

6.1

5.2

5.9

7.2

7.5

11.8

14.3

13.4

11.3

15.0

21.1

0 5 10 15 20 25 30

Saudi Arabia

Jordan


Thailand, Bangkok

Kuwait

Oman

Australia

Qatar

Bahrain

Wales

Poland


Canada

SCR2006 Part03.indd 59 09-04-2010 3:28:48 AM

60

There were 140 cases of corpus uteri cancer among females accounting for 3.4 % of all newly diagnosed cases for females (4,156) in year 2006. This cancer ranked sixth among female population. The ASR was 3.6 100,000 for female population. The five regions

with the highest ASR were Makkah region at 4.4/100,000, Eastern region at 4.2/100,000, Riyadh region at 3.8/100,000, Jouf region at 3.5/100,000 and Baha region at 2.8/100,000. The median age at diagnosis was 61 years (range 26-94 years).

ig re Age-Specific Incidence Rate (AIR) for orp s terine ancer in Sa di Ara ia

Table 3.13.1 Morphological Distribution of Corpus uteri Cancer in Saudi Arabia, 2006

Figure 3.13.2 Stage Distribution of Corpus uteri Cancer, 2006

Corpus uteri (C 54)

0

5

10

15

20

25

30

35

40

female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Female %

8380 Endometrioid adenocarcinoma, NOS 71 50.78140 Adenocarcinoma, NOS 25 17.98950 Mullerian mixed tumor 8 5.78930 Endometrial stromal sarcoma, NOS 5 3.68460 Papillary serous cystadenocarcinoma 4 2.98560 Adenosquamous carcinoma 4 2.98890 Leiomyosarcoma, NOS 4 2.9

Endometrial stromal sarcoma, low grade 4 2.9Others 15 10.7

16.4%

16.4% 10.7%

56.4%

Female

Distant Localised

RegionalUnknown

SCR2006 Part03.indd 60 09-04-2010 3:28:48 AM

61

Figure 3.13.4 Comparison of ASR for Corpus uterine Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.13.3 ASR* Regional Distribution of Corpus uteri Cancer in Saudi Arabia, 2006


4.4

4.2

3.8

3.5

2.8

2.2

2.1

1.8

1.8

1.8

1.2

1.0

0.6

0 1 2 3 4 5

Jazan

Hail

Najran

Tabuk

Asir

Qassim

Northern

Madinah

Baha

Jouf

Riyadh

Eastern

Makkah

0 5 10 15 20 25

19.5

17.1

16.0

15.5

13.7

12.0

9.6

6.6

5.9

3.9

3.6

2.7

1.9Oman


Saudi Arabia

Thailand, Bangkok

Kuwait

Bahrain

Qatar

Australia

Poland

Norway

Wales


Canada

SCR2006 Part03.indd 61 09-04-2010 3:28:48 AM

62

ig re Age-Specific Incidence Rate (AIR) for arian ancer in Sa di Ara ia

Ta le orp ological Distri tion of arian ancer in Sa di Ara ia

There were 132 cases of ovarian cancer among females accounting for 3.2% of all newly diagnosed cases among females (4,156) in year 2006. This cancer ranked eighth among female population. The ASR was 2. 100,000 for females. The five

regions with the highest ASR were Jouf region at 5.9/100,000, Tabuk region at 3.6/100,000, Eastern and Najran regions at 3.5/100,000, and Riyadh region at 3.4/100,000. The median age at diagnosis was 54years (range 10-98 years).

ig re Stage Distri tion of arian ancer

arian ancer ( )

02

4

6

8

10

12

14

161820

female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

Distant Localised

RegionalUnknown13.6%

12.9%

15.2%

58.3%

Female

ICD-O-3 Code Morphology Female %

8140 Adenocarcinoma, NOS 25 18.98460 Papillary serous cystadenocarcinoma 24 18.28441 Serous cystadenocarcinoma, NOS 13 9.88000 Neoplasm, malignant 11 8.38470 Mucinous cystadenocarcinoma, NOS 10 7.68461 Serous surface papillary carcinoma 9 6.88380 Endometrioid adenocarcinoma, NOS 8 6.18010 Carcinoma, NOS 4 3.08480 Mucinous adenocarcinoma 4 3.09060 Dysgerminoma 4 3.08980 Carcinosarcoma, NOS 2 1.59064 Germinoma 2 1.59080 Teratoma, malignant, NOS 2 1.59085 Mixed germ cell tumor 2 1.5

Others 12 9.1

SCR2006 Part03.indd 62 09-04-2010 3:28:49 AM

63

ig re omparison of ASR for arian ancer among Sa di emales it ASR in Selected o ntries

ig re ASR Regional Distri tion of arian ancer in Sa di Ara ia


0 1 2 3 4 5 6 7

5.9

3.6

3.5

3.5

3.4

2.5

2.2

2.0

2.0

1.9

1.5

0.7

0.4Hail

Jazan

Northern

Baha

Qassim

Madinah

Asir

Makkah

Riyadh

Najran

Eastern

Tabuk

Jouf

0 2 4 6 8 10 12 14

13.1

12.7

11.5

11.2

10.8

9.3

8.5

7.7

5.1

5.1

4.8

4.2

2.8Saudi Arabia


Oman

Kuwait

Thailand, Bangkok

Qatar

Bahrain


Poland

Norway

Canada

Australia

Wales

SCR2006 Part03.indd 63 09-04-2010 3:28:49 AM

64

** Sources:

1 Cancer Incidence in Wales, 2002-2006 Available from:http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=27758 andhttp://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=28752

2 Cancer Incidence in Canada. 2005 and 2006, Second edition http://www.statcan.gc.ca/pub/82-231-x/82-231-x2008002-eng.pdf

3 Surveillance Epidemiology and End Results (SEER Cancer Statistics Review 1975-2006). Avaiable from:http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_table.10.html

4 Cancer Incidence, Mortality, Survival and Prevalence in Norway. Cancer in Norway, 2007.

5 Cancer Incidence in Oman, 2006.

6 Cancer Incidence in Jordan, 2006.

7 Eight Year Cancer Incidence among Nationals of the GCC States 1998-2005.

8 Ovarian Cancer in Australia: An overview, 2006. Available from: http://www.aihw.gov.au/publications/can/oca06/oca06.pdf

9 Breast Cancer in Australia: an overview, 2006. Available from:http://www.aihw.gov.au/publications/can/bca06/bca06.pdf

10 Australian Cancer Incidence and Mortality (ACIM). Bowel Cancer Incidence and Mortality. http://www.aihw.gov.au/publications/can/nbcspmr08/nbcspmr08_c04.pdf

11 Australian association of Cancer Registry. Available from: http://www.aihw.gov.au/cancer/data/acim_books/index.cfm

12 Croatian National Cancer Registry. Available from:http://www.hzjz.hr/cancer/bilten06.htm

13 Bangkok Cancer Registry. Annual Incidence, Bangkok, 1998-2000. Available from:http://www.nci.go.th/File_download/Cancer%20In%20Thailand%20IV/APP-G.PDF

14 Cancer in Poland in 2006. Available from:http://www.onkologia.org.pl/doc/Biuletyn2006.pdf

15 Descriptive Epidemiology Group, IARC. GLOBOCAN 2002. Available from:http://www-dep.iarc.fr/

SCR2006 Part03.indd 64 09-04-2010 3:28:49 AM

PART IVCANCER AMONG NON-SAUDIS

2006

SCR2006 Part04.indd 65 09-04-2010 3:29:17 AM

66

SCR2006 Part04.indd 66 09-04-2010 3:29:17 AM

67

Between January and December 2006, a total of 2,395 cancer cases were reported among the Non-Saudi population. Sixty three in situ cases and seven cases of ICD-10 were excluded from the analysis. As a result, the total number of cases analyzed were 2,324 out of this 1234(53.1%) were males and 1,090 (46.9%) were females. The male to female ratio was 113:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly, the pattern of

cancer had some significant differences. Those over 60 years represented 20 % and the 20 to 54 age-group represented 60 % of non-Saudi population. During 2006, approximately 5 % of all cancers occurred before the age of 15, 28.3 % occurred between the ages 15 to 40 years, 51.8% were between the ages 41-64, and 14.9 % occured after the age of 64. The median age at diagnosis was 51 years in males (range 0-100 years) and 45 years in females (range 0-90 years).

Table 4.1 Ten Most common Cancers among non-Saudis, 2006

Table 4.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency

Cancer Among Non-Saudi Population 2006

Cancer No. %

Breast 390 16.8Colo-rectal 232 10.0NHL 153 6.6Skin 129 5.6Lung 119 5.1Leukemia 115 4.9Thyroid 96 4.1Prostate 86 3.7Stomach 84 3.6Bladder 72 3.1Other sites 848 36.5

Nationality Male % Female % All %

Yemen 231 18.7 177 16.2 408 17.6Sudan 149 12.1 101 9.3 250 10.8Egypt 131 10.6 115 10.6 246 10.6Philippines 76 6.2 111 10.2 187 8.0Pakistan 70 5.7 76 7.0 146 6.3India 63 5.1 35 3.2 98 4.2Syrian Arab Republic 53 4.3 39 3.6 92 4.0Bangladesh 72 5.8 10 0.9 82 3.5Jordan 44 3.6 25 2.3 69 3.0Indonesia 7 0.6 52 4.8 59 2.5Gaza Strip (Palestine) 30 2.4 27 2.5 57 2.5United States of America 29 2.4 21 1.9 50 2.2Eritrea 20 1.6 24 2.2 44 1.9Lebanon 23 1.9 17 1.6 40 1.7Afghanistan 16 1.3 23 2.1 39 1.7Nigeria 25 2.0 14 1.3 39 1.7Bahrain 13 1.1 21 1.9 34 1.5Occupied Palestinian Territory 15 1.2 18 1.7 33 1.4Somalia 11 0.9 22 2.0 33 1.4Ethiopia 13 1.1 19 1.7 32 1.4Chad 8 0.6 23 2.1 31 1.3United Kingdom 22 1.8 7 0.6 29 1.2Myanmar (formerly Burma) 16 1.3 8 0.7 24 1.0GCCR Nationalities 9 0.7 19 1.7 28 1.2Other Nationalities 88 7.1 86 7.9 174 7.5Total 1234 100.0 1090 100.0 2324 100.0

SCR2006 Part04.indd 67 09-04-2010 3:29:17 AM

68

ig re Age-Specific Incidence Rate (AIR) for All ancers among non-Sa dis in Sa di Ara ia

Figure 4.1 Ten Most Common Cancer among non-Saudis, 2006


150Colo-rectal

104NHL

90Lung

88Skin

86Prostate

67Leukemia

66Bladder

64Stomach

57Liver

40Thyroid

382 35.0%12.2%

8.4%

7.3%

7.1%

7.0%

5.4%

5.3%

5.2%

4.6%

3.2%

7.5%

5.1%

4.5%

4.4%

4.2%

4.1%

3.8%

3.4%

2.7%

Breast

82Colo-rectal

56Thyroid

49NHL

48Leukemia

46Cervix Uteri

45Corpus Uteri

41Skin

37Ovary

29Lung

0

100

200

300

400

500

600

700

male female

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

SCR2006 Part04.indd 68 09-04-2010 3:29:17 AM

69

PART VTABLES

SCR2006 Part05.indd 69 09-04-2010 3:29:36 AM

70

Tab

le 5

.1.1

Age

Dis

trib

uti

on

of

Can

cer

Cas

es a

mo

ng

Sau

di M

ales

, 200

6

C00

Lip

60

00

00

00

00

00

00

00

24

0.2%

C01-

C02

Tong

ue37

00

00

00

02

41

43

63

42

80.

9%C0

3-C0

6M

outh

300

00

00

11

02

03

00

37

58

0.8%

C07-

C08

Saliv

ary

glan

ds14

00

10

03

00

03

01

20

02

20.

4%C0

9To

nsil

00

00

00

00

00

00

00

00

00

0.0%

C10

Oth

er O

roph

aryn

x0

00

00

00

00

00

00

00

00

00.

0%C1

1Na

soph

aryn

x95

01

13

72

83

1110

812

55

67

62.

4%C1

2-C1

3Hy

poph

aryn

x9

00

00

00

00

00

04

01

10

30.

2%C1

4Ph

aryn

x un

spec

ified

30

00

00

00

00

00

00

00

03

0.1%

C15

Oes

opha

gus

550

00

00

00

00

13

23

85

726

1.4%

C16

Stom

ach

162

00

00

01

17

05

1311

916

2133

454.

2%C1

7Sm

all in

test

ine

180

00

01

01

01

20

20

43

13

0.5%

C18

Colo

n23

20

00

00

13

513

1327

2230

2826

3430

6.0%

C19-

C20

Rect

um18

20

00

01

02

56

1220

1318

2829

1632

4.7%

C21

Anus

80

00

00

00

00

01

11

13

01

0.2%

C22

Live

r29

10

31

02

21

23

412

1828

3455

4482

7.5%

C23-

C24

Gal

lbla

dder

etc

.46

00

00

00

00

01

22

54

97

161.

2%C2

5Pa

ncre

as93

00

00

00

21

25

410

813

2118

92.

4%C3

0-C3

1No

se, s

inus

es e

tc.

100

20

01

00

10

01

00

00

05

0.3%

C32

Lary

nx62

00

00

01

01

13

46

711

116

111.

6%C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g23

20

00

00

11

21

616

1524

3047

4346

6.0%

C37-

C38

Oth

er T

hora

cic o

rgan

s14

01

11

21

12

00

20

10

01

10.

4%C4

0-C4

1Bo

ne64

01

715

1810

22

11

11

02

20

11.

6%C4

3M

elan

oma

of S

kin11

00

00

00

00

03

21

00

12

20.

3%C4

4O

ther

Skin

193

10

02

15

55

45

1211

924

2425

605.

0%C4

5M

esot

helio

ma

80

00

00

00

10

01

10

02

21

0.2%

C46

Kapo

si sa

rcom

a22

00

00

00

00

03

11

62

31

50.

6%C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue57

07

22

63

24

42

23

25

24

71.

5%C5

0Br

east

181

00

00

00

04

11

03

40

04

0.5%

C60

Peni

s1

00

00

00

00

00

00

00

10

00.

0%C6

1Pr

osta

te22

80

10

00

00

00

15

1015

2242

3993

5.8%

C62

Test

is38

01

00

26

84

52

62

00

02

01.

0%C6

3O

ther

mal

e ge

nita

l3

00

00

00

00

00

00

01

20

00.

1%C6

4Ki

dney

111

09

50

02

14

44

1415

712

178

92.

8%C6

5Re

nal P

elvis

50

00

00

00

00

00

01

20

20

0.1%

C66

Uret

er1

00

00

00

00

00

00

00

01

00.

0%C6

7Bl

adde

r16

90

00

00

10

43

1015

1813

2125

2237

4.3%

C68

Oth

er U

rinar

y or

gans

00

00

00

00

00

00

00

00

00

0.0%

C69

Eye

260

161

10

10

20

00

11

01

20

0.7%

C70-

C72

Brai

n, N

ervo

us s

yste

m14

90

1916

116

410

37

84

613

99

1212

3.8%

C73

Thyr

oid

117

00

02

56

910

117

1810

67

812

63.

0%C7

4Ad

rena

l gla

nd19

011

01

02

01

10

11

00

10

00.

5%C7

5O

ther

End

ocrin

e5

00

03

10

00

00

10

00

00

00.

1%C8

1Ho

dgkin

dise

ase

173

11

824

243 1

1712

1311

88

24

02

74.

4%C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a35

10

621

1112

227

1925

2721

2423

2227

2757

9.0%

C88

Imm

unop

rolife

rativ

e di

s.0

00

00

00

00

00

00

00

00

00.

0%C9

0M

ultip

le M

yelo

ma

480

00

01

01

02

05

43

68

108

1.2%

C91

Lym

phoi

d Le

ukem

ia15

50

3919

1515

68

32

27

42

59

712

4.0%

C92-

C94

Mye

loid

Leu

kem

ia11

50

116

39

1115

84

84

25

35

813

3.0%

C95

Leuk

emia

uns

pecifi

ed26

14

30

42

01

00

00

00

14

60.

7%O

ther

Oth

er &

uns

pecifi

ed18

60

71

07

22

48

37

1916

2125

2539

4.8%

All

All s

ites

Tota

l38

984

140

9394

125

127

108

118

142

164

256

264

274

361

463

445

720

100.

0%No

t C44

All s

ites

but C

4437

053

140

9392

124

122

103

113

138

159

244

253

265

337

439

420

660

95.0

%

0-4

5-9

30-3

435

-39

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k40

-44

45-4

910

-14

15-1

920

-24

25-2

9%

of T

otal

50-5

455

-59

70-7

475

+60

-64

65-6

9

SCR2006 Part05.indd 70 09-04-2010 3:29:36 AM

71

Tab

le 5

.1.2

Age

Dis

trib

uti

on

of

Can

cer

Cas

es a

mo

ng

Sau

di F

emal

es, 2

006

C00

Lip

40

00

00

00

00

00

00

11

02

0.1%

C01-

C02

Tong

ue26

00

00

00

01

11

32

36

24

30.

6%C0

3-C0

6M

outh

340

00

00

00

22

42

33

62

46

0.8%

C07-

C08

Saliv

ary

glan

ds12

00

00

02

01

02

10

11

01

30.

3%C0

9To

nsil

20

00

00

00

10

00

00

00

01

0.0%

C10

Oth

er O

roph

aryn

x0

00

00

00

00

00

00

00

00

00.

0%C1

1Na

soph

aryn

x43

00

01

41

16

32

67

16

02

31.

0%C1

2-C1

3Hy

poph

aryn

x11

00

00

01

00

12

15

10

00

00.

3%C1

4Ph

aryn

x un

spec

ified

10

00

00

00

00

00

00

01

00

0.0%

C15

Oes

opha

gus

641

00

00

10

32

23

52

810

1215

1.5%

C16

Stom

ach

113

10

00

14

33

68

711

611

1916

172.

7%C1

7Sm

all in

test

ine

140

00

00

01

10

01

24

22

01

0.3%

C18

Colo

n22

70

00

00

57

1110

1923

2324

3831

1917

5.5%

C19-

C20

Rect

um14

30

00

00

02

25

1520

1821

1521

420

3.4%

C21

Anus

90

00

00

00

00

02

14

01

10

0.2%

C22

Live

r12

50

30

00

00

34

48

109

279

2127

3.0%

C23-

C24

Gal

lbla

dder

etc

.70

00

00

00

00

44

68

810

69

151.

7%C2

5Pa

ncre

as73

00

00

00

20

26

511

39

1113

111.

8%C3

0-C3

1No

se, s

inus

es e

tc.

100

00

01

10

01

10

00

02

04

0.2%

C32

Lary

nx9

00

00

10

10

11

11

11

10

00.

2%C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g80

00

00

10

41

16

85

613

1111

131.

9%C3

7-C3

8O

ther

Tho

racic

org

ans

100

20

00

00

11

00

11

02

02

0.2%

C40-

C41

Bone

360

23

86

27

20

30

00

00

12

0.9%

C43

Mel

anom

a of

Skin

120

00

00

00

01

01

11

31

13

0.3%

C44

Oth

er S

kin13

42

00

13

12

68

513

1012

613

1438

3.2%

C45

Mes

othe

liom

a5

00

00

00

00

01

00

01

12

00.

1%C4

6Ka

posi

sarc

oma

140

10

00

00

10

11

21

41

11

0.3%

C47;

C49

Conn

ectiv

e, S

oft t

issue

370

21

72

31

15

42

42

02

01

0.9%

C50

Brea

st98

12

00

01

737

7512

616

318

210

586

7843

3839

23.6

%C5

1Vu

lva4

00

00

00

00

00

10

11

00

10.

1%C5

2Va

gina

10

00

00

00

00

00

00

00

01

0.0%

C53

Cerv

ix Ut

eri

740

10

00

01

27

1511

74

59

48

1.8%

C54

Corp

us U

teri

140

10

00

00

36

38

815

2226

278

133.

4%C5

5Ut

erus

uns

pecifi

ed.

220

00

00

01

02

00

24

21

55

0.5%

C56

Ova

ry13

20

00

25

64

53

1414

1713

1514

911

3.2%

C57

Oth

er F

emal

e G

enita

l9

00

00

00

10

10

01

12

02

10.

2%C5

8Pl

acen

ta19

00

00

20

61

33

30

00

00

10.

5%C6

4Ki

dney

780

74

11

14

23

89

98

46

65

1.9%

C65

Rena

l Pel

vis4

00

00

00

00

01

10

10

00

10.

1%C6

6Ur

eter

20

00

00

00

00

00

00

00

02

0.0%

C67

Blad

der

421

00

00

00

22

21

23

54

812

1.0%

C68

Oth

er U

rinar

y or

gans

00

00

00

00

00

00

00

00

00

0.0%

C69

Eye

190

130

00

00

00

01

00

21

02

0.5%

C70-

C72

Brai

n, N

ervo

us s

yste

m10

30

1011

146

46

65

72

73

106

42

2.5%

C73

Thyr

oid

424

00

16

1232

6056

6343

5115

2125

1610

1410

.2%

C74

Adre

nal g

land

100

72

00

00

01

00

00

00

00

0.2%

C75

Oth

er E

ndoc

rine

50

10

00

01

00

00

00

03

00

0.1%

C81

Hodg

kin d

iseas

e12

00

210

1518

2413

83

62

13

18

42

2.9%

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

234

05

54

119

811

1516

1617

2126

1725

285.

6%C8

8Im

mun

opro

lifera

tive

dis.

00

00

00

00

00

00

00

00

00

0.0%

C90

Mul

tiple

Mye

lom

a26

00

00

00

11

11

23

51

44

30.

6%C9

1Ly

mph

oid

Leuk

emia

900

3919

63

21

20

12

12

05

16

2.2%

C92-

C94

Mye

loid

Leu

kem

ia11

30

62

68

610

48

813

65

108

76

2.7%

C95

Leuk

emia

uns

pecifi

ed9

01

01

11

00

10

01

00

21

00.

2%O

ther

Oth

er &

uns

pecifi

ed17

70

61

13

02

411

1413

1113

2224

1933

4.3%

All

All s

ites

Tota

l41

568

108

5973

9011

319

023

131

640

144

635

033

040

334

829

140

110

0.0%

Not C

44Al

l site

s bu

t C44

4022

610

859

7287

112

188

225

308

396

433

340

318

397

335

277

363

96.8

%

50-5

455

-59

60-6

475

+%

of T

otal

70-7

445

-49

0-4

5-9

10-1

465

-69

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k15

-19

20-2

425

-29

30-3

435

-39

40-4

4

SCR2006 Part05.indd 71 09-04-2010 3:29:36 AM

72

Tab

le 5

.1.3

Can

cer

Inci

den

ce C

ases

am

on

g S

aud

i Mal

es b

y A

ge G

rou

p (

per

100

,000

), 20

06

C00

Lip

60

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.4

4.8

0.1

0.1

C01-

C02

Tong

ue37

00.

00.

00.

00.

00.

00.

00.

30.

70.

21.

11.

13.

32.

15.

32.

49.

60.

40.

8C0

3-C0

6M

outh

300

0.0

0.0

0.0

0.0

0.1

0.1

0.0

0.4

0.0

0.8

0.0

0.0

2.1

9.3

6.0

9.6

0.3

0.8

C07-

C08

Saliv

ary

glan

ds14

00.

00.

10.

00.

00.

30.

00.

00.

00.

70.

00.

41.

10.

00.

02.

42.

40.

20.

2C0

9To

nsil

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C10

Oth

er O

roph

aryn

x0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C1

1Na

soph

aryn

x95

00.

10.

10.

30.

70.

21.

00.

52.

02.

32.

24.

52.

83.

67.

98.

47.

21.

11.

7C1

2-C1

3Hy

poph

aryn

x9

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

50.

00.

71.

30.

03.

60.

10.

2C1

4Ph

aryn

x un

spec

ified

30

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.6

0.0

0.1

C15

Oes

opha

gus

550

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.8

0.8

1.7

5.7

6.6

8.4

31.2

0.6

1.4

C16

Stom

ach

162

00.

00.

00.

00.

00.

10.

11.

10.

01.

13.

64.

15.

011

.427

.839

.854

.01.

93.

9C1

7Sm

all in

test

ine

180

0.0

0.0

0.0

0.1

0.0

0.1

0.0

0.2

0.5

0.0

0.8

0.0

2.8

4.0

1.2

3.6

0.2

0.4

C18

Colo

n23

20

0.0

0.0

0.0

0.0

0.1

0.4

0.8

2.4

2.9

7.6

8.3

16.6

19.9

34.4

41.0

36.0

2.7

5.3

C19-

C20

Rect

um18

20

0.0

0.0

0.0

0.1

0.0

0.3

0.8

1.1

2.7

5.6

4.9

10.0

19.9

38.4

19.3

38.4

2.1

4.4

C21

Anus

80

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.4

0.6

0.7

4.0

0.0

1.2

0.1

0.2

C22

Live

r29

10

0.3

0.1

0.0

0.2

0.2

0.1

0.3

0.6

0.9

3.4

6.8

15.5

24.2

72.8

53.1

98.4

3.4

7.5

C23-

C24

Gal

lbla

dder

etc

.46

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

60.

82.

82.

811

.98.

419

.20.

51.

2C2

5Pa

ncre

as93

00.

00.

00.

00.

00.

00.

30.

20.

41.

11.

13.

84.

49.

327

.821

.710

.81.

12.

4C3

0-C3

1No

se, s

inus

es e

tc.

100

0.2

0.0

0.0

0.1

0.0

0.0

0.2

0.0

0.0

0.3

0.0

0.0

0.0

0.0

0.0

6.0

0.1

0.2

C32

Lary

nx62

00.

00.

00.

00.

00.

10.

00.

20.

20.

71.

12.

33.

97.

814

.67.

213

.20.

71.

6C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g23

20

0.0

0.0

0.0

0.0

0.1

0.1

0.3

0.2

1.4

4.5

5.6

13.3

21.4

62.2

51.9

55.2

2.7

6.1

C37-

C38

Oth

er T

hora

cic o

rgan

s14

00.

10.

10.

10.

20.

10.

10.

30.

00.

00.

60.

00.

60.

00.

01.

21.

20.

20.

2C4

0-C4

1Bo

ne64

00.

10.

71.

51.

91.

10.

30.

30.

20.

20.

30.

40.

01.

42.

60.

01.

20.

70.

7C4

3M

elan

oma

of S

kin11

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

60.

40.

00.

01.

32.

42.

40.

10.

2C4

4O

ther

Skin

193

10.

00.

00.

20.

10.

50.

60.

80.

71.

13.

44.

15.

017

.131

.830

.272

.02.

24.

6C4

5M

esot

helio

ma

80

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.0

0.3

0.4

0.0

0.0

2.6

2.4

1.2

0.1

0.2

C46

Kapo

si sa

rcom

a22

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

30.

43.

31.

44.

01.

26.

00.

30.

5C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue57

00.

60.

20.

20.

60.

30.

30.

60.

70.

50.

61.

11.

13.

62.

64.

88.

40.

70.

9C5

0Br

east

181

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.2

0.3

0.0

1.7

2.8

0.0

0.0

4.8

0.2

0.4

C60

Peni

s1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

30.

00.

00.

00.

0C6

1Pr

osta

te22

80

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

1.4

3.8

8.3

15.7

55.6

47.0

111.

62.

66.

1C6

2Te

stis

380

0.1

0.0

0.0

0.2

0.7

1.0

0.6

0.9

0.5

1.7

0.8

0.0

0.0

0.0

2.4

0.0

0.4

0.5

C63

Oth

er m

ale

geni

tal

30

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

2.6

0.0

0.0

0.0

0.1

C64

Kidn

ey11

10

0.8

0.5

0.0

0.0

0.2

0.1

0.6

0.7

0.9

3.9

5.6

3.9

8.5

22.5

9.7

10.8

1.3

2.4

C65

Rena

l Pel

vis5

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

61.

40.

02.

40.

00.

10.

1C6

6Ur

eter

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.2

0.0

0.0

0.0

C67

Blad

der

169

00.

00.

00.

00.

00.

10.

00.

60.

62.

34.

26.

87.

215

.033

.126

.544

.42.

04.

1C6

8O

ther

Urin

ary

orga

ns0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C6

9Ey

e26

01.

40.

10.

10.

00.

10.

00.

30.

00.

00.

00.

40.

60.

01.

32.

40.

00.

30.

3C7

0-C7

2Br

ain,

Ner

vous

sys

tem

149

01.

71.

51.

10.

60.

41.

30.

51.

31.

81.

12.

37.

26.

411

.914

.514

.41.

72.

5C7

3Th

yroi

d11

70

0.0

0.0

0.2

0.5

0.7

1.1

1.6

2.0

1.6

5.0

3.8

3.3

5.0

10.6

14.5

7.2

1.4

2.1

C74

Adre

nal g

land

190

1.0

0.0

0.1

0.0

0.2

0.0

0.2

0.2

0.0

0.3

0.4

0.0

0.0

1.3

0.0

0.0

0.2

0.2

C75

Oth

er E

ndoc

rine

50

0.0

0.0

0.3

0.1

0.0

0.0

0.0

0.0

0.0

0.3

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C81

Hodg

kin d

iseas

e17

31

0.1

0.8

2.4

2.5

3.4

2.2

1.9

2.4

2.5

2.2

3.0

1.1

2.8

0.0

2.4

8.4

2.0

2.1

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

351

00.

52.

01.

11.

32.

40.

93.

04.

66.

15.

99.

012

.715

.735

.732

.668

.44.

16.

6C8

8Im

mun

opro

lifera

tive

dis.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a48

00.

00.

00.

00.

10.

00.

10.

00.

40.

01.

41.

51.

74.

310

.612

.19.

60.

61.

2C9

1Ly

mph

oid

Leuk

emia

155

03.

41.

81.

51.

60.

71.

00.

50.

40.

52.

01.

51.

13.

611

.98.

414

.41.

82.

3C9

2-C9

4M

yelo

id L

euke

mia

115

01.

00.

60.

31.

01.

21.

91.

20.

71.

81.

10.

82.

82.

16.

69.

715

.61.

31.

8C9

5Le

ukem

ia u

nspe

cified

261

0.3

0.3

0.0

0.4

0.2

0.0

0.2

0.0

0.0

0.0

0.0

0.0

0.0

1.3

4.8

7.2

0.3

0.4

Oth

erO

ther

& u

nspe

cified

186

00.

60.

10.

00.

70.

20.

30.

61.

50.

72.

07.

28.

915

.033

.130

.246

.82.

14.

3Al

lAl

l site

s To

tal

3898

412

. 09.

09.

013

.014

.014

.018

.026

.037

.072

.099

.015

2.0

257.

061

3.0

537.

086

4.0

45.0

83.6

Not C

44Al

l site

s bu

t C44

3705

312

.09.

09.

013

.013

.013

.018

.026

.036

.068

.095

.014

7.0

240.

058

1.0

507.

079

2.0

42.8

79.0

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k0-

440

-44

45-4

9Cr

ude

Rate

ASR

Wor

ld65

-69

70-7

475

+50

-54

55-5

95-

910

-14

15-1

960

-64

20-2

425

-29

30-3

435

-39

SCR2006 Part05.indd 72 09-04-2010 3:29:37 AM

73

Table 5.1.4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2006

C00 Lip 4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.3 0.0 2.2 0.0 0.1C01-C02 Tongue 26 0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.9 0.8 1.7 4.4 2.7 5.6 3.4 0.3 0.6C03-C06 Mouth 34 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.9 0.6 1.2 1.7 4.4 2.7 5.6 6.7 0.4 0.8C07-C08 Salivary glands 12 0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.5 0.3 0.0 0.6 0.7 0.0 1.4 3.4 0.1 0.2C09 Tonsil 2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0C10 Other Oropharynx 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C11 Nasopharynx 43 0 0.0 0.0 0.1 0.4 0.1 0.1 0.9 0.6 0.5 1.8 2.8 0.6 4.4 0.0 2.8 3.4 0.5 0.8C12-C13 Hypopharynx 11 0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.5 0.3 2.0 0.6 0.0 0.0 0.0 0.0 0.1 0.2C14 Pharynx unspecified. 1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0C15 Oesophagus 64 1 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.4 0.5 0.9 2.0 1.1 5.9 13.3 16.7 16.8 0.7 1.6C16 Stomach 113 1 0.0 0.0 0.0 0.1 0.4 0.4 0.5 1.1 1.8 2.1 4.4 3.4 8.2 25.2 22.3 19.1 1.3 2.7C17 Small intestine 14 0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.3 0.8 2.3 1.5 2.7 0.0 1.1 0.2 0.3C18 Colon 227 0 0.0 0.0 0.0 0.0 0.5 0.9 1.7 1.8 4.4 6.8 9.3 13.6 28.2 41.1 26.4 19.1 2.6 5.3C19-C20 Rectum 143 0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.9 3.4 5.9 7.2 11.9 11.1 27.8 5.6 22.4 1.7 3.3C21 Anus 9 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.4 2.3 0.0 1.3 1.4 0.0 0.1 0.2C22 Liver 125 0 0.3 0.0 0.0 0.0 0.0 0.0 0.5 0.7 0.9 2.4 4.0 5.1 20.0 11.9 29.2 30.3 1.5 3.1C23-C24 Gallbladder etc. 70 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 1.8 3.2 4.5 7.4 8.0 12.5 16.8 0.8 1.7C25 Pancreas 73 0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 1.4 1.5 4.4 1.7 6.7 14.6 18.1 12.3 0.8 1.8C30-C31 Nose, sinuses etc. 10 0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 2.7 0.0 4.5 0.1 0.2C32 Larynx 9 0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.2 0.3 0.4 0.6 0.7 1.3 0.0 0.0 0.1 0.2C33-C34 Trachea, Bronchus, Lung 80 0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2 1.4 2.4 2.0 3.4 9.6 14.6 15.3 14.6 0.9 2.0C37-C38 Other Thoracic organs 10 0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.4 0.6 0.0 2.7 0.0 2.2 0.1 0.2C40-C41 Bone 36 0 0.2 0.3 0.8 0.6 0.2 0.9 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 1.4 2.2 0.4 0.4C43 Melanoma of Skin 12 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.4 0.6 2.2 1.3 1.4 3.4 0.1 0.3C44 Other Skin 134 2 0.0 0.0 0.1 0.3 0.1 0.3 0.9 1.5 1.1 3.8 4.0 6.8 4.4 17.2 19.5 42.6 1.6 3.0C45 Mesothelioma 5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 1.3 2.8 0.0 0.1 0.1C46 Kaposi sarcoma 14 0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.3 0.8 0.6 3.0 1.3 1.4 1.1 0.2 0.3C47; C49 Connective, Soft tissue 37 0 0.2 0.1 0.7 0.2 0.3 0.1 0.2 0.9 0.9 0.6 1.6 1.1 0.0 2.7 0.0 1.1 0.4 0.6C50 Breast 981 2 0.0 0.0 0.0 0.1 0.8 4.9 11.6 23.2 37.4 53.7 42.3 48.6 57.8 57.0 52.9 43.7 11.4 18.1C51 Vulva 4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.7 0.0 0.0 1.1 0.0 0.1C52 Vagina 1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0C53 Cervix Uteri 74 0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 1.3 3.4 3.2 2.8 2.3 3.7 11.9 5.6 9.0 0.9 1.5C54 Corpus Uteri 140 1 0.0 0.0 0.0 0.0 0.0 0.4 0.9 0.6 1.8 2.4 6.0 12.4 19.3 35.8 11.1 14.6 1.6 3.6C55 Uterus unspecified. 22 0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.8 2.3 1.5 1.3 7.0 5.6 0.3 0.5C56 Ovary 132 0 0.0 0.0 0.2 0.5 0.6 0.5 0.8 0.6 3.2 4.1 6.8 7.3 11.1 18.6 12.5 12.3 1.5 2.8C57 Other Female Genital 9 0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.4 0.6 1.5 0.0 2.8 1.1 0.1 0.2C58 Placenta 19 0 0.0 0.0 0.0 0.2 0.0 0.8 0.2 0.6 0.7 0.9 0.0 0.0 0.0 0.0 0.0 1.1 0.2 0.2C64 Kidney 78 0 0.6 0.4 0.1 0.1 0.1 0.5 0.3 0.6 1.8 2.7 3.6 4.5 3.0 8.0 8.4 5.6 0.9 1.5C65 Renal Pelvis 4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.6 0.0 0.0 0.0 1.1 0.0 0.1C66 Ureter 2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0C67 Bladder 42 1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.5 0.3 0.8 1.7 3.7 5.3 11.1 13.4 0.5 1.0C68 Other Urinary organs 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C69 Eye 19 0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 1.5 1.3 0.0 2.2 0.2 0.3C70-C72 Brain, Nervous system 103 0 0.9 1.0 1.4 0.6 0.4 0.8 0.9 0.9 1.6 0.6 2.8 1.7 7.4 8.0 5.6 2.2 1.2 1.6C73 Thyroid 425 0 0.0 0.1 0.6 1.3 3.4 7.9 8.6 11.6 9.9 15.1 6.0 11.9 18.5 21.2 13.9 15.7 4.9 6.5C74 Adrenal gland 10 0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1C75 Other Endocrine 5 0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.1 0.1C81 Hodgkin disease 120 0 0.2 0.9 1.5 1.9 2.6 1.7 1.2 0.6 1.4 0.6 0.4 1.7 0.7 10.6 5.6 2.2 1.4 1.6C82-C85; C96 Non-Hodgkin lymphoma 234 0 0.4 0.5 0.4 1.2 1.0 1.1 1.7 2.8 3.7 4.7 6.8 11.9 19.3 22.5 34.8 31.4 2.7 4.8C88 Immunoproliferative dis. 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C90 Multiple Myeloma 26 0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.6 1.2 2.8 0.7 5.3 5.6 3.4 0.3 0.6C91 Lymphoid Leukemia 90 0 3.5 1.8 0.6 0.3 0.2 0.1 0.3 0.0 0.2 0.6 0.4 1.1 0.0 6.6 1.4 6.7 1.0 1.2C92-C94 Myeloid Leukemia 113 0 0.5 0.2 0.6 0.8 0.6 1.3 0.6 1.5 1.8 3.8 2.4 2.8 7.4 10.6 9.7 6.7 1.3 2.0C95 Leukemia unspecified. 9 0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 2.7 1.4 0.0 0.1 0.2Other Other & unspecified 177 0 0.5 0.1 0.1 0.3 0.0 0.3 0.6 2.0 3.2 3.8 4.4 7.3 16.3 31.8 26.4 37.0 2.1 4.1All All sites Total 4156 8 10.0 6.0 7.0 9.0 12.0 25.0 36.0 58.0 92.0 132.0 141.0 186.0 299.0 461.0 406.0 449.0 48.4 82.8Not C44 All sites but C44 4022 6 10.0 6.0 7.0 9.0 12.0 25.0 35.0 57.0 91.0 128.0 137.0 180.0 294.0 444.0 387.0 407.0 46.8 79.9

0-4 5-9ICD (10th) Site All Ages

Age Unk 30-34 35-39 40-44 45-4910-14 15-19 20-24 25-29 ASR

WorldCrude

Rate50-54 55-59 70-74 75+60-64 65-69

SCR2006 Part05.indd 73

09-04-2010 3:29:37 AM

74

Tab

le 5

.2.1

Nu

mb

er,

Rel

ativ

e F

req

uen

cies

, Age

Sta

nd

ard

ized

an

d C

rud

e R

ates

fo

r A

ll C

ance

r C

ases

Am

on

g S

aud

i Mal

es b

y S

ite

and

Ad

min

istr

ativ

e R

egio

n,

2006

C00

Lip

20.

7%0.

30.

30

0.0%

0.0

0.0

11.

3%0.

20.

3C0

1-C0

2To

ngue

62.

0%0.

81.

21

1.6%

0.6

0.8

56.

4%1.

01.

7C0

3-C0

6M

outh

20.

7%0.

30.

30

0.0%

0.0

0.0

45.

1%0.

81.

1C0

7-C0

8Sa

livar

y gl

ands

20.

7%0.

30.

40

0.0%

0.0

0.0

11.

3%0.

20.

2C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

0O

ther

Oro

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x7

2.3%

1.0

1.1

11.

6%0.

60.

83

3.8%

0.6

0.7

C12-

C13

Hypo

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

4Ph

aryn

x un

spec

.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C15

Oes

opha

gus

31.

0%0.

40.

54

6.6%

2.5

2.4

22.

6%0.

40.

5C1

6St

omac

h22

7.2%

3.0

4.2

34.

9%1.

91.

55

6.4%

1.0

1.4

C17

Smal

l inte

stin

e3

1.0%

0.4

0.7

00.

0%0.

00.

00

0.0%

0.0

0.0

C18

Colo

n15

4.9%

2.1

3.2

23.

3%1.

31.

72

2.6%

0.4

0.7

C19-

C20

Rect

um11

3.6%

1.5

2.2

58.

2%3.

24.

64

5.1%

0.8

1.2

C21

Anus

10.

3%0.

10.

21

1.6%

0.6

0.5

00.

0%0.

00.

0C2

2Li

ver

237.

5%3.

24.

43

4.9%

1.9

2.2

33.

8%0.

60.

6C2

3-C2

4G

allb

ladd

er e

tc.

72.

3%1.

01.

31

1.6%

0.6

0.8

11.

3%0.

20.

3C2

5Pa

ncre

as5

1.6%

0.7

0.8

11.

6%0.

60.

81

1.3%

0.2

0.4

C30-

C31

Nose

, sin

uses

etc

.1

0.3%

0.1

0.1

00.

0%0.

00.

01

1.3%

0.2

0.2

C32

Lary

nx2

0.7%

0.3

0.4

00.

0%0.

00.

00

0.0%

0.0

0.0

C33-

C34

Trac

hea,

Bron

chus

,Lun

g9

3.0%

1.2

1.8

46.

6%2.

52.

95

6.4%

1.0

1.4

C37-

C38

Oth

er T

hora

cic o

rgan

s1

0.3%

0.1

0.2

00.

0%0.

00.

00

0.0%

0.0

0.0

C40-

C41

Bone

62.

0%0.

80.

72

3.3%

1.3

1.0

11.

3%0.

20.

1C4

3M

elan

oma

of S

kin1

0.3%

0.1

0.2

23.

3%1.

31.

00

0.0%

0.0

0.0

C44

Oth

er S

kin28

9.2%

3.9

5.5

58.

2%3.

24.

47

9.0%

1.4

2.0

C45

Mes

othe

liom

a0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C46

Kapo

si sa

rcom

a6

2.0%

0.8

1.1

00.

0%0.

00.

00

0.0%

0.0

0.0

C47;

C49

Conn

ectiv

e,So

ft tis

sue

62.

0%0.

81.

00

0.0%

0.0

0.0

11.

3%0.

20.

4C5

0Br

east

10.

3%0.

10.

10

0.0%

0.0

0.0

11.

3%0.

20.

3C6

0Pe

nis

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

1Pr

osta

te21

6.9%

2.9

3.8

11.

6%0.

60.

52

2.6%

0.4

0.7

C62

Test

is3

1.0%

0.4

0.4

00.

0%0.

00.

00

0.0%

0.0

0.0

C63

Oth

er m

ale

geni

tal

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

4Ki

dney

62.

0%0.

81.

21

1.6%

0.6

0.8

11.

3%0.

20.

3C6

5Re

nal P

elvis

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

6Ur

eter

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

7Bl

adde

r17

5.6%

2.3

3.2

23.

3%1.

31.

31

1.3%

0.2

0.3

C68

Oth

er U

rinar

y or

gans

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

9Ey

e0

0.0%

0.0

0.0

11.

6%0.

60.

60

0.0%

0.0

0.0

C70-

C72

Brai

n, N

ervo

us s

yste

m9

3.0%

1.2

1.7

00.

0%0.

00.

06

7.7%

1.2

1.3

C73

Thyr

oid

41.

3%0.

60.

80

0.0%

0.0

0.0

00.

0%0.

00.

0C7

4Ad

rena

l gla

nd0

0.0%

0.0

0.0

11.

6%0.

60.

61

1.3%

0.2

0.2

C75

Oth

er E

ndoc

rine

10.

3%0.

10.

10

0.0%

0.0

0.0

11.

3%0.

20.

1C8

1Ho

dgkin

dise

ase

62.

0%0.

80.

85

8.2%

3.2

3.2

56.

4%1.

01.

0C8

2-C8

5;C9

6No

n-Ho

dgkin

lym

phom

a24

7.9%

3.3

4.3

711

.5%

4.4

6.0

911

.5%

1.8

2.5

C88

Imm

unop

rolife

rativ

e di

s.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C90

Mul

tiple

Mye

lom

a3

1.0%

0.4

0.6

00.

0%0.

00.

00

0.0%

0.0

0.0

C91

Lym

phoi

d Le

ukae

mia

165.

2%2.

22.

25

8.2%

3.2

2.9

11.

3%0.

20.

1C9

2-C9

4M

yelo

id L

euka

emia

103.

3%1.

41.

42

3.3%

1.3

1.1

11.

3%0.

20.

2C9

5Le

ukae

mia

uns

pec.

20.

7%0.

30.

20

0.0%

0.0

0.0

00.

0%0.

00.

0O

ther

Oth

er &

uns

pecifi

ed13

4.3%

1.8

2.9

11.

6%0.

60.

82

2.6%

0.4

0.5

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

All

All s

ites

Tota

l30

510

0.0%

42.1

55.8

6110

0.0%

38.5

43.3

7810

0.0%

15.2

20.8

Not C

44Al

l site

s bu

t C44

277

90.8

%38

.350

.356

91.8

%35

.438

.971

91.0

%13

.818

.8

ICD

(10t

h)Si

te%

of T

otalAs

irAl

l Age

sCr

ude

Rate

ASR

Wor

ldAS

R W

orld

Jaza

nAl

l Age

sBa

ha%

of T

otal

Crud

e Ra

te%

of T

otal

Crud

e Ra

teAS

R W

orld

All A

ges

SCR2006 Part05.indd 74 09-04-2010 3:29:37 AM

75

Tab

le 5

.2.2

Nu

mb

er, R

elat

ive

Fre

qu

enci

es, A

ge S

tan

dar

diz

ed a

nd

Cru

de

Rat

es fo

r A

ll C

ance

r C

ases

am

on

g S

aud

i Mal

es b

y S

ite

and

Ad

min

istr

ativ

e R

egio

n, 2

006

C00

Lip

00.

0%0.

00.

01

1.3%

0.4

0.4

00.

0%0.

00.

0C0

1-C0

2To

ngue

20.

7%0.

30.

40

0.0%

0.0

0.0

00.

0%0.

00.

0C0

3-C0

6M

outh

20.

7%0.

30.

70

0.0%

0.0

0.0

10.

6%0.

20.

5C0

7-C0

8Sa

livar

y gl

ands

10.

4%0.

20.

32

2.5%

0.9

0.9

10.

6%0.

20.

4C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

0O

ther

Oro

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x10

3.6%

1.7

2.4

00.

0%0.

00.

08

5.0%

1.9

2.5

C12-

C13

Hypo

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

21.

3%0.

50.

7C1

4Ph

aryn

x un

spec

ified.

20.

7%0.

30.

50

0.0%

0.0

0.0

00.

0%0.

00.

0C1

5O

esop

hagu

s1

0.4%

0.2

0.3

11.

3%0.

40.

65

3.1%

1.2

1.8

C16

Stom

ach

62.

2%1.

01.

77

8.9%

3.0

3.9

21.

3%0.

50.

6C1

7Sm

all in

test

ine

10.

4%0.

20.

21

1.3%

0.4

0.6

00.

0%0.

00.

0C1

8Co

lon

134.

7%2.

24.

07

8.9%

3.0

3.8

106.

3%2.

43.

8C1

9-C2

0Re

ctum

145.

0%2.

43.

98

10.1

%3.

55.

07

4.4%

1.6

2.8

C21

Anus

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C2

2Li

ver

3211

.5%

5.4

9.9

00.

0%0.

00.

011

6.9%

2.6

4.3

C23-

C24

Gal

lbla

dder

etc

.2

0.7%

0.3

0.6

00.

0%0.

00.

00

0.0%

0.0

0.0

C25

Panc

reas

51.

8%0.

81.

71

1.3%

0.4

0.5

21.

3%0.

50.

9C3

0-C3

1No

se, s

inus

es e

tc.

20.

7%0.

30.

51

1.3%

0.4

0.4

10.

6%0.

20.

2C3

2La

rynx

31.

1%0.

50.

63

3.8%

1.3

1.9

10.

6%0.

20.

3C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g16

5.7%

2.7

4.9

00.

0%0.

00.

05

3.1%

1.2

2.0

C37-

C38

Oth

er T

hora

cic o

rgan

s0

0.0%

0.0

0.0

00.

0%0.

00.

02

1.3%

0.5

0.4

C40-

C41

Bone

20.

7%0.

30.

41

1.3%

0.4

0.4

31.

9%0.

70.

6C4

3M

elan

oma

of S

kin1

0.4%

0.2

0.3

11.

3%0.

40.

60

0.0%

0.0

0.0

C44

Oth

er S

kin19

6.8%

3.2

5.4

810

.1%

3.5

3.9

85.

0%1.

92.

8C4

5M

esot

helio

ma

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C4

6Ka

posi

sarc

oma

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C4

7; C

49Co

nnec

tive,

Soft

tissu

e2

0.7%

0.3

0.5

33.

8%1.

31.

51

0.6%

0.2

0.4

C50

Brea

st0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C60

Peni

s0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C61

Pros

tate

93.

2%1.

52.

82

2.5%

0.9

1.3

74.

4%1.

62.

4C6

2Te

stis

20.

7%0.

30.

40

0.0%

0.0

0.0

31.

9%0.

70.

9C6

3O

ther

mal

e ge

nita

l0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C64

Kidn

ey11

3.9%

1.9

3.2

33.

8%1.

32.

02

1.3%

0.5

0.5

C65

Rena

l Pel

vis0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C66

Uret

er0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C67

Blad

der

134.

7%2.

23.

61

1.3%

0.4

0.4

42.

5%0.

91.

2C6

8O

ther

Urin

ary

orga

ns0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C69

Eye

10.

4%0.

20.

31

1.3%

0.4

0.4

31.

9%0.

70.

6C7

0-C7

2Br

ain,

Ner

vous

sys

tem

113.

9%1.

91.

93

3.8%

1.3

1.1

74.

4%1.

62.

3C7

3Th

yroi

d11

3.9%

1.9

2.5

67.

6%2.

63.

69

5.7%

2.1

2.8

C74

Adre

nal g

land

10.

4%0.

20.

10

0.0%

0.0

0.0

10.

6%0.

20.

2C7

5O

ther

End

ocrin

e0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C81

Hodg

kin d

iseas

e11

3.9%

1.9

2.1

56.

3%2.

22.

214

8.8%

3.3

3.8

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

259.

0%4.

25.

53

3.8%

1.3

1.8

148.

8%3.

34.

1C8

8Im

mun

opro

lifera

tive

dis.

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C9

0M

ultip

le M

yelo

ma

20.

7%0.

30.

51

1.3%

0.4

0.6

00.

0%0.

00.

0C9

1Ly

mph

oid

Leuk

emia

113.

9%1.

91.

74

5.1%

1.7

1.4

95.

7%2.

12.

6C9

2-C9

4M

yelo

id L

euke

mia

72.

5%1.

21.

62

2.5%

0.9

1.1

42.

5%0.

91.

0C9

5Le

ukem

ia u

nspe

cified

51.

8%0.

81.

30

0.0%

0.0

0.0

10.

6%0.

20.

2O

ther

Oth

er &

uns

pecifi

ed23

8.2%

3.9

6.3

33.

8%1.

32.

111

6.9%

2.6

3.9

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

All

All s

ites

Tota

l27

910

0.0%

47.1

73.2

7910

0.0%

34.4

42.2

159

100.

0%37

.451

.3No

t C44

All s

ites

but C

4426

093

.2%

43.9

67.8

7189

.9%

30.9

38.4

151

95.0

%35

.548

.5

Crud

e Ra

teAS

R W

orld

Mad

inah

All A

ges

ICD

(10t

h)Si

teAl

l Age

s%

of T

otal

% o

f Tot

alCr

ude

Rate

ASR

Wor

ldHa

ilQ

assi

mAl

l Age

s%

of T

otal

Crud

e Ra

teAS

R W

orld

SCR2006 Part05.indd 75 09-04-2010 3:29:38 AM

76

Tab

le 5

.2.3

Nu

mb

er, R

elat

ive

Fre

qu

enci

es, A

ge S

tan

dar

diz

ed a

nd

Cru

de

Rat

es fo

r A

ll C

ance

r C

ases

am

on

g S

aud

i Mal

es b

y S

ite

and

Ad

min

istr

ativ

e R

egio

n, 2

006

C00

Lip

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C01-

C02

Tong

ue0

0.0%

0.0

0.0

22.

9%1.

21.

72

1.4%

0.6

0.9

00.

0%0.

00.

0C0

3-C0

6M

outh

00.

0%0.

00.

00

0.0%

0.0

0.0

32.

2%0.

92.

80

0.0%

0.0

0.0

C07-

C08

Saliv

ary

glan

ds0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C10

Oth

er O

roph

aryn

x0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x2

3.2%

1.1

2.5

22.

9%1.

22.

52

1.4%

0.6

1.1

00.

0%0.

00.

0C1

2-C1

3Hy

poph

aryn

x1

1.6%

0.5

1.1

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

4Ph

aryn

x un

spec

ified

00.

0%0.

00.

00

0.0%

0.0

0.0

10.

7%0.

31.

00

0.0%

0.0

0.0

C15

Oes

opha

gus

11.

6%0.

51.

12

2.9%

1.2

2.3

21.

4%0.

61.

80

0.0%

0.0

0.0

C16

Stom

ach

23.

2%1.

12.

63

4.3%

1.8

4.0

21.

4%0.

61.

62

3.8%

1.6

3.6

C17

Smal

l inte

stin

e0

0.0%

0.0

0.0

11.

4%0.

61.

21

0.7%

0.3

1.1

11.

9%0.

81.

7C1

8Co

lon

46.

3%2.

25.

33

4.3%

1.8

3.0

53.

6%1.

53.

74

7.5%

3.2

4.9

C19-

C20

Rect

um0

0.0%

0.0

0.0

00.

0%0.

00.

03

2.2%

0.9

3.0

00.

0%0.

00.

0C2

1An

us0

0.0%

0.0

0.0

00.

0%0.

00.

02

1.4%

0.6

2.0

00.

0%0.

00.

0C2

2Li

ver

1523

.8%

8.1

17.4

34.

3%1.

84.

65

3.6%

1.5

4.6

00.

0%0.

00.

0C2

3-C2

4G

allb

ladd

er e

tc.

11.

6%0.

51.

01

1.4%

0.6

1.7

21.

4%0.

61.

80

0.0%

0.0

0.0

C25

Panc

reas

11.

6%0.

51.

31

1.4%

0.6

1.1

21.

4%0.

61.

62

3.8%

1.6

4.9

C30-

C31

Nose

, sin

uses

etc

.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C3

2La

rynx

00.

0%0.

00.

00

0.0%

0.0

0.0

21.

4%0.

61.

91

1.9%

0.8

1.6

C33-

C34

Trac

hea,

Bro

nchu

s, L

ung

23.

2%1.

12.

24

5.7%

2.5

5.1

96.

5%2.

87.

92

3.8%

1.6

5.5

C37-

C38

Oth

er T

hora

cic o

rgan

s0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C4

0-C4

1Bo

ne0

0.0%

0.0

0.0

34.

3%1.

81.

34

2.9%

1.2

1.2

00.

0%0.

00.

0C4

3M

elan

oma

of S

kin0

0.0%

0.0

0.0

00.

0%0.

00.

01

0.7%

0.3

1.1

00.

0%0.

00.

0C4

4O

ther

Skin

69.

5%3.

26.

45

7.1%

3.1

6.6

85.

8%2.

57.

21

1.9%

0.8

1.1

C45

Mes

othe

liom

a1

1.6%

0.5

1.2

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C4

6Ka

posi

sarc

oma

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

01

1.9%

0.8

3.2

C47;

C49

Conn

ectiv

e,So

ft tis

sue

11.

6%0.

50.

53

4.3%

1.8

2.9

32.

2%0.

91.

81

1.9%

0.8

1.6

C50

Brea

st0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

0Pe

nis

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C61

Pros

tate

23.

2%1.

12.

23

4.3%

1.8

3.6

42.

9%1.

24.

21

1.9%

0.8

1.4

C62

Test

is0

0.0%

0.0

0.0

00.

0%0.

00.

02

1.4%

0.6

0.9

00.

0%0.

00.

0C6

3O

ther

mal

e ge

nita

l0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

11.

9%0.

82.

3C6

4Ki

dney

23.

2%1.

12.

63

4.3%

1.8

3.3

21.

4%0.

61.

32

3.8%

1.6

2.3

C65

Rena

l Pel

vis0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

6Ur

eter

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C67

Blad

der

23.

2%1.

11.

92

2.9%

1.2

2.4

85.

8%2.

56.

85

9.4%

4.0

7.9

C68

Oth

er U

rinar

y or

gans

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C69

Eye

23.

2%1.

10.

90

0.0%

0.0

0.0

10.

7%0.

30.

21

1.9%

0.8

3.2

C70-

C72

Brai

n, N

ervo

us s

yste

m1

1.6%

0.5

1.1

34.

3%1.

82.

311

8.0%

3.4

7.7

35.

7%2.

42.

7C7

3Th

yroi

d0

0.0%

0.0

0.0

45.

7%2.

53.

56

4.3%

1.9

2.8

23.

8%1.

63.

3C7

4Ad

rena

l gla

nd1

1.6%

0.5

0.4

11.

4%0.

60.

51

0.7%

0.3

0.2

00.

0%0.

00.

0C7

5O

ther

End

ocrin

e0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

11.

9%0.

81.

7C8

1Ho

dgkin

dise

ase

46.

3%2.

22.

63

4.3%

1.8

2.0

107.

2%3.

13.

84

7.5%

3.2

2.5

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

812

.7%

4.3

4.8

912

.9%

5.5

4.8

128.

7%3.

77.

43

5.7%

2.4

2.8

C88

Imm

unop

rolife

rativ

e di

s.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C9

0M

ultip

le M

yelo

ma

00.

0%0.

00.

02

2.9%

1.2

1.9

00.

0%0.

00.

01

1.9%

0.8

1.7

C91

Lym

phoi

d Le

ukem

ia2

3.2%

1.1

0.9

11.

4%0.

61.

14

2.9%

1.2

0.9

47.

5%3.

24.

3C9

2-C9

4M

yelo

id L

euke

mia

23.

2%1.

11.

92

2.9%

1.2

1.0

42.

9%1.

22.

06

11.3

%4.

84.

5C9

5Le

ukem

ia u

nspe

cified

00.

0%0.

00.

00

0.0%

0.0

0.0

21.

4%0.

61.

31

1.9%

0.8

0.7

Oth

erO

ther

& u

nspe

cified

00.

0%0.

00.

04

5.7%

2.5

5.2

128.

7%3.

78.

13

5.7%

2.4

6.3

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

All

All s

ites

Tota

l63

100.

0%34

.162

.070

100.

0%43

.069

.613

810

0.0%

42.6

95.8

5310

0.0%

42.4

75.8

Not C

44Al

l site

s bu

t C44

5790

.5%

30.8

55.5

6592

.9%

40.0

62.9

130

94.2

%40

.188

.652

98.1

%41

.674

.6

ASR

Wor

ld

North

ern

Regi

onTa

buk

All A

ges

% o

f To

tal

Crud

e Ra

teAl

l Age

s%

of

Tota

lCr

ude

Rate

ASR

Wor

ldCr

ude

Rate

ASR

Wor

ld

Jouf

Crud

e Ra

teAS

R W

orld

Najra

nAl

l Age

sIC

D (1

0th)

Site

All A

ges

% o

f To

tal

% o

f To

tal

SCR2006 Part05.indd 76 09-04-2010 3:29:38 AM

77

Tab

le 5

.2.4

Nu

mb

er, R

elat

ive

Fre

qu

enci

es, A

ge S

tan

dar

diz

ed a

nd

Cru

de

Rat

es fo

r A

ll C

ance

r C

ases

am

on

g S

aud

i Mal

es b

y S

ite

and

Ad

min

istr

ativ

e R

egio

n, 2

006

C00

Lip

10.

1%0

0.1

10.

1%0.

10.

10

0.0%

00

C01-

C02

Tong

ue9

0.9%

0.4

0.8

70.

8%0.

40.

53

0.5%

0.2

0.7

C03-

C06

Mou

th6

0.6%

0.3

0.7

80.

9%0.

40.

83

0.5%

0.2

0.6

C07-

C08

Saliv

ary

glan

ds4

0.4%

0.2

0.3

10.

1%0.

10

20.

3%0.

10.

1C0

9To

nsil

00.

0%0

00

0.0%

00

00.

0%0

0C1

0O

ther

Oro

phar

ynx

00.

0%0

00

0.0%

00

00.

0%0

0C1

1Na

soph

aryn

x19

1.9%

0.9

1.4

212.

3%1.

11.

520

3.2%

1.5

2.2

C12-

C13

Hypo

phar

ynx

10.

1%0

0.1

30.

3%0.

20.

32

0.3%

0.1

0.3

C14

Phar

ynx

unsp

ecifie

d0

0.0%

00

00.

0%0

00

0.0%

00

C15

Oes

opha

gus

101.

0%0.

51.

118

1.9%

11.

66

1.0%

0.4

1.2

C16

Stom

ach

323.

1%1.

63.

553

5.7%

2.9

4.7

203.

2%1.

53.

8C1

7Sm

all in

test

ine

40.

4%0.

20.

55

0.5%

0.3

0.4

10.

2%0.

10.

1C1

8Co

lon

757.

3%3.

77.

258

6.2%

3.1

5.3

325.

2%2.

45.

4C1

9-C2

0Re

ctum

515.

0%2.

55.

246

5.0%

2.5

4.2

325.

2%2.

45.

2C2

1An

us0

0.0%

00

30.

3%0.

20.

31

0.2%

0.1

0.1

C22

Live

r96

9.4%

4.8

11.2

576.

1%3.

15.

237

6.0%

2.7

5.8

C23-

C24

Gal

lbla

dder

etc

.16

1.6%

0.8

1.9

70.

8%0.

40.

67

1.1%

0.5

1.3

C25

Panc

reas

202.

0%1

2.1

353.

8%1.

93.

515

2.4%

1.1

3C3

0-C3

1No

se, s

inus

es e

tc.

20.

2%0.

10.

11

0.1%

0.1

01

0.2%

0.1

0.1

C32

Lary

nx19

1.9%

0.9

2.1

232.

5%1.

22.

17

1.1%

0.5

2C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g55

5.4%

2.7

6.3

697.

4%3.

76.

651

8.2%

3.7

10.4

C37-

C38

Oth

er T

hora

cic o

rgan

s4

0.4%

0.2

0.2

40.

4%0.

20.

33

0.5%

0.2

0.2

C40-

C41

Bone

222.

2%1.

11.

214

1.5%

0.8

0.7

61.

0%0.

40.

3C4

3M

elan

oma

of S

kin2

0.2%

0.1

0.1

20.

2%0.

10.

21

0.2%

0.1

0.1

C44

Oth

er S

kin40

3.9%

24.

241

4.4%

2.2

3.4

172.

7%1.

22.

8C4

5M

esot

helio

ma

20.

2%0.

10.

12

0.2%

0.1

0.2

30.

5%0.

20.

9C4

6Ka

posi

sarc

oma

50.

5%0.

20.

56

0.6%

0.3

0.5

40.

6%0.

30.

5C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue17

1.7%

0.8

1.2

101.

1%0.

50.

69

1.4%

0.7

0.9

C50

Brea

st7

0.7%

0.3

0.6

60.

6%0.

30.

53

0.5%

0.2

0.4

C60

Peni

s0

0.0%

00

10.

1%0.

10.

10

0.0%

00

C61

Pros

tate

696.

8%3.

47.

870

7.5%

3.8

6.6

355.

6%2.

67.

7C6

2Te

stis

101.

0%0.

50.

54

0.4%

0.2

0.2

121.

9%0.

90.

9C6

3O

ther

mal

e ge

nita

l0

0.0%

00

10.

1%0.

10.

11

0.2%

0.1

0.4

C64

Kidn

ey30

2.9%

1.5

2.9

252.

7%1.

32

223.

5%1.

63.

4C6

5Re

nal P

elvis

10.

1%0

0.1

30.

3%0.

20.

31

0.2%

0.1

0.2

C66

Uret

er0

0.0%

00

10.

1%0.

10.

10

0.0%

00

C67

Blad

der

424.

1%2.

14.

448

5.2%

2.6

4.6

243.

9%1.

84.

1C6

8O

ther

Urin

ary

orga

ns0

0.0%

00

00.

0%0

00

0.0%

00

C69

Eye

20.

2%0.

10.

18

0.9%

0.4

0.4

50.

8%0.

40.

4C7

0-C7

2Br

ain,

Ner

vous

sys

tem

403.

9%2

2.8

293.

1%1.

62.

124

3.9%

1.8

2.9

C73

Thyr

oid

373.

6%1.

82.

517

1.8%

0.9

1.3

193.

1%1.

43.

1C7

4Ad

rena

l gla

nd2

0.2%

0.1

0.1

50.

5%0.

30.

35

0.8%

0.4

0.4

C75

Oth

er E

ndoc

rine

20.

2%0.

10.

10

0.0%

00

00.

0%0

0C8

1Ho

dgkin

dise

ase

373.

6%1.

81.

839

4.2%

2.1

2.1

294.

7%2.

12

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

918.

9%4.

57.

680

8.6%

4.3

6.2

619.

8%4.

57.

8C8

8Im

mun

opro

lifera

tive

dis.

00.

0%0

00

0.0%

00

00.

0%0

0C9

0M

ultip

le M

yelo

ma

191.

9%0.

92.

213

1.4%

0.7

1.2

71.

1%0.

51.

2C9

1Ly

mph

oid

Leuk

emia

434.

2%2.

12.

722

2.4%

1.2

1.5

304.

8%2.

23.

6C9

2-C9

4M

yelo

id L

euke

mia

333.

2%1.

62.

220

2.2%

1.1

1.3

193.

1%1.

41.

8C9

5Le

ukem

ia u

nspe

cified

50.

5%0.

20.

35

0.5%

0.3

0.4

50.

8%0.

40.

7O

ther

Oth

er &

uns

pecifi

ed40

3.9%

23.

837

4.0%

23.

236

5.8%

2.6

6.5

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

All

All s

ites

Tota

l10

2210

0.0%

51.1

94.4

929

100.

0%50

78.4

621

100.

0%45

.695

.6No

t C44

All s

ites

but C

4498

296

.1%

49.1

90.2

888

95.6

%47

.875

604

97.3

%44

.492

.8

ASR

Wor

ldEa

ster

n Pr

ovin

ceM

akka

hAl

l Age

s%

of T

otal

Crud

e Ra

te%

of T

otal

All A

ges

Crud

e Ra

teAS

R W

orld

Crud

e Ra

teAS

R W

orld

Riya

dhIC

D (1

0th)

Site

All A

ges

% o

f Tot

al

SCR2006 Part05.indd 77 09-04-2010 3:29:38 AM

78

Tab

le 5

.3.1

Nu

mb

er,

Rel

ativ

e F

req

uen

cies

, Age

Sta

nd

ard

ized

an

d C

rud

e R

ates

fo

r A

ll C

ance

r C

ases

Am

on

g S

aud

i Fem

ales

by

Sit

e an

d R

egio

n,

2006

C00

Lip

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C0

1-C0

2To

ngue

31.

0%0.

40.

70

0.0%

0.0

0.0

99.

1%1.

73.

5C0

3-C0

6M

outh

00.

0%0.

00.

00

0.0%

0.0

0.0

1414

.1%

2.6

4.6

C07-

C08

Saliv

ary

glan

ds0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C09

Tons

il0

0.0%

0.0

0.0

12.

0%0.

60.

51

1.0%

0.2

0.2

C10

Oth

er O

roph

aryn

x0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C11

Naso

phar

ynx

20.

7%0.

30.

21

2.0%

0.6

0.9

11.

0%0.

20.

3C1

2-C1

3Hy

poph

aryn

x1

0.3%

0.1

0.1

12.

0%0.

60.

90

0.0%

0.0

0.0

C14

Phar

ynx

unsp

ecifie

d0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C15

Oes

opha

gus

20.

7%0.

30.

20

0.0%

0.0

0.0

44.

0%0.

71.

6C1

6St

omac

h12

4.1%

1.6

2.6

12.

0%0.

60.

92

2.0%

0.4

0.6

C17

Smal

l inte

stin

e1

0.3%

0.1

0.1

00.

0%0.

00.

01

1.0%

0.2

0.3

C18

Colo

n16

5.5%

2.1

3.5

12.

0%0.

61.

03

3.0%

0.6

0.7

C19-

C20

Rect

um12

4.1%

1.6

2.7

36.

0%1.

72.

00

0.0%

0.0

0.0

C21

Anus

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C2

2Li

ver

103.

4%1.

32.

11

2.0%

0.6

0.4

33.

0%0.

61.

1C2

3-C2

4G

allb

ladd

er e

tc.

20.

7%0.

30.

52

4.0%

1.1

1.9

44.

0%0.

71.

2C2

5Pa

ncre

as2

0.7%

0.3

0.4

12.

0%0.

60.

93

3.0%

0.6

1.3

C30-

C31

Nose

, sin

uses

etc

.2

0.7%

0.3

0.2

00.

0%0.

00.

00

0.0%

0.0

0.0

C32

Lary

nx2

0.7%

0.3

0.5

00.

0%0.

00.

00

0.0%

0.0

0.0

C33-

C34

Trac

hea,

Bro

nchu

s, L

ung

31.

0%0.

40.

70

0.0%

0.0

0.0

00.

0%0.

00.

0C3

7-C3

8O

ther

Tho

racic

org

ans

10.

3%0.

10.

20

0.0%

0.0

0.0

00.

0%0.

00.

0C4

0-C4

1Bo

ne2

0.7%

0.3

0.2

00.

0%0.

00.

02

2.0%

0.4

0.3

C43

Mel

anom

a of

Skin

31.

0%0.

40.

50

0.0%

0.0

0.0

11.

0%0.

20.

4C4

4O

ther

Skin

217.

2%2.

84.

13

6.0%

1.7

1.7

22.

0%0.

40.

9C4

5M

esot

helio

ma

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C4

6Ka

posi

sarc

oma

00.

0%0.

00.

01

2.0%

0.6

0.4

22.

0%0.

40.

5C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue4

1.4%

0.5

0.6

00.

0%0.

00.

01

1.0%

0.2

0.2

C50

Brea

st48

16.4

%6.

39.

47

14.0

%3.

95.

29

9.1%

1.7

2.6

C51

Vulva

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C5

2Va

gina

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C5

3Ce

rvix

Uter

i6

2.1%

0.8

1.3

12.

0%0.

60.

91

1.0%

0.2

0.3

C54

Corp

us U

teri

93.

1%1.

21.

83

6.0%

1.7

2.8

22.

0%0.

40.

6C5

5Ut

erus

uns

pecifi

ed2

0.7%

0.3

0.5

00.

0%0.

00.

00

0.0%

0.0

0.0

C56

Ova

ry11

3.8%

1.4

2.2

24.

0%1.

11.

91

1.0%

0.2

0.7

C57

Oth

er F

emal

e G

enita

l0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C58

Plac

enta

20.

7%0.

30.

22

4.0%

1.1

1.6

00.

0%0.

00.

0C6

4Ki

dney

41.

4%0.

50.

61

2.0%

0.6

0.9

22.

0%0.

40.

5C6

5Re

nal P

elvis

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

6Ur

eter

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

7Bl

adde

r5

1.7%

0.7

0.8

12.

0%0.

60.

92

2.0%

0.4

0.9

C68

Oth

er U

rinar

y or

gans

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

9Ey

e0

0.0%

0.0

0.0

00.

0%0.

00.

02

2.0%

0.4

0.6

C70-

C72

Brai

n, N

ervo

us s

yste

m4

1.4%

0.5

0.4

12.

0%0.

61.

02

2.0%

0.4

0.6

C73

Thyr

oid

3411

.6%

4.5

5.7

612

.0%

3.4

4.2

55.

1%0.

91.

1C7

4Ad

rena

l gla

nd1

0.3%

0.1

0.1

00.

0%0.

00.

01

1.0%

0.2

0.2

C75

Oth

er E

ndoc

rine

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C8

1Ho

dgkin

dise

ase

103.

4%1.

31.

81

2.0%

0.6

0.6

33.

0%0.

60.

6C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a15

5.1%

2.0

3.2

36.

0%1.

71.

96

6.1%

1.1

2.1

C88

Imm

unop

rolife

rativ

e di

s.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C90

Mul

tiple

Mye

lom

a1

0.3%

0.1

0.2

00.

0%0.

00.

00

0.0%

0.0

0.0

C91

Lym

phoi

d Le

ukem

ia9

3.1%

1.2

1.2

36.

0%1.

71.

62

2.0%

0.4

0.3

C92-

C94

Mye

loid

Leu

kem

ia11

3.8%

1.4

1.8

12.

0%0.

60.

54

4.0%

0.7

0.9

C95

Leuk

emia

uns

pecifi

ed3

1.0%

0.4

0.4

00.

0%0.

00.

01

1.0%

0.2

0.3

Oth

erO

ther

& u

nspe

cified

165.

5%2.

13.

72

4.0%

1.1

1.1

33.

0%0.

60.

6---

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

--Al

lAl

l site

s To

tal

292

100.

0%38

.455

.550

100.

0%28

.236

.299

100.

0%18

.530

.7No

t C44

All s

ites

but C

4427

192

.8%

35.6

51.4

4794

.0%

26.5

34.5

9798

.0%

18.2

29.8

Crud

e Ra

teAS

R W

orld

Asir

All A

ges

ICD

(10t

h)Si

teAl

l Age

s%

of T

otal

% o

f Tot

alCr

ude

Rate

ASR

Wor

ldBa

haJa

zan

All A

ges

% o

f Tot

alCr

ude

Rate

ASR

Wor

ld

SCR2006 Part05.indd 78 09-04-2010 3:29:39 AM

79

Tab

le 5

.3.2

Nu

mb

er,

Rel

ativ

e F

req

uen

cies

, Age

Sta

nd

ard

ized

an

d C

rud

e R

ates

fo

r A

ll C

ance

r C

ases

Am

on

g S

aud

i Fem

ales

by

Sit

e an

d R

egio

n,

2006

C00

Lip

00.

0%0.

00.

01

1.2%

0.4

0.6

00.

0%0.

00.

0C0

1-C0

2To

ngue

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C0

3-C0

6M

outh

10.

3%0.

20.

30

0.0%

0.0

0.0

10.

6%0.

20.

4C0

7-C0

8Sa

livar

y gl

ands

10.

3%0.

20.

40

0.0%

0.0

0.0

21.

2%0.

51.

1C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

0O

ther

Oro

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x6

1.9%

1.0

1.2

56.

0%2.

12.

82

1.2%

0.5

1.1

C12-

C13

Hypo

phar

ynx

10.

3%0.

20.

30

0.0%

0.0

0.0

00.

0%0.

00.

0C1

4Ph

aryn

x un

spec

ified

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

5O

esop

hagu

s13

4.1%

2.2

3.7

00.

0%0.

00.

04

2.3%

0.9

1.7

C16

Stom

ach

103.

2%1.

73.

23

3.6%

1.2

1.9

63.

5%1.

42.

6C1

7Sm

all in

test

ine

20.

6%0.

30.

50

0.0%

0.0

0.0

00.

0%0.

00.

0C1

8Co

lon

216.

7%3.

55.

72

2.4%

0.8

1.2

105.

8%2.

33.

9C1

9-C2

0Re

ctum

134.

1%2.

23.

83

3.6%

1.2

1.8

31.

7%0.

71.

3C2

1An

us2

0.6%

0.3

0.4

00.

0%0.

00.

00

0.0%

0.0

0.0

C22

Live

r11

3.5%

1.8

3.3

11.

2%0.

40.

73

1.7%

0.7

1.5

C23-

C24

Gal

lbla

dder

etc

.5

1.6%

0.8

1.3

33.

6%1.

21.

93

1.7%

0.7

1.7

C25

Panc

reas

41.

3%0.

71.

30

0.0%

0.0

0.0

21.

2%0.

50.

7C3

0-C3

1No

se, s

inus

es e

tc.

20.

6%0.

30.

60

0.0%

0.0

0.0

00.

0%0.

00.

0C3

2La

rynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g8

2.5%

1.3

2.4

00.

0%0.

00.

04

2.3%

0.9

1.3

C37-

C38

Oth

er T

hora

cic o

rgan

s1

0.3%

0.2

0.1

00.

0%0.

00.

01

0.6%

0.2

0.4

C40-

C41

Bone

20.

6%0.

30.

31

1.2%

0.4

0.3

31.

7%0.

70.

6C4

3M

elan

oma

of S

kin4

1.3%

0.7

1.1

00.

0%0.

00.

00

0.0%

0.0

0.0

C44

Oth

er S

kin14

4.5%

2.3

3.9

44.

8%1.

72.

28

4.6%

1.9

3.0

C45

Mes

othe

liom

a0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C46

Kapo

si sa

rcom

a0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C47;

C49

Conn

ectiv

e, S

oft t

issue

31.

0%0.

50.

61

1.2%

0.4

0.3

10.

6%0.

20.

3C5

0Br

east

6621

.0%

10.9

16.6

2732

.1%

11.2

16.0

4727

.2%

11.0

14.8

C51

Vulva

10.

3%0.

20.

30

0.0%

0.0

0.0

00.

0%0.

00.

0C5

2Va

gina

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C5

3Ce

rvix

Uter

i4

1.3%

0.7

1.1

11.

2%0.

40.

60

0.0%

0.0

0.0

C54

Corp

us U

teri

72.

2%1.

22.

22

2.4%

0.8

1.0

42.

3%0.

91.

8C5

5Ut

erus

uns

pecifi

ed.

10.

3%0.

20.

41

1.2%

0.4

0.6

00.

0%0.

00.

0C5

6O

vary

82.

5%1.

32.

01

1.2%

0.4

0.4

52.

9%1.

22.

0C5

7O

ther

Fem

ale

Gen

ital

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C5

8Pl

acen

ta1

0.3%

0.2

0.2

11.

2%0.

40.

42

1.2%

0.5

0.4

C64

Kidn

ey5

1.6%

0.8

1.0

22.

4%0.

81.

11

0.6%

0.2

0.4

C65

Rena

l Pel

vis1

0.3%

0.2

0.3

00.

0%0.

00.

00

0.0%

0.0

0.0

C66

Uret

er0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C67

Blad

der

20.

6%0.

30.

60

0.0%

0.0

0.0

00.

0%0.

00.

0C6

8O

ther

Urin

ary

orga

ns0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C69

Eye

20.

6%0.

30.

70

0.0%

0.0

0.0

00.

0%0.

00.

0C7

0-C7

2Br

ain,

Ner

vous

sys

tem

175.

4%2.

84.

06

7.1%

2.5

2.8

31.

7%0.

70.

6C7

3Th

yroi

d21

6.7%

3.5

4.2

910

.7%

3.7

4.4

2615

.0%

6.1

7.2

C74

Adre

nal g

land

10.

3%0.

20.

21

1.2%

0.4

0.4

10.

6%0.

20.

2C7

5O

ther

End

ocrin

e0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C81

Hodg

kin d

iseas

e7

2.2%

1.2

1.1

44.

8%1.

71.

311

6.4%

2.6

2.7

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

247.

6%4.

06.

91

1.2%

0.4

0.4

42.

3%0.

92.

0C8

8Im

mun

opro

lifera

tive

dis.

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C9

0M

ultip

le M

yelo

ma

20.

6%0.

30.

70

0.0%

0.0

0.0

42.

3%0.

91.

2C9

1Ly

mph

oid

Leuk

emia

20.

6%0.

30.

30

0.0%

0.0

0.0

42.

3%0.

91.

2C9

2-C9

4M

yelo

id L

euke

mia

61.

9%1.

01.

11

1.2%

0.4

0.4

21.

2%0.

50.

5C9

5Le

ukem

ia u

nspe

cified

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0O

ther

Oth

er &

uns

pecifi

ed12

3.8%

2.0

3.2

33.

6%1.

22.

06

3.5%

1.4

2.5

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

All

All s

ites

Tota

l31

410

0.0%

52.0

81.2

8410

0.0%

34.9

45.7

173

100.

0%40

.659

.1No

t C44

All s

ites

but C

4430

095

.5%

49.7

77.4

8095

.2%

33.2

43.5

165

95.4

%38

.856

.2

% o

f Tot

alCr

ude

Rate

ASR

Wor

ldHa

ilQ

assi

mAl

l Age

s%

of T

otal

Crud

e Ra

teAS

R W

orld

Crud

e Ra

teAS

R W

orld

Mad

inah

All A

ges

ICD

(10t

h)Si

teAl

l Age

s%

of T

otal

SCR2006 Part05.indd 79 09-04-2010 3:29:39 AM

80

Tab

le 5

.3.3

Nu

mb

er,

Rel

ativ

e F

req

uen

cies

, Age

Sta

nd

ard

ized

an

d C

rud

e R

ates

fo

r A

ll C

ance

r C

ases

Am

on

g S

aud

i Fem

ales

by

Sit

e an

d R

egio

n,

2006

C00

Lip

00.

0%0.

00.

00

0.0%

0.0

0.0

10.

7%0.

31.

10

0.0%

0.0

0.0

C01-

C02

Tong

ue0

0.0%

0.0

0.0

11.

9%0.

61.

60

0.0%

0.0

0.0

00.

0%0.

00.

0C0

3-C0

6M

outh

00.

0%0.

00.

02

3.7%

1.2

2.4

21.

5%0.

71.

70

0.0%

0.0

0.0

C07-

C08

Saliv

ary

glan

ds0

0.0%

0.0

0.0

11.

9%0.

61.

10

0.0%

0.0

0.0

00.

0%0.

00.

0C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C10

Oth

er O

roph

aryn

x0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x0

0.0%

0.0

0.0

00.

0%0.

00.

02

1.5%

0.7

1.8

00.

0%0.

00.

0C1

2-C1

3Hy

poph

aryn

x0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

12.

7%0.

81.

2C1

4Ph

aryn

x un

spec

ified

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C15

Oes

opha

gus

00.

0%0.

00.

00

0.0%

0.0

0.0

32.

2%1.

03.

10

0.0%

0.0

0.0

C16

Stom

ach

24.

4%1.

11.

52

3.7%

1.2

2.7

21.

5%0.

71.

40

0.0%

0.0

0.0

C17

Smal

l inte

stin

e0

0.0%

0.0

0.0

00.

0%0.

00.

01

0.7%

0.3

1.0

00.

0%0.

00.

0C1

8Co

lon

24.

4%1.

11.

82

3.7%

1.2

3.4

75.

1%2.

35.

01

2.7%

0.8

1.3

C19-

C20

Rect

um1

2.2%

0.5

0.8

00.

0%0.

00.

01

0.7%

0.3

1.1

12.

7%0.

81.

7C2

1An

us0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C2

2Li

ver

36.

7%1.

62.

50

0.0%

0.0

0.0

21.

5%0.

71.

61

2.7%

0.8

1.3

C23-

C24

Gal

lbla

dder

etc

.1

2.2%

0.5

0.8

00.

0%0.

00.

00

0.0%

0.0

0.0

25.

4%1.

64.

1C2

5Pa

ncre

as2

4.4%

1.1

2.0

47.

4%2.

55.

46

4.4%

2.0

4.9

12.

7%0.

83.

2C3

0-C3

1No

se, s

inus

es e

tc.

00.

0%0.

00.

01

1.9%

0.6

2.3

00.

0%0.

00.

00

0.0%

0.0

0.0

C32

Lary

nx0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g0

0.0%

0.0

0.0

23.

7%1.

23.

51

0.7%

0.3

1.1

25.

4%1.

64.

4C3

7-C3

8O

ther

Tho

racic

org

ans

00.

0%0.

00.

00

0.0%

0.0

0.0

10.

7%0.

30.

30

0.0%

0.0

0.0

C40-

C41

Bone

00.

0%0.

00.

00

0.0%

0.0

0.0

42.

9%1.

31.

01

2.7%

0.8

0.5

C43

Mel

anom

a of

Skin

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C44

Oth

er S

kin0

0.0%

0.0

0.0

47.

4%2.

54.

76

4.4%

2.0

4.0

25.

4%1.

63.

0C4

5M

esot

helio

ma

00.

0%0.

00.

01

1.9%

0.6

1.6

00.

0%0.

00.

01

2.7%

0.8

1.7

C46

Kapo

si sa

rcom

a0

0.0%

0.0

0.0

00.

0%0.

00.

01

0.7%

0.3

1.1

00.

0%0.

00.

0C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue1

2.2%

0.5

0.8

00.

0%0.

00.

01

0.7%

0.3

0.2

00.

0%0.

00.

0C5

0Br

east

613

.3%

3.2

4.5

1018

.5%

6.2

9.8

3022

.1%

9.8

16.7

718

.9%

5.6

13.3

C51

Vulva

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C52

Vagi

na0

0.0%

0.0

0.0

00.

0%0.

00.

01

0.7%

0.3

0.6

00.

0%0.

00.

0C5

3Ce

rvix

Uter

i4

8.9%

2.1

4.5

11.

9%0.

61.

10

0.0%

0.0

0.0

00.

0%0.

00.

0C5

4Co

rpus

Ute

ri1

2.2%

0.5

1.2

23.

7%1.

23.

52

1.5%

0.7

1.8

25.

4%1.

62.

1C5

5Ut

erus

uns

pecifi

ed.

12.

2%0.

50.

60

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C56

Ova

ry3

6.7%

1.6

3.5

35.

6%1.

95.

95

3.7%

1.6

3.6

12.

7%0.

81.

5C5

7O

ther

Fem

ale

Gen

ital

00.

0%0.

00.

01

1.9%

0.6

0.6

00.

0%0.

00.

00

0.0%

0.0

0.0

C58

Plac

enta

12.

2%0.

50.

41

1.9%

0.6

1.1

00.

0%0.

00.

01

2.7%

0.8

0.6

C64

Kidn

ey2

4.4%

1.1

2.4

00.

0%0.

00.

02

1.5%

0.7

0.5

25.

4%1.

62.

6C6

5Re

nal P

elvis

12.

2%0.

50.

80

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C66

Uret

er0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

7Bl

adde

r0

0.0%

0.0

0.0

11.

9%0.

61.

12

1.5%

0.7

2.3

00.

0%0.

00.

0C6

8O

ther

Urin

ary

orga

ns0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C6

9Ey

e0

0.0%

0.0

0.0

11.

9%0.

61.

11

0.7%

0.3

0.2

00.

0%0.

00.

0C7

0-C7

2Br

ain,

Ner

vous

sys

tem

36.

7%1.

61.

61

1.9%

0.6

0.5

32.

2%1.

01.

61

2.7%

0.8

0.6

C73

Thyr

oid

24.

4%1.

10.

82

3.7%

1.2

1.8

1712

.5%

5.5

8.5

35.

4%2.

44.

4C7

4Ad

rena

l gla

nd0

0.0%

0.0

0.0

11.

9%0.

60.

51

0.7%

0.3

0.2

00.

0%0.

00.

0C7

5O

ther

End

ocrin

e0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C8

1Ho

dgkin

dise

ase

12.

2%0.

50.

42

3.7%

1.2

0.8

42.

9%1.

31.

01

2.7%

0.8

1.2

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

24.

4%1.

11.

85

9.3%

3.1

5.2

85.

9%2.

65.

80

0.0%

0.0

0.0

C88

Imm

unop

rolife

rativ

e di

s.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C9

0M

ultip

le M

yelo

ma

12.

2%0.

50.

80

0.0%

0.0

0.0

21.

5%0.

72.

40

0.0%

0.0

0.0

C91

Lym

phoi

d Le

ukem

ia1

2.2%

0.5

0.8

11.

9%0.

62.

34

2.9%

1.3

1.4

12.

7%0.

81.

7C9

2-C9

4M

yelo

id L

euke

mia

24.

4%1.

11.

60

0.0%

0.0

0.0

64.

4%2.

02.

73

8.1%

2.4

5.1

C95

Leuk

emia

uns

pecifi

ed0

0.0%

0.0

0.0

00.

0%0.

00.

01

0.7%

0.3

1.0

12.

7%0.

83.

2O

ther

Oth

er &

uns

pecifi

ed2

4.4%

1.1

2.3

23.

7%1.

22.

06

4.4%

2.0

2.9

25.

4%1.

64.

9---

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

--Al

lAl

l site

s To

tal

4510

0.0%

24.1

38.0

5410

0.0%

33.5

66.4

136

100.

0%44

.383

.338

100.

0%30

.263

.6No

t C44

All s

ites

but C

4445

100.

0%24

.138

.050

92.6

%31

.161

.613

095

.6%

42.3

79.4

3694

.6%

28.6

60.6

ICD

(10t

h)Si

teAl

l Age

s%

of

Tota

lCr

ude

Rate

Najra

n%

of

Tota

lAl

l Age

sCr

ude

Rate

ASR

Wor

ld

Jouf

ASR

Wor

ld

North

ern

Regi

onAl

l Age

s%

of

Tota

lCr

ude

Rate

ASR

Wor

ldAl

l Age

s%

of

Tota

lCr

ude

Rate

ASR

Wor

ld

Tabu

k

SCR2006 Part05.indd 80 09-04-2010 3:29:40 AM

81

Tab

le 5

.3.4

Nu

mb

er,

Rel

ativ

e F

req

uen

cies

, Age

Sta

nd

ard

ized

an

d C

rud

e R

ates

fo

r A

ll C

ance

r C

ases

Am

on

g S

aud

i Fem

ales

by

Sit

e an

d R

egio

n,

2006

C00

Lip

00.

0%0.

00.

02

0.2%

0.1

0.2

00.

0%0.

00.

0C0

1-C0

2To

ngue

40.

3%0.

20.

48

0.8%

0.4

0.7

10.

1%0.

10.

2C0

3-C0

6M

outh

60.

5%0.

30.

65

0.5%

0.3

0.5

30.

4%0.

20.

4C0

7-C0

8Sa

livar

y gl

ands

50.

4%0.

30.

32

0.2%

0.1

0.1

10.

1%0.

10.

1C0

9To

nsil

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

0O

ther

Oro

phar

ynx

00.

0%0.

00.

00

0.0%

0.0

0.0

00.

0%0.

00.

0C1

1Na

soph

aryn

x9

0.8%

0.5

0.6

111.

1%0.

60.

84

0.6%

0.3

0.5

C12-

C13

Hypo

phar

ynx

30.

3%0.

20.

32

0.2%

0.1

0.1

20.

3%0.

20.

2C1

4Ph

aryn

x un

spec

ified

00.

0%0.

00.

01

0.1%

0.1

0.1

00.

0%0.

00.

0C1

5O

esop

hagu

s9

0.8%

0.5

1.0

161.

7%0.

91.

512

1.7%

0.9

2.2

C16

Stom

ach

292.

5%1.

52.

828

2.9%

1.5

2.5

131.

8%1.

01.

9C1

7Sm

all in

test

ine

40.

3%0.

20.

43

0.3%

0.2

0.3

10.

1%0.

10.

2C1

8Co

lon

655.

6%3.

46.

956

5.8%

3.0

5.0

395.

4%3.

05.

5C1

9-C2

0Re

ctum

514.

4%2.

75.

432

3.3%

1.7

2.6

233.

2%1.

83.

5C2

1An

us4

0.3%

0.2

0.5

20.

2%0.

10.

21

0.1%

0.1

0.1

C22

Live

r43

3.7%

2.2

4.7

192.

0%1.

01.

825

3.5%

1.9

4.2

C23-

C24

Gal

lbla

dder

etc

.19

1.6%

1.0

2.0

131.

4%0.

71.

216

2.2%

1.2

2.8

C25

Panc

reas

232.

0%1.

22.

717

1.8%

0.9

1.6

81.

1%0.

61.

2C3

0-C3

1No

se, s

inus

es e

tc.

20.

2%0.

10.

21

0.1%

0.1

0.0

20.

3%0.

20.

2C3

2La

rynx

10.

1%0.

10.

04

0.4%

0.2

0.3

20.

3%0.

20.

1C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g23

2.0%

1.2

2.5

222.

3%1.

22.

014

2.0%

1.1

2.4

C37-

C38

Oth

er T

hora

cic o

rgan

s2

0.2%

0.1

0.1

30.

3%0.

20.

31

0 .1%

0.1

0.2

C40-

C41

Bone

60.

5%0.

30.

312

1.3%

0.6

0.7

30.

4%0.

20.

2C4

3M

elan

oma

of S

kin2

0.2%

0.1

0.2

10.

1%0.

10.

11

0.1%

0.1

0.1

C44

Oth

er S

kin30

2.6%

1.6

2.6

232.

4%1.

22.

117

2.4%

1.3

2.6

C45

Mes

othe

liom

a1

0.1%

0.1

0.2

00.

0%0.

00.

02

0.3%

0.2

0.3

C46

Kapo

si sa

rcom

a4

0.3%

0.2

0.4

10.

1%0.

10.

15

0.7%

0.4

0.8

C47;

C49

Conn

ectiv

e, S

oft t

issue

111.

0%0.

60.

89

0.9%

0.5

0.6

50.

7%0.

40.

3C5

0Br

east

275

23.5

%14

.322

.624

025

.1%

12.9

18.2

204

28.5

%15

.725

.4C5

1Vu

lva0

0.0%

0.0

0.0

30.

3%0.

20.

30

0.0%

0.0

0.0

C52

Vagi

na0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C53

Cerv

ix Ut

eri

161.

4%0.

81.

227

2.8%

1.5

2.2

131.

8%1.

01.

8C5

4Co

rpus

Ute

ri36

3.1%

1.9

3.8

454.

7%2.

44.

424

3.4%

1.8

4.2

C55

Uter

us u

nspe

cified

30.

3%0.

20.

312

1.3%

0.6

1.0

20.

3%0.

20.

4C5

6O

vary

373.

2%1.

93.

428

2.9%

1.5

2.5

273.

8%2.

13.

5C5

7O

ther

Fem

ale

Gen

ital

30.

3%0.

20.

35

0.5%

0.3

0.5

00.

0%0.

00.

0C5

8Pl

acen

ta3

0.3%

0.2

0.2

20.

2%0.

10.

13

0.4%

0.2

0.3

C64

Kidn

ey28

2.4%

1.5

2.4

171.

8%0.

91.

312

1.7%

0.9

1.7

C65

Rena

l Pel

vis0

0.0%

0.0

0.0

00.

0%0.

00.

02

0.3%

0.2

0.3

C66

Uret

er1

0.1%

0.1

0.1

10.

1%0.

10.

10

0.0%

0.0

0.0

C67

Blad

der

131.

1%0.

71.

410

1.0%

0.5

0.8

60.

8%0.

51.

1C6

8O

ther

Urin

ary

orga

ns0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C69

Eye

30.

3%0.

20.

18

0.8%

0.4

0.5

20.

3%0 .

20.

1C7

0-C7

2Br

ain,

Ner

vous

sys

tem

252.

1%1.

31.

821

2.2%

1.1

1.3

142.

0%1.

11.

3C7

3Th

yroi

d14

112

.0%

7.3

9.5

838.

7%4.

55.

673

10.2

%5.

67.

1C7

4Ad

rena

l gla

nd0

0.0%

0.0

0.0

10.

1%0.

10.

01

0.1%

0.1

0.1

C75

Oth

er E

ndoc

rine

00.

0%0.

00.

01

0.1%

0.1

0.1

40.

6%0.

30.

6C8

1Ho

dgkin

dise

ase

342.

9%1.

81.

913

1.4%

0.7

0.8

294.

1%2.

22.

2C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a75

6.4%

3.9

6.9

515.

3%2.

83.

839

5.4%

3.0

5.1

C88

Imm

unop

rolife

rativ

e di

s.0

0.0%

0.0

0.0

00.

0%0.

00.

00

0.0%

0.0

0.0

C90

Mul

tiple

Mye

lom

a7

0.6%

0.4

0.6

40.

4%0.

20.

45

0.7%

0.4

0.9

C91

Lym

phoi

d Le

ukem

ia32

2.7%

1.7

1.8

141.

5%0.

80.

916

2.2%

1.2

1.2

C92-

C94

Mye

loid

Leu

kem

ia32

2.7%

1.7

3.0

232.

4%1.

21.

821

2.9%

1.6

2.2

C95

Leuk

emia

uns

pecifi

ed0

0.0%

0.0

0.0

30.

3%0.

20.

20

0.0%

0.0

0.0

Oth

erO

ther

& u

nspe

cified

504.

3%2.

64.

853

5.5%

2.9

4.8

182.

5%1.

42.

7---

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

--Al

lAl

l site

s To

tal

1170

100.

0%60

.910

1.9

958

100.

0%51

.776

.971

610

0.0%

55.0

92.4

Not C

44Al

l site

s bu

t C44

1140

97.4

%59

.499

.393

597

.6%

50.4

74.8

699

97.6

%53

.789

.8

East

ern

Prov

ince

All A

ges

% o

f Tot

alCr

ude

Rate

ASR

Wor

ldRi

yadh

All A

ges

% o

f Tot

alCr

ude

Rate

ASR

Wor

ldM

akka

hIC

D (1

0th)

Site

All A

ges

% o

f Tot

alCr

ude

Rate

ASR

Wor

ld

SCR2006 Part05.indd 81 09-04-2010 3:29:40 AM

82

Tab

le 5

.4.1

Age

Dis

trib

uti

on

of

Can

cer

Cas

es a

mo

ng

no

n-S

aud

i Mal

es, 2

006

C00

Lip

40

00

00

00

00

00

03

10

00

0.3%

C01-

C02

Tong

ue5

00

00

00

00

12

20

00

00

00.

4%C0

3-C0

6M

outh

70

00

00

00

00

22

21

00

00

0.6%

C07-

C08

Saliv

ary

glan

ds5

00

00

00

20

02

00

01

00

00.

4%C0

9To

nsil

10

00

00

00

00

00

10

00

00

0.1%

C10

Oth

er O

roph

aryn

x1

00

00

00

00

00

00

10

00

00.

1%C1

1Na

soph

aryn

x21

00

00

01

03

13

70

50

10

01.

7%C1

2-C1

3Hy

poph

aryn

x5

00

00

00

00

10

10

12

00

00.

4%C1

4Ph

aryn

x un

spec

ified.

00

00

00

00

00

00

00

00

00

0.0%

C15

Oes

opha

gus

130

00

00

00

10

23

01

21

12

1.1%

C16

Stom

ach

640

00

00

10

13

89

128

104

35

5.2%

C17

Smal

l inte

stin

e7

00

00

00

00

12

02

00

10

10.

6%C1

8Co

lon

870

00

00

21

410

1111

1511

103

45

7.1%

C19-

C20

Rect

um63

00

00

00

26

58

810

69

53

15.

1%C2

1An

us8

00

00

00

00

10

04

21

00

00.

6%C2

2Li

ver

570

10

00

10

10

59

106

88

53

4.6%

C23-

C24

Gal

lbla

dder

etc

.14

00

00

00

00

02

03

12

13

21.

1%C2

5Pa

ncre

as21

00

00

00

01

03

32

22

32

31.

7%C3

0-C3

1No

se, s

inus

es e

tc.

30

00

00

00

10

01

10

00

00

0.2%

C32

Lary

nx23

00

00

00

11

02

51

52

41

11.

9%C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g90

00

10

00

03

28

1015

1116

127

57.

3%C3

7-C3

8O

ther

Tho

racic

org

ans

60

01

00

01

12

00

01

00

00

0.5%

C40-

C41

Bone

130

00

33

31

00

21

00

00

00

1.1%

C43

Mel

anom

a of

Skin

70

00

00

00

11

10

20

01

01

0.6%

C44

Oth

er S

kin88

00

10

01

34

76

1417

1110

55

47.

1%C4

5M

esot

helio

ma

70

00

00

00

01

03

10

20

00

0.6%

C46

Kapo

si sa

rcom

a5

00

00

01

01

00

00

20

00

10.

4%C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue30

02

00

24

32

33

14

22

01

12.

4%C5

0Br

east

80

00

00

00

11

02

01

20

01

0.6%

C60

Peni

s0

00

00

00

00

00

00

00

00

00.

0%C6

1Pr

osta

te86

10

00

00

00

01

314

2317

97

117.

0%C6

2Te

stis

180

10

02

22

23

11

20

20

00

1.5%

C63

Oth

er m

ale

geni

tal

00

00

00

00

00

00

00

00

00

0.0%

C64

Kidn

e y29

03

00

00

00

16

17

27

10

12.

4%C6

5Re

nal P

elvis

40

00

00

00

00

10

10

00

11

0.3%

C66

Uret

er1

00

00

00

00

00

10

00

00

00.

1%C6

7Bl

adde

r66

10

00

00

12

37

126

98

75

55.

3%C6

8O

ther

Urin

ary

orga

ns0

00

00

00

00

00

00

00

00

00.

0%C6

9Ey

e6

04

00

00

10

00

00

01

00

00.

5%C7

0-C7

2Br

ain,

Ner

vous

sys

tem

300

43

20

02

22

32

51

10

30

2.4%

C73

Thyr

oid

400

00

00

23

47

57

65

01

00

3.2%

C74

Adre

nal g

land

30

01

10

01

00

00

00

00

00

0.2%

C75

Oth

er E

ndoc

rine

10

00

10

00

00

00

00

00

00

0.1%

C81

Hodg

kin d

iseas

e28

00

20

25

41

25

31

30

00

02.

3%C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a10

40

42

03

46

611

1212

1113

113

15

8.4%

C88

Imm

unop

rolife

rativ

e di

s.0

00

00

00

00

00

00

00

00

00.

0%C9

0M

ultip

le M

yelo

ma

180

00

00

00

01

14

44

31

00

1.5%

C91

Lym

phoi

d Le

ukem

ia29

08

51

24

10

02

20

11

02

02.

4%C9

2-C9

4M

yelo

id L

euke

mia

290

30

20

04

33

26

31

10

01

2.4%

C95

Leuk

emia

uns

pecifi

ed9

00

01

00

11

10

12

10

00

10.

7%O

ther

Oth

er &

uns

pecifi

ed70

01

00

00

46

83

913

73

27

75.

7%Al

lAl

l site

s To

tal

1234

231

1611

1431

4459

8212

115

617

715

113

773

6168

100.

0%No

t C44

All s

ites

but C

4411

462

3115

1114

3041

5575

115

142

160

140

127

6856

6492

.9%

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k0-

470

-74

75+

% o

f To

tal

45-4

950

-54

55-5

960

-64

65-6

95-

940

-44

35-3

910

-14

15-1

920

-24

25-2

930

-34

SCR2006 Part05.indd 82 09-04-2010 3:29:41 AM

83

Tab

le 5

.4.2

Age

Dis

trib

uti

on

of

Can

cer

Cas

es a

mo

ng

no

n-S

aud

i Fem

ales

, 200

6

C00

Lip

10

00

00

00

00

00

01

00

00

0.1%

C01-

C02

Tong

ue6

00

00

00

00

11

01

10

20

00.

6%C0

3-C0

6M

outh

10

00

10

00

00

00

00

00

00

0.1%

C07-

C08

Saliv

ary

glan

ds10

00

00

00

20

24

10

01

00

00.

9%C0

9To

nsil

00

00

00

00

00

00

00

00

00

0.0%

C10

Oth

er O

roph

aryn

x1

00

00

00

00

00

00

10

00

00.

1%C1

1Na

soph

aryn

x7

00

00

11

02

01

10

00

10

00.

6%C1

2-C1

3Hy

poph

aryn

x1

00

00

00

00

00

00

00

01

00.

1%C1

4Ph

aryn

x un

spec

ified

00

00

00

00

00

00

00

00

00

0.0%

C15

Oes

opha

gus

160

00

00

00

01

04

41

31

11

1.5%

C16

Stom

ach

200

00

01

10

22

12

51

02

21

1.8%

C17

Smal

l inte

stin

e1

00

00

00

00

00

01

00

00

00.

1%C1

8Co

lon

480

00

00

01

43

76

46

34

55

4.4%

C19-

C20

Rect

um34

00

00

02

41

83

24

44

11

03.

1%C2

1An

us4

00

00

01

00

00

10

20

00

00.

4%C2

2Li

ver

140

00

00

00

11

01

14

20

22

1.3%

C23-

C24

Gal

lbla

dder

etc

.9

00

00

00

01

01

12

10

11

10.

8%C2

5Pa

ncre

as9

00

00

10

00

10

30

20

10

10.

8%C3

0-C3

1No

se, s

inus

es e

tc.

10

00

00

00

01

00

00

00

00

0.1%

C32

Lary

nx4

00

00

00

00

10

10

10

10

00.

4%C3

3-C3

4Tr

ache

a,Br

onch

us,L

ung

290

00

00

00

51

62

13

53

30

2.7%

C37-

C38

Oth

er T

hora

cic o

rgan

s4

00

00

00

10

02

00

01

00

00.

4%C4

0-C4

1Bo

ne7

00

12

21

00

10

00

00

00

00.

6%C4

3M

elan

oma

of S

kin2

00

00

00

01

00

00

01

00

00.

2%C4

4O

ther

Skin

410

00

01

00

24

15

59

91

13

3.8%

C45

Mes

othe

liom

a0

00

00

00

00

00

00

00

00

00.

0%C4

6Ka

posi

sarc

oma

10

00

00

00

10

00

00

00

00

0.1%

C47;

C49

Conn

ectiv

e, S

oft t

issue

120

30

02

00

20

10

20

02

00

1.1%

C50

Brea

st38

20

00

00

313

4372

6874

4924

148

77

35.0

%C5

1Vu

lva2

00

00

00

00

01

00

00

10

00.

2%C5

2Va

gina

10

00

00

00

00

00

10

00

00

0.1%

C53

Cerv

ix Ut

eri

460

00

00

01

66

611

55

31

11

4.2%

C54

Corp

us U

teri

450

00

00

12

41

66

86

34

31

4.1%

C55

Uter

us u

nspe

cified

100

00

00

00

00

21

32

01

01

0.9%

C56

Ova

ry37

00

10

00

05

49

45

13

20

33.

4%C5

7O

ther

Fem

ale

Gen

ital

30

00

00

00

00

01

01

01

00

0.3%

C58

Plac

enta

20

00

00

00

00

10

10

00

00

0.2%

C64

Kidn

ey23

03

20

00

10

33

22

24

10

02.

1%C6

5Re

nal P

elvis

00

00

00

00

00

00

00

00

00

0.0%

C66

Uret

er0

00

00

00

00

00

00

00

00

00.

0%C6

7Bl

adde

r6

00

00

00

01

20

10

10

00

10.

6%C6

8O

ther

Urin

ary

orga

ns0

00

00

00

00

00

00

00

00

00.

0%C6

9Ey

e4

03

01

00

00

00

00

00

00

00.

4%C7

0-C7

2Br

ain,

Ner

vous

sys

tem

110

22

00

02

00

10

11

11

00

1.0%

C73

Thyr

oid

560

00

02

88

58

89

40

21

10

5.1%

C74

Adre

nal g

land

30

21

00

00

00

00

00

00

00

0.3%

C75

Oth

er E

ndoc

rine

00

00

00

00

00

00

00

00

00

0.0%

C81

Hodg

kin d

iseas

e16

00

11

23

21

21

01

10

10

01.

5%C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a49

03

00

23

23

82

35

46

51

24.

5%C8

8Im

mun

opro

lifera

tive

dis.

00

00

00

00

00

00

00

00

00

0.0%

C90

Mul

tiple

Mye

lom

a8

00

00

00

02

01

10

11

20

00.

7%C9

1Ly

mph

oid

Leuk

emia

190

92

12

02

10

00

01

01

00

1.7%

C92-

C94

Mye

loid

Leu

kem

ia19

01

10

23

12

14

20

10

10

01.

7%C9

5Le

ukem

ia u

nspe

cified

100

31

10

10

10

00

10

11

00

0.9%

Oth

erO

ther

& u

nspe

cified

550

00

01

13

64

48

97

51

15

5.0%

All

All s

ites

Tota

l10

900

2912

719

2945

102

138

145

153

125

9572

5331

3510

0.0%

Not C

44Al

l site

s bu

t C44

1049

029

127

1829

4510

013

414

414

812

086

6352

3032

96.2

%

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k10

-14

0-4

5-9

75+

% o

f Tot

al15

-19

20-2

425

-29

30-3

435

-39

45-4

950

-54

55-5

960

-64

65-6

970

-74

40-4

4

SCR2006 Part05.indd 83 09-04-2010 3:29:41 AM

84

Tab

le 5

.4.3

In

cid

ence

Rat

es fo

r C

ance

r C

ases

am

on

g n

on

-Sau

di M

ales

by

Age

Gro

up

(p

er 1

00,0

00),

2006

C00

Lip

40

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.8

2.4

0.0

0.0

0.0

0.1

0.2

C01-

C02

Tong

ue5

00.

00.

00.

00.

00.

00.

00.

00.

10.

40.

50.

00.

00.

00.

00.

00.

00.

10.

1C0

3-C0

6M

outh

70

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.5

0.9

0.9

0.0

0.0

0.0

0.0

0.2

0.1

C07-

C08

Saliv

ary

glan

ds5

00.

00.

00.

00.

00.

00.

40.

00.

00.

40.

00.

00.

02.

40.

00.

00.

00.

10.

1C0

9To

nsil

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C10

Oth

er O

roph

aryn

x1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

90.

00.

00.

00.

00.

00.

0C1

1Na

soph

aryn

x21

00.

00.

00.

00.

00.

50.

00.

40.

10.

51.

90.

04.

70.

05.

80.

00.

00.

50.

6C1

2-C1

3Hy

poph

aryn

x5

00.

00.

00.

00.

00.

00.

00.

00.

10.

00.

30.

00.

94.

70.

00.

00.

00.

10.

3C1

4Ph

aryn

x un

spec

ified

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C15

Oes

opha

gus

130

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.4

0.8

0.0

0.9

4.7

5.8

9.3

16.1

0.3

1.0

C16

Stom

ach

640

0.0

0.0

0.0

0.0

0.5

0.0

0.1

0.4

1.4

2.4

5.4

7.5

23.6

23.1

28.0

40.3

1.4

3.9

C17

Smal

l inte

stin

e7

00.

00.

00.

00.

00.

00.

00.

00.

10.

40.

00.

90.

00.

05.

80.

08.

10.

20.

4C1

8Co

lon

870

0.0

0.0

0.0

0.0

1.0

0.2

0.5

1.3

2.0

3.0

6.8

10.3

23.6

17.4

37.3

40.3

2.0

4.3

C19-

C20

Rect

um63

00.

00.

00.

00.

00.

00.

40.

80.

61.

42.

14.

55.

621

.328

.928

.08.

11.

43.

2C2

1An

us8

00.

00.

00.

00.

00.

00.

00.

00.

10.

00.

01.

81.

92.

40.

00.

00.

00.

20.

3C2

2Li

ver

570

0.4

0.0

0.0

0.0

0.5

0.0

0.1

0.0

0.9

2.4

4.5

5.6

18.9

46.3

46.7

24.2

1.3

4.3

C23-

C24

Gal

lbla

dder

etc

.14

00.

00.

00.

00.

00.

00.

00.

00.

00.

40.

01.

40.

94.

75.

828

.016

.10.

31.

4C2

5Pa

ncre

as21

00.

00.

00.

00.

00.

00.

00.

10.

00.

50.

80.

91.

94.

717

.418

.724

.20.

51.

8C3

0-C3

1No

se, s

inus

es e

tc.

30

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.3

0.5

0.0

0.0

0.0

0.0

0.0

0.1

0.0

C32

Lary

nx23

00.

00.

00.

00.

00.

00.

20.

10.

00.

41.

30.

54.

74.

723

.19.

38.

10.

51.

6C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g90

00.

00.

40.

00.

00.

00.

00.

40.

31.

42.

76.

810

.337

.869

.465

.440

.32.

06.

8C3

7-C3

8O

ther

Tho

racic

org

ans

60

0.0

0.4

0.0

0.0

0.0

0.2

0.1

0.3

0.0

0.0

0.0

0.9

0.0

0.0

0.0

0.0

0.1

0.1

C40-

C41

Bone

130

0.0

0.0

1.6

2.1

1.5

0.2

0.0

0.0

0.4

0.3

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.5

C43

Mel

anom

a of

Skin

70

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

0.2

0.0

0.9

0.0

0.0

5.8

0.0

8.1

0.2

0.4

C44

Oth

er S

kin88

00.

00.

40.

00.

00.

50.

50.

50.

91.

13.

87.

710

.323

.628

.946

.732

.22.

04.

7C4

5M

esot

helio

ma

70

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.8

0.5

0.0

4.7

0.0

0.0

0.0

0.2

0.3

C46

Kapo

si sa

rcom

a5

00.

00.

00.

00.

00.

50.

00.

10.

00.

00.

00.

01.

90.

00.

00.

08.

10.

10.

3C4

7; C

49Co

nnec

tive,

Sof

t tiss

ue30

00.

90.

00.

01.

41.

90.

50.

30.

40.

50.

31.

81.

94.

70.

09.

38.

10.

71.

2C5

0Br

east

80

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

0.0

0.5

0.0

0.9

4.7

0.0

0.0

8.1

0.2

0.4

C60

Peni

s0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C6

1Pr

osta

te86

10.

00.

00.

00.

00.

00.

00.

00.

00.

20.

86.

321

.540

.252

.165

.488

.71.

97.

6C6

2Te

stis

180

0.4

0.0

0.0

1.4

1.0

0.4

0.3

0.4

0.2

0.3

0.9

0.0

4.7

0.0

0.0

0.0

0.4

0.6

C63

Oth

er m

ale

geni

tal

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C64

Kidn

ey29

01.

30.

00.

00.

00.

00.

00.

00.

11.

10.

33.

21.

916

.55.

80.

08.

10.

71.

5C6

5Re

nal P

elvis

40

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.5

0.0

0.0

0.0

9.3

8.1

0.1

0.4

C66

Uret

er1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

00.

00.

0C6

7Bl

adde

r66

10.

00.

00.

00.

00.

00.

20.

30.

41.

33.

22.

78.

418

.940

.546

.740

.31.

54.

6C6

8O

ther

Urin

ary

orga

ns0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C6

9Ey

e6

01.

70.

00.

00.

00.

00.

20.

00.

00.

00.

00.

00.

02.

40.

00.

00.

00.

10.

3C7

0-C7

2Br

ain,

Ner

vous

sys

tem

300

1.7

1.3

1.1

0.0

0.0

0.4

0.3

0.3

0.5

0.5

2.3

0.9

2.4

0.0

28.0

0.0

0.7

1.4

C73

Thyr

oid

400

0.0

0.0

0.0

0.0

1.0

0.5

0.5

0.9

0.9

1.9

2.7

4.7

0.0

5.8

0.0

0.0

0.9

0.9

C74

Adre

nal g

land

30

0.0

0.4

0.5

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C75

Oth

er E

ndoc

rine

10

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C81

Hodg

kin d

iseas

e28

00.

00.

90.

01.

42.

40.

70.

10.

30.

90.

80.

52.

80.

00.

00.

00.

00.

60.

7C8

2-C8

5; C

96No

n-Ho

dgkin

lym

phom

a10

40

1.7

0.9

0.0

2.1

1.9

1.1

0.8

1.4

2.1

3.2

5.0

12.1

26.0

17.4

9.3

40.3

2.4

4.5

C88

Imm

unop

rolife

rativ

e di

s.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C9

0M

ultip

le M

yelo

ma

180

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.2

1.1

1.8

3.7

7.1

5.8

0.0

0.0

0.4

0.8

C91

Lym

phoi

d Le

ukem

ia29

03.

42.

20.

51.

41.

90.

20.

00.

00.

40.

50.

00.

92.

40.

018

.70.

00.

71.

5C9

2-C9

4M

yelo

id L

euke

mia

290

1.3

0.0

1.1

0.0

0.0

0.7

0.4

0.4

0.4

1.6

1.4

0.9

2.4

0.0

0.0

8.1

0.7

0.8

C95

Leuk

emia

uns

pecifi

ed9

00.

00.

00.

50.

00.

00.

20.

10.

10.

00.

30.

90.

90.

00.

00.

08.

10.

20.

3O

ther

Oth

er &

uns

pecifi

ed70

00.

40.

00.

00.

00.

00.

70.

81.

00.

52.

45.

96.

57.

111

.665

.456

.41.

64.

0Al

lAl

l site

s To

tal

1234

213

.07.

06.

010

.015

.08.

08.

011

.022

.042

.080

.014

1.0

324.

042

2.0

570.

054

8.0

27.9

68.2

Not C

44Al

l site

s bu

t C44

1146

213

.07.

06.

010

.015

.08.

07.

010

.021

.038

.072

.013

1.0

300.

039

3.0

523.

051

6.0

25.9

63.5

ASR

Wor

ldCr

ude

Rate

ICD

(10t

h)Si

teAl

l Ag

es60

-64

65-6

970

-74

75+

55-5

920

-24

25-2

9Ag

e Un

k0-

45-

950

-54

10-1

430

-34

35-3

940

-44

45-4

915

-19

SCR2006 Part05.indd 84 09-04-2010 3:29:42 AM

85

Tab

le 5

.4.4

In

cid

ence

Rat

es fo

r C

ance

r C

ases

am

on

g n

on

-Sau

di F

emal

es b

y A

ge G

rou

p (

per

100

,000

), 20

06

C00

Lip

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.8

0.0

0.0

0.0

0.0

0.1

0.2

C01-

C02

Tong

ue6

00.

00.

00.

00.

00.

00.

00.

00.

40.

80.

02.

23.

80.

022

.40.

00.

00.

31.

0C0

3-C0

6M

outh

10

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C07-

C08

Saliv

ary

glan

ds10

00.

00.

00.

00.

00.

00.

90.

00.

83.

01.

40.

00.

06.

90.

00.

00.

00.

50.

7C0

9To

nsil

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C10

Oth

er O

roph

aryn

x1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

03.

80.

00.

00.

00.

00.

10.

2C1

1Na

soph

aryn

x7

00.

00.

00.

00.

70.

70.

00.

70.

00.

81.

40.

00.

00.

011

.20.

00.

00.

40.

6C1

2-C1

3Hy

poph

aryn

x1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

011

.90.

00.

10.

2C1

4Ph

aryn

x un

spec

ified.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C15

Oes

opha

gus

160

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

5.5

8.7

3.8

20.8

11.2

11.9

12.9

0.8

2.6

C16

Stom

ach

200

0.0

0.0

0.0

0.7

0.7

0.0

0.7

0.8

0.8

2.7

10.8

3.8

0.0

22.4

23.8

12.9

1.0

2.5

C17

Smal

l inte

stin

e1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

20.

00.

00.

00.

00.

00.

10.

1C1

8Co

lon

480

0.0

0.0

0.0

0.0

0.0

0.4

1.3

1.2

5.3

8.2

8.7

23.1

20.8

44.7

59.5

64.6

2.4

7.0

C19-

C20

Rect

um34

00.

00.

00.

00.

01.

41.

80.

33.

32.

32.

78.

715

.427

.811

.211

.90.

01.

73.

5C2

1An

us4

00.

00.

00.

00.

00.

70.

00.

00.

00.

01.

40.

07.

70.

00.

00.

00.

00.

20.

4C2

2Li

ver

140

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.4

0.0

1.4

2.2

15.4

13.9

0.0

23.8

25.9

0.7

2.4

C23-

C24

Gal

lbla

dder

etc

.9

00.

00.

00.

00.

00.

00.

00.

30.

00.

81.

44.

33.

80.

011

.211

.912

.90.

51.

4C2

5Pa

ncre

as9

00.

00.

00.

00.

70.

00.

00.

00.

40.

04.

10.

07.

70.

011

.20.

012

.90.

51.

2C3

0-C3

1No

se, s

inus

es e

tc.

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

C32

Lary

nx4

00.

00.

00.

00.

00.

00.

00.

00.

40.

01.

40.

03.

80.

011

.20.

00.

00.

20.

6C3

3-C3

4Tr

ache

a, B

ronc

hus,

Lun

g29

00.

00.

00.

00.

00.

00.

01.

70.

44.

52.

72.

211

.534

.733

.635

.70.

01.

54.

2C3

7-C3

8O

ther

Tho

racic

org

ans

40

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

1.5

0.0

0.0

0.0

6.9

0.0

0.0

0.0

0.2

0.4

C40-

C41

Bone

70

0.0

0.5

1.1

1.5

0.7

0.0

0.0

0.4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.4

C43

Mel

anom

a of

Skin

20

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.0

0.0

0.0

0.0

0.0

6.9

0.0

0.0

0.0

0.1

0.3

C44

Oth

er S

kin41

00.

00.

00.

00.

70.

00.

00.

71.

60.

86.

910

.834

.662

.511

.211

.938

.82.

16.

4C4

5M

esot

helio

ma

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C46

Kapo

si sa

rcom

a1

00.

00.

00.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

00.

00.

00.

00.

10.

0C4

7;C4

9Co

nnec

tive,

Sof

t tiss

ue12

01.

30.

00.

01.

50.

00.

00.

70.

00.

80.

04.

30.

00.

022

.40.

00.

00.

61.

3C5

0Br

east

382

00.

00.

00.

00.

02.

05.

814

.529

.651

.310

1.4

106.

392

.497

.289

.583

.390

.519

.331

.5C5

1Vu

lva2

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

00.

00.

00.

011

.20.

00.

00.

10.

4C5

2Va

gina

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.2

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C53

Cerv

ix Ut

eri

460

0.0

0.0

0.0

0.0

0.0

0.4

2.0

2.5

4.5

15.1

10.8

19.2

20.8

11.2

11.9

12.9

2.3

4.5

C54

Corp

us U

teri

450

0.0

0.0

0.0

0.0

0.7

0.9

1.3

0.4

4.5

8.2

17.4

23.1

20.8

44.7

35.7

12.9

2.3

5.9

C55

Uter

us u

nspe

cified

.10

00.

00.

00.

00.

00.

00.

00.

00.

01.

51.

46.

57.

70.

011

.20.

012

.90.

51.

4C5

6O

vary

370

0.0

0.5

0.0

0.0

0.0

0.0

1.7

1.6

6.8

5.5

10.8

3.8

20.8

22.4

0.0

38.8

1.9

4.0

C57

Oth

er F

emal

e G

enita

l3

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

40.

03.

80.

011

.20.

00.

00.

20.

6C5

8Pl

acen

ta2

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

02.

20.

00.

00.

00.

00.

00.

10.

2C6

4Ki

dney

230

1.3

1.0

0.0

0.0

0.0

0.4

0.0

1.2

2.3

2.7

4.3

7.7

27.8

11.2

0.0

0.0

1.2

2.6

C65

Rena

l Pel

vis0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C6

6Ur

eter

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C67

Blad

der

60

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.8

0.0

1.4

0.0

3.8

0.0

0.0

0.0

12.9

0.3

0.6

C68

Oth

er U

rinar

y or

gans

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C69

Eye

40

1.3

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

C70-

C72

Brai

n, N

ervo

us s

yste

m11

00.

91.

00.

00.

00.

00.

90.

00.

00.

80.

02.

23.

86.

911

.20.

00.

00.

61.

2C7

3Th

yroi

d56

00.

00.

00.

01.

55.

43.

61.

73.

36.

012

.38.

70.

013

.911

.211

.90.

02.

83.

8C7

4Ad

rena

l gla

nd3

00.

90.

50.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

2C7

5O

ther

End

ocrin

e0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C8

1Ho

dgkin

dise

ase

160

0.0

0.5

0.6

1.5

2.0

0.9

0.3

0.8

0.8

0.0

2.2

3.8

0.0

11.2

0.0

0.0

0.8

1.2

C82-

C85;

C96

Non-

Hodg

kin ly

mph

oma

490

1.3

0.0

0.0

1.5

2.0

0.9

1.0

3.3

1.5

4.1

10.8

15.4

41.7

55.9

11.9

25.9

2.5

6.4

C88

Imm

unop

rolife

rativ

e di

s.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C9

0M

ultip

le M

yelo

ma

80

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.0

0.8

1.4

0.0

3.8

6.9

22.4

0.0

0.0

0.4

1.3

C91

Lym

phoi

d Le

ukem

ia19

03.

91.

00.

61.

50.

00.

90.

30.

00.

00.

00.

03.

80.

011

.20.

00.

01.

01.

3C9

2-C9

4M

yelo

id L

euke

mia

190

0.4

0.5

0.0

1.5

2.0

0.4

0.7

0.4

3.0

2.7

0.0

3.8

0.0

11.2

0.0

0.0

1.0

1.3

C95

Leuk

emia

uns

pecifi

ed.

100

1.3

0.5

0.6

0.0

0.7

0.0

0.3

0.0

0.0

0.0

2.2

0.0

6.9

11.2

0.0

0.0

0.5

1.1

Oth

erO

ther

& u

nspe

cified

550

0.0

0.0

0.0

0.7

0.7

1.3

2.0

1.6

3.0

11.0

19.5

26.9

34.7

11.2

11.9

64.6

2.8

6.6

All

All s

ites

Tota

l10

900

13.0

6.0

4.0

14.0

20.0

20.0

34.0

57.0

109.

021

0.0

271.

036

6.0

500.

059

3.0

369.

045

2.0

55.0

113.

9No

t C44

All s

ites

but C

4410

490

13.0

6.0

4.0

13.0

20.0

20.0

34.0

55.0

109.

020

3.0

260.

033

1.0

437.

058

2.0

357.

041

4.0

53.0

107.

4

0-4

5-9

Crud

e Ra

teAS

R W

orld

ICD

(10t

h)Si

teAl

l Ag

esAg

e Un

k30

-34

35-3

940

-44

45-4

910

-14

15-1

920

-24

25-2

950

-54

55-5

970

-74

75+

60-6

465

-69

SCR2006 Part05.indd 85 09-04-2010 3:29:43 AM

86

Table 5.5.1 Number of New Cases by Primary Site and Years among Saudi Males, 1994-2006

ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006

C00 Lip 9 2 4 5 4 1 6 1 5 5 8 6 6C01-C02 Tongue 32 15 22 24 13 26 29 14 24 29 35 40 37C03-C06 Mouth 24 24 30 25 26 27 25 27 26 26 40 31 30C07-C08 Salivary glands 4 10 6 11 7 12 8 16 14 13 15 17 14C09 Tonsil 4 9 2 4 6 2 1 3 6 5 2 3 0C10 Other Oropharynx 2 3 3 2 1 3 0 3 3 0 2 3 0C11 Nasopharynx 78 61 87 100 109 99 89 122 85 89 104 118 95C12-C13 Hypopharynx 11 9 18 7 7 6 5 8 6 8 7 12 9C14 Pharynx unspecified 0 2 0 0 1 1 0 2 1 4 4 4 3C15 Oesophagus 77 71 67 64 79 58 69 63 70 68 55 57 55C16 Stomach 131 128 133 109 124 104 125 125 148 180 151 163 162C17 Small intestine 11 8 11 10 15 13 16 13 17 14 22 24 18C18 Colon 62 88 74 86 108 100 117 119 153 179 201 259 232C19-C20 Rectum 83 66 67 66 66 89 84 108 123 143 176 191 182C21 Anus 10 8 6 8 6 5 10 12 14 11 17 17 8C22 Liver 301 298 279 269 329 296 289 274 287 285 276 282 291C23-C24 Gallbladder etc. 24 31 25 22 28 25 27 39 42 39 27 36 46C25 Pancreas 50 49 53 45 60 59 68 53 74 84 82 99 93C30-C31 Nose, sinuses etc. 5 6 10 5 10 13 6 9 14 10 10 15 10C32 Larynx 49 48 44 41 47 43 44 51 33 60 53 53 62C33-C34 Trachea, Bronchus, Lung 189 186 190 164 223 206 196 190 194 203 254 280 232C37-C38 Other Thoracic organs 7 11 13 13 8 17 7 6 5 12 13 22 14C40-C41 Bone 48 50 34 46 51 56 52 67 50 46 67 55 64C43 Melanoma of Skin 21 8 8 8 6 7 11 9 12 10 13 13 11C44 Other Skin 104 121 113 111 100 121 114 157 149 166 142 154 193C45 Mesothelioma 5 4 5 5 7 2 7 5 3 5 6 8 8C46 Kaposi sarcoma 15 10 14 14 12 11 19 20 21 26 27 23 22C47;C49 Connective, Soft tissue 85 68 50 60 50 70 55 47 63 69 60 77 57C50 Breast 11 16 6 12 20 11 16 12 15 16 14 15 18C60 Penis 3 4 1 8 0 1 1 1 3 1 3 6 1C61 Prostate 150 148 155 125 163 147 185 170 199 193 245 269 228C62 Testis 32 22 25 29 39 31 34 36 44 38 46 46 38C63 Other male genital 1 2 0 3 1 2 3 3 3 4 3 2 3C64 Kidney 70 82 57 65 72 79 75 85 90 85 125 103 111C65 Renal Pelvis 5 5 0 0 10 2 6 2 1 7 8 3 5C66 Ureter 1 3 1 0 3 0 4 1 0 6 3 3 1C67 Bladder 165 155 129 128 156 152 159 143 160 180 174 164 169C68 Other Urinary organs 1 1 1 0 1 1 0 0 1 1 1 0 0C69 Eye 22 12 18 35 17 24 25 22 24 21 21 17 26C70-C72 Brain, Nervous system 132 99 127 125 103 121 142 120 121 147 154 140 149C73 Thyroid 73 63 60 73 85 85 75 74 93 89 95 93 117C74 Adrenal gland 8 9 8 8 4 9 11 7 7 15 6 10 19C75 Other Endocrine 2 3 5 1 2 2 1 4 1 5 3 6 5C81 Hodgkin disease 105 107 108 99 137 119 129 137 120 144 182 167 173C82-C85;C96 Non-Hodgkin lymphoma 275 216 233 226 285 270 269 245 273 328 355 361 351C88 Immunoproliferative dis. 0 0 0 1 0 1 0 0 0 1 2 0 0C90 Multiple Myeloma 60 41 30 36 47 37 46 36 28 39 45 60 48C91 Lymphoid Leukemia 152 118 148 144 156 137 152 158 142 164 149 160 155C92-C94 Myeloid Leukemia 95 91 83 107 94 110 93 127 112 89 112 105 115C95 Leukemia unspecified 10 5 5 5 9 8 14 13 12 13 16 15 26Other Other & unspecified 149 122 100 133 147 141 126 136 152 145 151 183 186All All sites Total 2963 2718 2668 2687 3054 2962 3045 3095 3243 3520 3782 3990 3898Not C44 All sites but C44 2859 2597 2555 2576 2954 2841 2931 2938 3094 3354 3640 3836 3705

SCR2006 Part05.indd 86 09-04-2010 3:29:43 AM

87

Table 5.5.2 Number of New Cases by Primary Site and Years among Saudi Females, 1994-2006

ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006

C00 Lip 3 3 4 2 1 6 4 3 7 5 8 6 4C01-C02 Tongue 23 20 28 28 29 31 23 19 30 30 27 21 26C03-C06 Mouth 23 40 37 22 33 40 26 27 29 29 23 43 34C07-C08 Salivary glands 8 7 6 3 12 9 14 8 6 10 12 14 12C09 Tonsil 0 3 3 3 1 1 3 1 5 4 1 1 2C10 Other Oropharynx 0 1 0 0 1 0 0 0 2 0 2 2 0C11 Nasopharynx 39 28 39 34 38 35 24 41 41 39 46 35 43C12-C13 Hypopharynx 19 11 15 15 19 16 10 12 12 2 16 17 11C14 Pharynx unspecified 2 3 1 1 1 1 2 0 3 1 3 0 1C15 Oesophagus 75 54 69 54 47 49 55 37 58 53 52 69 64C16 Stomach 67 74 64 59 67 71 62 73 77 76 78 75 113C17 Small intestine 9 11 9 10 16 8 10 15 8 10 13 13 14C18 Colon 64 80 86 75 74 107 108 143 135 146 183 200 227C19-C20 Rectum 44 51 52 59 57 86 74 88 106 109 119 146 143C21 Anus 6 4 2 3 5 2 4 2 5 9 6 9 9C22 Liver 110 89 100 87 125 93 121 101 117 128 119 113 125C23-C24 Gallbladder etc. 52 38 25 32 51 60 47 54 41 59 55 67 70C25 Pancreas 28 30 24 25 50 42 35 35 54 40 36 53 73C30-C31 Nose, sinuses etc. 6 9 5 4 8 8 6 6 8 2 6 10 10C32 Larynx 10 2 7 10 9 10 10 3 7 4 8 6 9C33-C34 Trachea,Bronchus,Lung 52 55 49 53 51 49 54 56 52 64 72 89 80C37-C38 Other Thoracic organs 7 6 6 6 5 5 8 5 3 10 10 12 10C40-C41 Bone 26 38 38 25 45 36 39 43 35 39 41 40 36C43 Melanoma of Skin 11 8 7 2 8 8 6 8 7 8 12 9 12C44 Other Skin 79 55 87 59 82 77 81 103 96 123 132 133 134C45 Mesothelioma 1 0 1 1 0 4 1 1 3 7 5 7 5C46 Kaposi sarcoma 0 3 0 8 7 8 4 5 3 6 5 9 14C47; C49 Connective, Soft tissue 42 57 42 46 61 50 49 43 39 53 75 51 37C50 Breast 434 435 469 487 534 521 611 564 671 714 831 964 981C51 Vulva 8 6 7 3 3 3 8 7 6 6 11 1 4C52 Vagina 5 6 2 6 2 3 1 5 5 1 5 7 1C53 Cervix Uteri 79 74 84 77 98 78 84 87 87 92 95 98 74C54 Corpus Uteri 59 47 39 50 61 58 92 81 89 113 122 152 140C55 Uterus unspecified 4 2 11 10 17 13 6 15 14 14 12 15 22C56 Ovary 96 98 97 114 111 100 103 109 110 128 117 140 132C57 Other Female Genital 1 1 0 2 2 4 3 5 4 5 10 6 9C58 Placenta 16 10 11 7 9 12 9 14 15 6 8 14 19C64 Kidney 61 37 50 57 53 64 49 69 68 67 85 63 78C65 Renal Pelvis 0 1 0 2 3 3 2 1 1 2 1 4 4C66 Ureter 0 1 1 0 1 1 0 1 1 1 2 4 2C67 Bladder 29 40 23 31 41 37 40 52 41 45 44 37 42C68 Other Urinary organs 0 0 0 0 0 1 1 0 0 0 1 1 0C69 Eye 15 16 18 14 11 26 25 18 20 16 19 21 19C70-C72 Brain, Nervous system 78 75 76 93 88 78 89 84 85 93 110 106 103C73 Thyroid 206 221 201 217 271 281 265 258 277 367 348 398 424C74 Adrenal gland 10 6 10 11 9 10 13 8 8 13 17 10 10C75 Other Endocrine 2 1 2 1 2 3 1 0 0 1 2 5 5C81 Hodgkin disease 59 70 59 62 74 76 90 77 76 112 109 105 120C82-C85; C96 Non-Hodgkin lymphoma 145 149 141 148 190 179 188 201 203 238 246 262 234C88 Immunoproliferative dis. 0 0 0 1 0 1 1 1 0 1 0 0 0C90 Multiple Myeloma 20 33 20 13 24 27 26 18 19 16 26 26 26C91 Lymphoid Leukemia 77 89 80 80 75 95 112 85 102 92 83 83 90C92-C94 Myeloid Leukemia 79 80 74 90 83 92 93 103 104 96 122 101 113C95 Leukemia unspecified 6 6 0 5 7 11 9 4 5 11 11 15 9Other Other & unspecified 105 96 94 96 143 129 126 116 120 165 183 151 177All All sites Total 2400 2380 2375 2403 2815 2818 2927 2916 3120 3481 3785 4039 4156Not C44 All sites but C44 2321 2325 2288 2344 2733 2741 2846 2813 3024 3358 3653 3906 4022

SCR2006 Part05.indd 87 09-04-2010 3:29:43 AM

88

Table 5.5.3 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Males, 1994-2006

ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006

C00 Lip 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.1C01-C02 Tongue 0.9 0.5 0.6 0.6 0.3 0.6 0.8 0.3 0.6 0.6 0.9 0.9 0.8C03-C06 Mouth 0.7 0.7 0.9 0.6 0.7 0.6 0.5 0.7 0.6 0.6 0.8 0.7 0.8C07-C08 Salivary glands 0.1 0.3 0.2 0.3 0.1 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.2C09 Tonsil 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0C10 Other Oropharynx 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0C11 Nasopharynx 2.1 1.6 2.3 2.5 2.6 2.3 2.0 2.5 1.9 1.7 2.1 2.3 1.7C12-C13 Hypopharynx 0.3 0.2 0.4 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.2C14 Pharynx unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1C15 Oesophagus 2.2 1.9 1.7 1.6 1.9 1.3 1.6 1.6 1.6 1.6 1.2 1.3 1.4C16 Stomach 3.7 3.6 3.5 2.7 3.0 2.4 3.0 2.9 3.2 4.2 3.5 3.6 3.9C17 Small intestine 0.3 0.2 0.3 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.5 0.5 0.4C18 Colon 1.8 2.4 2.0 2.1 2.7 2.5 2.9 2.8 3.5 4.1 4.4 5.8 5.3C19-C20 Rectum 2.4 1.9 1.6 1.7 1.7 2.4 2.1 2.5 2.7 3.3 4.1 4.3 4.4C21 Anus 0.3 0.2 0.2 0.2 0.2 0.1 0.3 0.3 0.3 0.3 0.4 0.4 0.2C22 Liver 8.8 8.6 7.5 7.1 8.4 7.5 7.2 7.3 6.9 7.1 6.6 6.6 7.5C23-C24 Gallbladder etc. 0.7 0.9 0.7 0.6 0.7 0.6 0.7 1.0 1.0 1.0 0.7 0.8 1.2C25 Pancreas 1.4 1.3 1.5 1.2 1.5 1.4 1.6 1.3 1.7 2.0 2.0 2.3 2.4C30-C31 Nose, sinuses etc. 0.1 0.2 0.3 0.1 0.2 0.3 0.1 0.3 0.3 0.2 0.2 0.3 0.2C32 Larynx 1.5 1.4 1.2 1.1 1.2 1.1 1.1 1.4 0.8 1.4 1.3 1.3 1.6C33-C34 Trachea, Bronchus, Lung 5.6 5.4 5.1 4.4 5.8 5.2 5.0 4.9 5.0 5.2 5.9 6.5 6.1C37-C38 Other Thoracic organs 0.2 0.2 0.3 0.2 0.2 0.3 0.1 0.1 0.1 0.3 0.3 0.4 0.2C40-C41 Bone 0.7 0.7 0.5 0.7 0.7 0.7 0.7 0.8 0.6 0.6 0.7 0.6 0.7C43 Melanoma of Skin 0.6 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.3 0.2C44 Other Skin 2.7 3.1 2.8 2.9 2.4 2.7 2.5 3.6 3.2 3.7 3.1 3.3 4.6C45 Mesothelioma 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.2C46 Kaposi sarcoma 0.5 0.3 0.3 0.3 0.3 0.2 0.4 0.5 0.5 0.6 0.6 0.5 0.5C47;C49 Connective, Soft tissue 1.8 1.4 1.0 1.2 0.8 1.2 1.0 0.8 1.0 1.2 0.9 1.1 0.9C50 Breast 0.3 0.5 0.1 0.3 0.5 0.2 0.4 0.3 0.4 0.4 0.3 0.3 0.4C60 Penis 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0C61 Prostate 4.0 3.9 3.8 3.0 4.0 3.5 4.1 4.3 4.4 4.6 5.8 6.3 6.1C62 Testis 0.7 0.4 0.5 0.5 0.7 0.6 0.6 0.5 0.7 0.5 0.6 0.5 0.5C63 Other male genital 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1C64 Kidney 1.8 2.0 1.4 1.6 1.7 1.6 1.7 1.8 1.8 1.8 2.6 2.1 2.4C65 Renal Pelvis 0.1 0.1 0.0 0.0 0.3 0.1 0.1 0.0 0.0 0.2 0.2 0.0 0.1C66 Ureter 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.0C67 Bladder 4.6 4.3 3.5 3.3 3.9 3.7 4.0 3.5 3.4 4.2 4.1 3.5 4.1C68 Other Urinary organs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C69 Eye 0.5 0.2 0.3 0.5 0.2 0.4 0.3 0.5 0.4 0.3 0.4 0.3 0.3C70-C72 Brain, Nervous system 2.9 1.8 2.4 2.2 1.7 2.2 2.4 2.1 2.0 2.4 2.4 2.2 2.5C73 Thyroid 1.9 1.5 1.5 1.8 1.9 1.7 1.5 1.6 1.9 1.8 1.7 1.6 2.1C74 Adrenal gland 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2C75 Other Endocrine 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1C81 Hodgkin disease 2.1 1.9 1.8 1.5 2.2 1.8 1.8 1.9 1.7 1.9 2.3 2.1 2.1C82-C85; C96 Non-Hodgkin lymphoma 6.7 5.1 5.5 5.0 6.2 6.1 5.5 4.9 5.3 6.4 6.3 6.7 6.6C88 Immunoproliferative dis. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0C90 Multiple Myeloma 1.8 1.1 0.8 1.0 1.3 1.0 1.1 0.9 0.6 0.9 1.1 1.3 1.2C91 Lymphoid Leukemia 2.2 1.8 2.1 2.1 2.4 1.9 2.1 2.4 1.9 2.2 2.1 1.9 2.3C92-C94 Myeloid Leukemia 1.9 1.7 1.7 2.0 2.0 1.8 1.7 2.0 1.9 1.5 1.7 1.6 1.8C95 Leukemia unspecified 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.2 0.2 0.3 0.2 0.2 0.4Other Other & unspecified 4.0 3.1 2.6 3.4 3.5 3.4 2.8 3.4 3.4 3.4 3.3 3.9 4.3All All sites Total 76.3 67.5 63.8 61.7 69.5 65.1 65.6 67.6 67.1 74.2 76.8 79.8 83.6Not C44 All sites but C44 73.6 64.4 60.9 58.8 67.1 62.5 63.1 64.0 63.9 70.4 73.6 76.5 79.0

SCR2006 Part05.indd 88 09-04-2010 3:29:44 AM

89

Table 5.5.4 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Females, 1994-2006

ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006

C00 Lip 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1C01-C02 Tongue 0.8 0.7 0.9 0.8 0.9 0.9 0.6 0.5 0.8 0.7 0.6 0.5 0.6C03-C06 Mouth 0.7 1.3 1.1 0.7 1.1 1.1 0.7 0.6 0.7 0.7 0.5 0.9 0.8C07-C08 Salivary glands 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.2 0.3 0.2 0.2C09 Tonsil 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0C10 Other Oropharynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0C11 Nasopharynx 0.9 0.6 1.0 0.8 0.9 0.8 0.5 0.7 0.8 0.7 0.9 0.7 0.8C12-C13 Hypopharynx 0.6 0.3 0.5 0.5 0.6 0.4 0.3 0.3 0.2 0.0 0.4 0.4 0.2C14 Pharynx unspecified 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0C15 Oesophagus 2.7 1.8 2.2 1.7 1.5 1.4 1.5 1.0 1.5 1.3 1.2 1.6 1.6C16 Stomach 2.4 2.4 2.1 1.8 2.0 1.9 1.6 1.7 1.8 1.8 1.7 1.7 2.7C17 Small intestine 0.3 0.4 0.3 0.3 0.5 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.3C18 Colon 2.2 2.7 2.6 2.2 2.2 2.9 2.6 3.4 3.1 3.4 4.2 4.3 5.3C19-C20 Rectum 1.6 1.7 1.6 1.9 1.7 2.3 1.8 2.0 2.4 2.5 2.7 3.1 3.3C21 Anus 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.2 0.2C22 Liver 3.9 3.1 3.3 2.9 3.8 2.7 3.2 2.7 2.8 3.3 2.9 2.6 3.1C23-C24 Gallbladder etc. 1.8 1.4 0.8 1.0 1.6 1.7 1.3 1.4 1.1 1.5 1.3 1.6 1.7C25 Pancreas 1.1 1.1 0.8 0.9 1.6 1.2 0.9 0.8 1.4 1.0 0.9 1.3 1.8C30-C31 Nose, sinuses etc. 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.0 0.1 0.2 0.2C32 Larynx 0.3 0.1 0.2 0.3 0.3 0.3 0.3 0.1 0.2 0.1 0.2 0.1 0.2C33-C34 Trachea, Bronchus, Lung 1.9 2.0 1.5 1.6 1.6 1.4 1.5 1.4 1.2 1.6 1.7 2.0 2.0C37-C38 Other Thoracic organs 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.2C40-C41 Bone 0.4 0.7 0.7 0.4 0.6 0.5 0.5 0.5 0.4 0.5 0.5 0.4 0.4C43 Melanoma of Skin 0.3 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.3C44 Other Skin 2.7 1.8 2.7 1.9 2.4 2.1 2.0 2.5 2.2 2.9 3.0 2.9 3.0C45 Mesothelioma 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.2 0.1C46 Kaposi sarcoma 0.0 0.1 0.0 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.3C47; C49 Connective, Soft tissue 0.9 1.3 1.0 1.0 1.1 1.0 0.8 0.6 0.6 0.8 1.3 0.7 0.5C50 Breast 13.4 13.0 13.4 13.3 14.3 12.6 13.7 12.1 13.9 14.6 16.5 18.7 18.0C51 Vulva 0.3 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.0 0.1C52 Vagina 0.2 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.0C53 Cervix Uteri 2.4 2.2 2.5 2.3 2.9 2.0 1.9 2.0 1.8 1.9 2.0 2.1 1.5C54 Corpus Uteri 2.1 1.4 1.4 1.6 2.0 1.6 2.5 2.1 2.2 2.8 2.9 3.6 3.6C55 Uterus unspecified. 0.1 0.1 0.3 0.3 0.5 0.4 0.1 0.4 0.3 0.3 0.3 0.4 0.5C56 Ovary 2.9 2.9 2.7 3.1 3.1 2.2 2.2 2.4 2.3 2.5 2.4 2.9 2.8C57 Other Female Genital 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2C58 Placenta 0.4 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2C64 Kidney 1.5 1.0 1.1 1.3 1.4 1.4 0.9 1.4 1.4 1.4 1.8 1.2 1.5C65 Renal Pelvis 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1C66 Ureter 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0C67 Bladder 1.0 1.2 0.7 1.0 1.3 1.0 1.1 1.3 1.0 1.1 1.0 0.8 1.0C68 Other Urinary organs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C69 Eye 0.3 0.3 0.4 0.2 0.2 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.3C70-C72 Brain, Nervous system 1.4 1.5 1.4 1.8 1.5 1.4 1.5 1.5 1.3 1.5 1.7 1.4 1.6C73 Thyroid 5.5 5.3 4.6 5.0 5.7 5.4 4.8 4.6 4.7 6.1 5.7 6.4 6.5C74 Adrenal gland 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1C75 Other Endocrine 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1C81 Hodgkin disease 1.4 1.3 1.0 1.1 1.3 1.2 1.2 1.1 1.0 1.5 1.4 1.3 1.6C82-C85; C96 Non-Hodgkin lymphoma 4.3 4.2 4.1 4.0 5.0 4.3 4.1 4.4 4.4 5.0 5.0 5.3 4.8C88 Immunoproliferative dis. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C90 Multiple Myeloma 0.8 1.2 0.7 0.4 0.8 0.8 0.7 0.5 0.5 0.4 0.6 0.6 0.6C91 Lymphoid Leukemia 1.1 1.6 1.2 1.0 1.0 1.2 1.6 1.2 1.3 1.2 1.0 1.0 1.2C92-C94 Myeloid Leukemia 1.8 1.7 1.6 1.7 1.6 1.7 1.6 1.8 1.8 1.6 1.9 1.6 2.0C95 Leukemia unspecified. 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.2Other Other & unspecified 3.5 3.1 2.8 2.8 4.3 3.3 3.2 3.0 2.8 3.9 4.1 3.3 4.1All All sites Total 71.2 67.6 64.7 63.4 73.3 66.2 64.0 62.4 64.2 71.2 75.7 78.5 82.7Not C44 All sites but C44 68.5 65.8 61.9 61.6 70.9 64.1 62.1 59.9 62.0 68.3 72.7 75.6 79.8

SCR2006 Part05.indd 89 09-04-2010 3:29:44 AM

90

SCR2006 Part05.indd 90 09-04-2010 3:29:44 AM

PART VIAPPENDICES

SCR2006 Part06.indd 91 09-04-2010 3:30:15 AM

92

APPENDIX: A Reporting Health care Facilities

Abha General Hospital (Maternity) King Faisal Military HospitalAbha Private Hospital Mahael General HospitalAFH Military Hospital Majaridah General HospitalAhli Hospital (Abha) Namas General HospitalAsir Central Hospital (Abha) Prince Abdul Bin Abdul Aziz HospitalBalasmar General Hospital Rijal Al Maa HospitalBisha General Hospital Sarat Obeidah General HospitalDhahran Janoob Hospital Saudi German Hospital (Abha)Khamis Mushayt Civil Hospital Tathleeth General HospitalKing Fahad Hospital, AFH (Khamis Mushayt)

Baha National Hospital King Fahad Hospital (Baha)Baljurashi General Hospital Mandaq HospitalGhodran Hospital Mikhwah Hospital

Ahsa Hospital (Hofuf) King Fahad Hospital of the University (Khobar)AL Borg Lab (DM) King Fahad Military Medical Complex (AFH)Anak General Hospital King Fahad Specialist Hospital (DM)ARAMCO Clinic King Khalid General Hospital Armed Forces Hospital (Hafr Al Batin) King Khalid Military ComplexAstoon Hospital (Thomairy) Mana General Hospital (DM)Badr Rubaie Dispensary Mana General Hospital (Hofuf)Dammam Central Hospital Mana General Hospital (Jubail)Dossary Hospital (Khobar) Mana General Hospital (Khobar)Dr. Fakhry & Mouhawis Hospital Maternity & Children's Hospital (Hofuf)Dr. Noor Khan Hospital (Hafr Al Batin) Maternity & Children's Hospital (Khobar)Eastern Province Hospital Mousa Hospital (Hofuf)Fanateer Hospital Mouwasat Hospital (DM)Faraby Dispensary Naireia General HospitalHuwaylat Hospital Prince Saud Bin Jalawi HospitalImam Abdul Rahman Bin Faisal, NGHA (DM) Qatif Central HospitalJabir Eye & ENT Hospital Qatif General HospitalJubail General Hospital Ras Tanura Center (ARAMCO Clinic)Jubail Military Hospital Rowdha DispensaryJufer Hospital (Hofuf) Saad Specialist Hospital Center (Khobar)Khafji General Hospital Saddiq HospitalKhafji Joint Operation Salama HospitalKing Abdul Aziz Airbase Saudi ARAMCO Medical Services OrganizationsKing Abdul Aziz Port Clinic Tadawy General HospitalKing Abdul Aziz Navy Base Tapline Qaisuma Hospital (ARAMCO)King Abdulaziz (NGH Hospital Yousif HospitalKing Fahad Hospital (Hofuf) Zamil Hospital

AlBorg Lab (Hail) Rashid Hospital Baqa Hospital Safa Polyclinic (RY) Hail General Hospital Salamat Private Hospital King Khaled General Hospital Shamli (Hail) Maternity & Children's Hospital

Asir Region

Baha Region

Eastern Province

Hail Region

SCR2006 Part06.indd 92 09-04-2010 3:30:15 AM

93

APPENDIX: A (continued...)

Abu Arish General Hospital Jazan Hospital NOS Baysh General Hospital Jazan Military HospitalDarb Hospital King Fahad Central HospitalJazan General Hospital Samtah General Hospital

Dawamat Jandal Hospital Qurayat General Hospital Maternity & Children's Hospital Tabarjal General Hospital Pr AbdulRahman Sudairi General Hospital

Al Borg Lab Madinah Maternity & Children's HospitalAneis Al Khair Lab Magrabi Eye Hospital (MD) Ansar Hospital (MD) Mahd General Hospital Ansary Specialist Hospital Meeqat Hospital Badr General Hospital (Yanbu) Mouwasat Hospital (Madinah)Dr Erfan Saadi Hospital (Yanbu) Ohoud Hospital Hanakyah General Hospital Prince Abdul Mohsen Ola General HospitalKhaybar General Hospital Royal Commission Medical Center (Yanboa)King Abdul Aziz NGH Hospital Saudi German Hospital (MD) King Fahad Hospital (MD) Yanboa General Hospital Madina Hospital, NOS Zahra Private Hospital Madina National Hospital Zen Laboratory

Abdul Rahman Qari Center King Faisal Hospital (Taif)Abdullah Saeim Daher King Faisal Specialist Hospital (JD)Abuzinada Hospital King Saud Hospital (JD) Adwani General Hospital (Taif) Leeth Hospital Ahli Clinic Maghraby Eye Hospital (JD)Ajiyad General Hospital (MK) Makkah Hospital NOS Alawi Tunsi & Bros Hospital Maternity & Children's Hospital (JD)AlBorg Lab (JD) Maternity & Children's Hospital (TF)AlBorg Lab (MK) Maternity & Children's Hospital (MK)Amen Hospital (Taif) Muhammad Saleh BashrahiAnsar Hospital (JD) Misan Blhareth (Taif) Bugshan General Hospital (JD) Mustaqbal Hospital (Dhagastani)Chest Disease Hospital (Taif) Nahda National Hospital (TF)Dr Abdul Rahman Bakhsh Hospital National Saudi Hospital (JD)Dr Erfan & Bagedo Hospital New Jeddah Clinic Dr Ghassan Pharaon Hospital Noor Specialist Hospital (MK)Dr Khalid Idrissi Hospital Nourah Oncology CenterDr Solaiman Fakeeh Hospital Pioneers Laboratory Elaj Laboratory (JD) Qunfudah General Hospital Eye Hospital (JD) Rabegh General Hospital Ghannam Clinic Rafie Hospital (MK) Hada Military Hospital (AFH) Rahmah Polyclinic (JD)Hai Jamea Hospital Royal Commission Medical Center (Yanboa)Hayat Hospital (JD) Salam Hospital Hera General Hospital (MK) Salamah Hospital (Closed) International Medical Saudi German Hospital (JD)Jazerah Hospital (JD) Saudi Hospital

Jazan Region

Jouf Region

Madinah Region

Makkah Region

SCR2006 Part06.indd 93 09-04-2010 3:30:16 AM

94

APPENDIX: A (continued...)

Jedaani Hospital Saudia Airlines Medical ServicesJeddah Clinic Hospital Shaty Hospital (Closed) Jeddah General Hospital Sheffaa Hospital Khadra Lab (JD) Taif Chest Hospital King AbdulAziz Hospital & Oncology Center (JD) Taif Children's Hospital (Taif)King AbdulAziz Hospital (Al Zaher) (MK) Taif Medical Center King AbdulAziz Specialist Hospital (Taif) Thagher Hospital King AbdulAziz University Hospital (JD) Torbah Hospital King Fahad General Hospital Umm Qura General HospitalKing Fahad Hospital, AFH (JD) United Doctors Hospital (Shaty Hospital)King Fahd Air Base Hospital Zahra Hospital (JD) King Faisal (Al Shesha) Hospital (MK) Zahra Hospital (JD)

Dhafer Hospital (Najran) Najran General Hospital King Khaled Hospital (Najran) Najran Hospitalital NOS Maternity & Children's Hospital Sharourah Armed ForcesNajran Armed Forces Hospital Sharourah General Hospital

Arar Central Hospital Rafha General Hospital Northern Hospital, NO Turayf General Hospital

Bukairiya General Hospital Midhnab General Hospital Buraidah Central Hospital Qassim Hospital NOS King Fahd Specialist Hospital Rass General Hospital King Saud University Hospital Wafa Hospital Maternity & Children's Hospital

Abdullah Medical Clinic Ismail Raslan Polyclinic Adama Hospital Jafel International HoAdvance Cell Laboratory Jazeera Laboratories AFH Millitary (RKH) Jazeera Medical ClinicAfif General Hospital Khaleejy Medical ClinicAflaj General Hospital King Abdul Aziz Medical CityAhad Madina Polyclinic King Abdul Aziz UniversityAlam Medical Center King Fahad Medical CityAlBorg Lab (RY) King Faisal Specialist Hospital & Research CenterAmal Clinic (1) King Khaled Eye Specialist HospitalAmal Psychiatric Hospital King Khaled General HospitalAmeed Polyclinic (Kharj) King Khaled University HospitalAnda Medical Laborator Maghraby Eye Hospital (RY)Armed Forces (Wadi Dawasir) Mamlaka Hospital (Kingdom) Artwiyah Clinic Masaudi Clinic Ashbelia Medical Clinic Maternity & Children's Hospital (RY)Aziziah Medical Laboratory Mobarak Hospital Basheer Obaid Dental Clinic Mouwasat Hospital (Ry) Bustan Clinic Mowed Medical Center Chest Diseases Hospital (Kharj) Obeid Hospital (RY) Consultative Medical Center Olaya Medical Center

Makkah Region continued…..

Najran Region

Northern Region

Qassim Region

Riyadh Region

SCR2006 Part06.indd 94 09-04-2010 3:30:16 AM

95

APPENDIX: A (continued....)

Consulting Radiologist Osrah Clinic Dallah Hospital Osrah International HospitalDar Hekma Clinic (RY) Prince Nasser Bin SaadDar Shifa Hospital Prince Salman Bin Abdulaziz HospitalDawadmi General Hospital Quwayiyah General HospitalDawssary Polyclinic (Kharj) Rathawiah Medical SpecDelta Medical Laboratory Rawabi Qurtuba Clinic Digits Clinic Riyadh Care Hospital (Social Insurance)Dilem General Hospital (Kharj) Riyadh Hospital NOS Dr Abdul Rahman Mishari Hospital Riyadh Medical Center Dr Fahd Sheduokhy Polyclinic Riyadh Medical ComplexDr Hamed Mutabagani Med Saati Medical Center ClinicDr Moagel's Polyclinic Safa Makka Polyclinic Dr Mofarreh Polyclinic Saudi German HospitalDr Mohamed Anazi Medical Center Saudi Medical ServicesDr Mohamed Shaker Heto Security Forces Hospital Dr Suliman Habib Medical Center Shaqra General Hospital Elaj Laboratory Shibel National ClinicElite Medical & Surgical Shifa Health Center Eman General Hospital Specialized Medical CenterENT Medical Center Sports Medicine Hospital Faiha Medical Center Sughayyer Clinic Faleh International Hospital Sulail Hospital Finger Print Laboratory Taif Medical Center (RY)Green Cresent Hospital Tumayr (Majmaah) Gulf Radiology Center United Medical LaboratoryHammadi Hospital Wadi Dawasser Hospital Hayat Polyclinic (Kharj) Watan Clinic Hilah Medical Clinic Watani Hospital (RY)Hotta Bani Tammim Hospital Wroud Medical Clinic Howtat Sudair Hospital Yamamah Hospital Huraymila General Hospital Zulfi General Hospital Ibn Sina Lab (RY)

Badaa Hospital (Tabuk) Maternity & Children's HospitalDhuba General Hospital North West Armed Forces HospitalKing Abd Aziz Military Prince Fahad Bin Sultan HospitalKing Fahad Hospital (Tabuk) Taima General Hospital King Khalid Civil Umlujj General Hospital King Khalid General Hospital Wajh General Hospital

Bahrain Jordan Bangladesh Kuwait Canada Lebanon China Nigeria Cyprus Pakistan Egypt Philippines Eritrea Qatar Ethiopia Sudan France Syrian Arab Republic Germany United Arab Emirates India United Kingdom Iraq United States of AmericaIreland Yemen Japan

Riyadh Region continued…..

Tabuk Region

International Hospitals in the following Countries

SCR2006 Part06.indd 95 09-04-2010 3:30:16 AM

96

APPENDIX: B SCR Board Member Contact Information

SCR Main Office MBC 64 PO Box 3354, Riyadh 11211 Saudi Arabia Tel: 01 - 442 - 3929 Fax: 01 - 442 - 3924 Email:

Website: www.scr.org.sa

[email protected]

Email: [email protected]





[email protected]

Chairman:

Admin. Director: Tumor Registrar: Asst. Tumor Registrar: Secretary:

Shouki Bazarbashi, MD

Haya Al Eid, BDS, DFE, CTR Mohamed Hayder, CTR Maisoun KhaledMarielen S. Manalo

Armed Forces Hospitals Riyadh Military Hospital PO Box 7897, Riyadh 11159 Tel: 01 - 477 - 7714 x 6747 Fax: 01 - 477 - 6743 x 6743

Director: Rizqullah Assiri, MD

Central Region King Fahad Medical City PO Box 59046, Riyadh 11525 Tel: 01-288-9999 x 7086 Fax: 01-288-1965

Director: Abdulaziz Al Humaidi, MD

Eastern Region King Fahd Hospital of the University PO Box 40004, Al Khobar 31952 Tel: 03-896-6741 Fax: 03-869-6741

Director: Prof. Hassan Al Idrissi, MD

King Abdulaziz University Hospital Faculty of Medicine PO Box 80215, Jeddah 21589 Tel: 02-624-0000 x 18244/18253 Fax: 02-617-1412

Director: Prof. Mohmoud Shaheen Al Ahwal, MD

King Faisal Specialist Hospital & Research Center MBC-64 PO Box 3354, Riyadh 11211 Tel: 01-442-4286Fax: 01-442-4542

Directors: Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

SCR2006 Part06.indd 96 09-04-2010 3:30:16 AM

97

APPENDIX: B Continued....

Madinah & Northern Region King Fahad Hospital Madinah Al Monawarah Tel: 04-836-2000 x 2465/2462 Fax: 04-836-0937

Director: Ahmed Tarawa, MD

National Guard Hospitals King Abdulaziz Medical City (KKNGH) PO Box 9515, Jeddah 21423 Tel: 02-624-0000 x 24082 Fax: 02-624-0000 x 24081

Director: Abdulwahab Andejani, MD

Security Forces Hospital PO Box 3643, Riyadh 11481 Tel: 01-477-4480 x 1193 Fax: 01-475-3814

Director: Abdulaziz Saleh Aba Hussein, MD

Southern Region King Khalid University PO Box 641, Abha Tel: 07-224-0711 / 224 -7800 x 118 Fax: 07-224-0964 / 224 -7570

Director: Abdul Rahman Al Shehri, MD

Ministry of Health Kingdom of Saudi Arabia PO Box 335157, Riyadh 11314 Tel: 01-475-0426 x 201Fax: 01-475-0428

Representative: Mohammad Y. Saeedi, MD

Western Region King Abdulaziz Hosp. & Oncology Center PO Box 31467, Jeddah 21497 Tel: 02-637-5555 x 2276 Fax: 02-635-6410

Director: Hasnah Al Ghamdi, MD

Edward De Vol, PhD

Hadir Meir, MD

Susan E. Young, CCHRA©, CTR

Director

Director

Admin. Director

January 2001 - April 2006

Nasser Al Hamdan, Dep. Chairman 1992 - 2006

January 2001 - August 2005

Hassan Trabulsi, MD Director November 2001 - June 2007

Dahish Ajarim, MD Director 1999 - December 2009

March 2003- May 2006






SCR2006 Part06.indd 97 09-04-2010 3:30:16 AM

98

APPENDIX C: Cancer Registration Abstract Form

SAUDI CANCER REGISTRY CANCER REGISTRATION ABSTRACTMinistry of Health Revised 03, 2010

Kingdom of Saudi Arabia1. ACCESSION DATE 2. CanReg-4 No.

(Accession Number)

y y y y (Computer Assigned)

PATIENT3. First (Must be filled ) 4. FATHER (Must be filled) 5. GRANDFATHER 6. FAMILY (Must be filled)

Use SCR standardized name spellings

7. Saudi ID/Passport/ Iqama Number 8. Sex 10. Age at Diagnosis- -

1-Male2-Female (if only year is known, use 01/07//_ _ _ _ )9-Unknown

11.Nationality Code 12. Nationality Text (Must be filled) 13. Marital Status1. Single 4. Widowed2. Married3. Divorced

14. Address Code (Must be filled) 15. Address Details (Must be filled)City: Suburb /District P.O. Box Zip Code:

16. Mobile Number (Must be filled)

17. Telephone Number 1 (Must be filled)

TUMOR21. Date of Diagnosis (Must be filled)

(First time physician states that patient has a malignancy clinically or pathologically) (if only year is known, use 01/07/_ _ _ _ )

d d m m y y y y22. Topography Code (Must be filled)

0BC

24. Morphology Code 25. Morphology Text (Must be filled)

/(behavior)

26. Behavior 27. Grade 28. SEER Summary Stage (Extent)

2. In situ 1. Well differentiated / Differentiated, NOS 1. In situ3. Malignant/Invasive 2. Moderately / Moderately well differentiated 2. Localized

3. Poorly Differentiated 3. Regional by direct extent4. Undifferentiated / Anaplastic 4. Regional by lymph node5. T-Cell* 5. Regional (both 3 and 4)6. B-Cell/Pre-B/B-cursor* 6. Regional, NOS7. Null Cell/Non-T-Non-B* 7. Distant Metastasis / Systemic disease8. Natural Killer cell*

9. Unknown9. Unknown** for leukemias & lymphomas only

29. Laterality 30. Basis of Diagnosis

0. Not paired (unknown, ill defined) 0. DCO (death certificate only) 5. Cytology / Hematology1. Right 1. Clinical 6. Histology of Metastasis2. Left 2. Medical Imaging (Radiology) 7. Histology of Primary3. One side, but unknown 3. Surgery (Visualization without Biopsy) 8.Autopsy 4. Bilateral involvement, laterality origin unknown

4. Lab test (tumor marker) 9. Unknown9. Paired site, laterally not stated

23. Topography Text

18. Extension 1 19. Telephone Number 2 20. Extension 2

9. Unknown

d d

9. Date of Birth

y y y y m m

d d m m

SCR2006 Part06.indd 98 09-04-2010 3:30:17 AM

99

APPENDIX C: Cancer Registration Abstract Form

HOSPITAL

31. Date first seen at Source1 for this cancer (Must be filled)

d d

32. Source 1 33. Reporting Hospital Text 34. MRN 1 35. Path 1

36. Source 2 37. Referral Hospital Text 38. MRN 2 39. Path 2





FOLLOW-UP

57. Status 58. Cause of Death

1. Dead1. Cancer

2. Alive9. Unknown

3. Not Applicable9. Unknownd d m m y y y y

59. Coder ID # 60. Data Entry ID #

Signature: ___________________________________ Signature: __________________________________

QUESTIONS / QUERIES / PROBLEMS:

y y y y m m

56. Last Contact

2. Other

SCR2006 Part06.indd 99 09-04-2010 3:30:17 AM

100

APPENDIX D: Summary of Cancer Statistics in Saudi Arabia for the Year 2006

2006

14121992)(

.

.

1994.

.

.

200611,040.8,2532,395

.662:

ICD-10)In Situ( .

4003 4250 8253 1276 1119 2395 197 195 392 110403923 4178 8101 1238 1093 2331 189 193 382 1081477 72 149 37 26 63 8 2 10 22225 22 47 4 3 7 3 1 4 58

3898 4156 8054 1234 1090 2324 186 192 378 10378

8,05477.6%2,32422.4% .3,898

48.4 %4,15651.6% .

83.2100,000)83.682.7 .(

98.1100,00094

100,00089.6100,00077.7

100,000100,000 .

)99912.4%)784 (9.7 %

)585 (7.3 %)541 (6.7 %

)508 (6.3 %)416 (5.2 %)327 (4.1 %

)293 (3.6 %)275 (3.4 .%

)180 (31.7 %)81 (14.3 %

)73 (12.9 %)46 (8.1 %

)36 (6.3 %)31 (5.5 %)26 (4.6 %

)21 (3.7 %)9 (1.6

%)6 (1.1 .%

SCR2006 Part06.indd 100 09-04-2010 3:30:18 AM

101

SCR2006 Part06.indd 101 09-04-2010 3:30:18 AM

102

SCR2006 Part06.indd 102 09-04-2010 3:30:18 AM

cancer incidence report saudi arabia 2006

Documents